Book Edit:
1. Toi M, Benson J, Jatoi I (Eds). Screening and Risk Reduction Strategies for Breast Cancer. Springer 2023 (inprinting).
2. Dong-Young Noh, Wonshik Han and Masakazu Toi (Eds). Translational research in Breast Cancer Springer 2021.
3. Kusano M, Kokudo N, Toi M, Kaibori M (Eds). ICG Fluorescence Imaging and Navigation Surgery. Springer 2016.
4. Toi M, Winer E, Benson J, Klimberg S. (Eds). Personalized Treatment of Breast Cancer, Springer 2016.
5. Toi M and Winer EP (Eds). Local and systemic management of primary breast cancers. Kyoto University Press,
2010.
Book Chapter:
1. Toi M, Velaga R. Next-Generation Clinical Trials and Research with Successful Collaborations.
Biol 2021; 1187: 613-622.

Adv Exp Med

2. Takada M, Toi M. A new concept for axillary treatment of primary breast cancer using indocyanine green
fluorescence imaging. ICG Fluorescence Imaging and Navigation Surgery Edited by Kusano M, Kokudo N, Toi
M, Kaibori M. Springer 2016.
3. Yamashiro H, Takada M, Toi M. Local management after pre-operative chemotherapy. Local and systemic
management of primary breast cancers. Edited by Toi M and Winer EP. Kyoto University press 2011.
4. Inamoto T, Takada M, Toi M. Results of questionnaire survey of breast cancer specialists about optimal surgery
for patients with breast cancer. Local and systemic management of primary breast cancers. Edited by Toi M andWiner EP. Kyoto University press 2011.
5. Kuroi K, Toi M. Chapter III - Antiangiogenic Property of Metronomic Chemotherapy: New Research on
Angiogenesis Inhibitors. Edited by Elmer T. Skinard pp. 55-76, Nova Science Publishers, 2007.
6. Bando H, Toi M. Tumor angiogenesis, macrophages, and cytokines. Angiogenesis: From the Molecular to
Integrative Pharmacology. Edited by Maragoudakis, pp 267-284, Kluwer Academic/ Plenum Publishers, New
York, 2000.
Special Issue Edit:
1. Toi M, Benson JR. Latest Approaches to Loco-Regional and Systemic Therapies for Breast Cancer. Frontiers in
Oncology, Women’s Cancer 2017
2. Toi M, Kitai T. Scientific basis and clinical application of ICG (indocyanine green) fluorescence imaging insurgical oncology. Special issue, The Open Surgical Oncology Journal 2, 2010.
3. Toi M. Sensitization in breast cancer treatment. Breast Cancer 11, 2004.
Reviews:
1.

Kumar R, Abreu C, Toi M, Saini S, Casimiro S, Arora A, Paul AM, Velaga R, Rameshwar P, Lipton A, Gupta S,
Costa L. Oncobiology and treatment of breast cancer in young women.
Cancer Metastasis Rev.
2022;41:749-770. doi: 10.1007/s10555-022-10034-6. Epub 2022 Apr 30.

2.

Paul AM, George B, Saini S, Pillai MR, Toi M, Costa L, Kumar R. Delineation of pathogenomic insights ofbreast cancer in young women. Cells. 2022;11:1927. doi: 10.3390/cells11121927.

3.

Kawaguchi K, Maeshima Y, Toi M. Tumor immune microenvironment and systemic response in breast cancer.
Med Oncol. 2022, 29;39:208.
1

4.

Velaga R, Tanaka S, Toi M. Molecular vulnerabilities and therapeutic resistance in hormone receptor positive
and HER2 dependent breast cancer tumours. Cancer Drug Resist. 2022;5:487-497.

5.

Tarantino P, Modi S, Tolaney SM, Cortés J, Hamilton EP, Kim SB, Toi M, Andrè F, Curigliano G. Interstitiallung disease induced by anti-ERBB2 antibody-drug conjugates: a review. JAMA Oncol. 2021;7:1873-1881.
doi: 10.1001/jamaoncol.2021.3595.

6.

El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, de Freitas JR, Sur D, Amendola LC, Gharib
M, Kallala A, Arun I, Azmoudeh-Ardalan F, Fujimoto L, Sua LF, Liu SW, Lien HC, Kirtani P, Balancin M, El
Attar H, Guleria P, Yang W, Shash E, Chen IC, Bautista V, Do Prado Moura JF, Rapoport BL, Castaneda C,
Spengler E, Acosta-Haab G, Frahm I, Sanchez J, Castillo M, Bouchmaa N, Md Zin RR, Shui R, Onyuma T, Yang
W, Husain Z, Willard-Gallo K, Coosemans A, Perez EA, Provenzano E, Ericsson PG, Richardet E, Mehrotra R,
Sarancone S, Ehinger A, Rimm DL, Bartlett JMS, Viale G, Denkert C, Hida AI, Sotiriou C, Loibl S, Hewitt SM,
Badve S, Symmans WF, Kim RS, Pruneri G, Goel S, Francis PA, Inurrigarro G, Yamaguchi R, Garcia-Rivello H,
Horlings H, Afqir S, Salgado R, Adams S, Kok M, Dieci MV, Michiels S, Demaria S, Loi S; International
Immuno-Oncology Biomarker Working Group. The tale of TILs in breast cancer: A report from The International
Immuno-Oncology Biomarker Working Group.
NPJ Breast Cancer. 2021;7:150. doi: 10.1038/s41523-021-00346-1.

7.

Masuda N, Kosaka N, Iwata H, Toi M. Palbociclib as an early-line treatment for Japanese patients with hormone
receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: a review ofclinical trial and real-world data. Int J Clin Oncol. 2021;26:2179-2193. doi: 10.1007/s10147-021-02013-8.

8.

Chow LWC, Lie EF, Toi M. Advances in EGFR/HER2-directed clinical research on breast cancer. Adv Cancer
Res. 2020;147:375-428.

9.

Takada M, Toi M. Neoadjuvant treatment for HER2-positive breast cancer, Chin Clin Oncol 2020;9:32. doi:
10.21037/cco-20-123. Epub 2020 Jun 3

10. He C, Kawaguchi K, Toi M. DNA damage repair functions and targeted treatment in breast cancer, Breast
Cancer 2020;27:355-362. Epub 2020 Jan 2.
11. Yap YS, Lu YS, Tamura K, Lee JE, Ko EY, Park YH, Cao AY, Lin CH, Toi M, Wu J, Lee SC., Insights into
breast cancer in the East vs the West: A review, JAMA Oncol 2019;5:1489-1496.
12. Benson JR, Jatoi I, Toi M. Surgical management of multiple ipsilateral breast cancers, Future Oncol
15:1185-1191, 2019. Epub 2019 Mar 29.
13. Takada M, Toi M., Cryosurgery for primary breast cancers, its biological impact, and clinical outcomes. Int J
Clin Oncol 2019;24:608-613. Epub 2019 Apr 13.
14. Kotake T, Toi M. Abemaciclib for the treatment of breast cancer. Expert Opin Pharmacother 2018;19:517-524.
doi: 10.1080/14656566.2018.1448787. Epub 2018 Mar
15. Shiina T, Toi M, Yagi T. Development and clinical translation of photoacoustic mammography. Biomed Eng
Lett. 2018;8:157-165. doi: 10.1007/s13534-018-0070-7. eCollection 2018 May.
16. Toi M, Masuda N, Lee SJ. Capecitabine for primary breast cancer. Oncotarget. 2017;8:110739-110740. doi:
10.18632/oncotarget.22990. eCollection 2017 Dec 19. No abstract available.
17. Sagara Y, Julia W, Golshan M, Toi M. Paradigm shift toward reducing overtreatment of ductal carcinoma in situ
of breast. Front Oncol 2017; 7:192. doi: 10.3389/fonc.2017.00192. eCollection 2017. Review.
18. Sugie T, Toi M. Antitumor immunity and advances in cancer immunotherapy. Breast Cancer 2017;24:1-2. doi:
10.1007/s12282-016-0744-x.
219. Buyse M, Hurvitz SA, Andre F, Jiang Z, Burris HA, Toi M, Eiermann W, Lindsay MA, Slamon D. Statisticalcontroversies in clinical research: statistical significance - too much of a good thing. Ann Oncol 2016;27:760-2.
doi: 10.1093/annonc/mdw047. Epub 2016 Feb 9.
20. Benson JR, Jatoi I, Toi M. Treatment of low-risk ductal carcinoma in situ: is nothing better than something?
Lancet Oncol 17:e442-e451, 2016. doi: 10.1016/S1470-2045(16)30367-9.
21. Jatoi I, Benson JR, Toi M. De-escalation of axillary surgery in early breast cancer. Lancet Oncol 17:e430-e441,
2016. doi: 10.1016/S1470-2045(16)30311-4.
22. Sugie T, Ikeda T, Kawaguchi A, Shimizu A, Toi M. Sentinel lymph node biopsy using indocyanine green
fluorescence in early-stage breast cancer: a meta-analysis. Int J Clin Oncol 2017;22:11-17. 2016 Nov 19. [Epubahead of print]
23. Toi M, Masuda N, Ishiguro H, Saji S, Ohno S, Chow LW. Development of breast cancer therapy:
biomarker-driven and response-guided approaches in a neoadjuvant setting. Int J Biol Markers 2015;30:0. doi:
10.5301/jbm.5000136. [Epub ahead of print]
24. Sato F, Saji S, Toi M. Genomic tumor evolution of breast cancer. Breast Cancer 2015 May 22. [Epub ahead ofprint] 2016;23:4-11.
25. Fakhrejahani E, Asao Y, Toi M. Tumor microvasculature characteristics studied by image analysis:
Histologically-driven angiogenic profile. Int J Biol Markers 29:e204-7, 2014. doi: 10.5301/jbm.5000098.
26. Fakhrejahani E, Toi M. Antiangiogenesis Therapy for Breast Cancer: An Update and Perspectives from Clinical
Trials. Jpn J Clin Oncol 2014;44:197-207. 2014 Jan 27. [Epub]
27. Lertkhachonsuk AA, Yip CH, Khuhaprema T, Chen DS, Plummer M, Jee SH, Toi M, Wilailak S; Asian
Oncology Summit 2013. Cancer prevention in Asia: resource-stratified guidelines from the Asian Oncology
Summit 2013. Lancet Oncol 14:e497-507, 2013. doi: 10.1016/S1470-2045(13)70350-4. Review.
28. Horvath A, Pakala SB, Mudvari P, Reddy SD, Ohshiro K, Casimiro S, Pires R, Fuqua SA, Toi M, Costa L, Nair
SS, Sukumar S, Kumar R. Novel Insights into breast cancer genetic variance through RNA sequencing. Sci Rep
3:2256, 2013. doi: 10.1038/srep02256.
29. Li W, Saji S, Sato F, Noda M, Toi M. Potential clinical applications of matrix metalloproteinase
their future prospects. Int J Biol Markers 28:e117-30, 2013.

inhibitors and

30. Sugimoto M, Takada M, Toi M. Comparison of robustness against missing values of alternative decision tree
and multiple logistic regression for predicting clinical data in primary breast cancer. Conf Proc IEEE Eng Med
Biol Soc 2013:3054-7, 2013. doi: 10.1109/EMBC.2013.6610185.
31. Barrios C, Forbes JF, Jonat W, Conte P, Gradishar W, Buzdar A, Gelmon K, Gnant M, Bonneterre J, Toi M,
Hudis C, Robertson JF. The sequential use of endocrine treatment for advanced breast cancer: where are we?
Ann Oncol 23:1378-86, 2012. Epub 2012 Feb 8.
32. Suzuki R, Saji S, Toi M. Impact of body mass index on breast cancer in accordance with the life-stage of women.
Front Oncol 2012;2:123
33. Ueno T, Emi M, Sato H, Ito N, Muta M, Kuroi K, Toi M. Genome-wide copy number analysis in primary breast
cancer. Expert Opin Ther Targets 2012 Mar;16 Suppl 1:S31-5. Epub 2012 Feb 8
34. Eswaran J, Gupta S, Dutt A, Toi M, Pillai MR, Costa L, Knapp S, Badwe RA, Kumar R. The Global Cancer
Genomics Consortium: Interfacing genomics and cancer medicine. Cancer Res 2012 May 24. [Epub ahead ofprint]
3

35. Fakhrejahani E, Toi M. Tumor angiogenesis: pericytes and maturation are not to be ignored. J Oncol
2012:261750. Epub 2011 Oct 9
36. Chow LW, Toi M. Combat against cancer with science and medicine. Expert Opin Investig Drugs Suppl 1:S3-4,
2010.
37. Kumagai Y, Toi M, Kawada K, Kawano T. Angiogenesis in superficial esophageal squamous cell carcinoma:
Magnifying endoscopic observation and molecular analysis. Dig Endosc 22:259-67, 2010. d Epub 2010 Aug
12.
38. Tang Y, Xu F, Tao K, Qian N, Toi M. Clinical applications of sentinel lymph node biopsy in ductal carcinoma insitu of the breast: a dilemma. Tohoku J Exp Med 224:1-5, 2011. Review.
39. Toi M, Sugie T, Kitai T. Indocyanine green fluorescence navigation may be useful to personalize lymph nodes
dissection. Special issue, Open Surg Oncol 2, 29-30, 2010.
40. Ali AM, Toi M, Ueno T. Anti-angiogenic cancer therapy updates. Curr Mol Med 9:954-66, 2009.
41. Toi M, Yamashiro H, Tsuji W. Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast
cancer. Breast Cancer 16:207-218, 2009.
42. Toi M. Long-term outcomes of aromatase inhibition for breast cancer. Lancet Oncol 9:8-10, 2008.
43. Ishiguro H, Kitano T, Yoshibayashi H, Toi M, Ueno T, Yasuda H, Yanagihara K, Garbo CL, Fukushima M.
Prolonged neutropenia after dose-dense chemotherapy with pegfilgrastim. Ann Oncol 19:1019, 2008.
44. Yamashiro H, Toi M. Update of evidence in chemotherapy for breast cancer. Int J Clin Oncol 13:3-7, 2008.
45. Noguchi S, Toi M. Molecular target therapy: basics and clinical application. Breast Cancer 15: 47-48, 2008.
46. Toi M. What Does DNA Methylation Surrogate? Digestion 75:53 [Epub ahead of print] 2007.
47. Suzuki E, Toi M. Improving the efficacy of trastuzumab in breast cancer. Cancer Sci 2007 Jun;98(6):767-71.
Epub 2007 Apr 12.
48. Toi M, Iino Y. Who benefits from hormone therapy? Breast Cancer 13:117-122, 2006.
49. Dewan MZ, Ahmed S, Iwasaki Y, Ohba K, Toi M, Yamamoto N. Stromal cell-derived factor-1 and CXCR4
receptor interaction in tumor growth and metastasis of breast cancer. Biomed Pharmacother 60:273-276, 2006.
50. Kuroi K, Toi M, Tsuda H, Kurosumi M, Akiyama F. Issues in the assessment of the pathologic effect ofprimary systemic therapy for breast cancer. Breast Cancer 13:38-48, 2006.
51. Suzuki T, Toi M, Saji S, Horiguchi K, Aruga T, Suzuki E, Horiguchi S, Funata N, Karasawa K, Kamata N. Early
breast cancer. Int J Clin Oncol 11:108-119, 2006.
52. Kondo M, Toi M. Cost-effective treatment options in first-line therapy for advanced breast cancer in Japan.
Expert Rev Anticancer Ther 6:197-204, 2006.
53. Nakanishi C, Toi M. Nuclear factor k-B inhibitors as sensitizer of anticancer drugs. Nat Rev Cancer 5:297-309,
2005.
54. Gasparini G, Longo R, Toi M, Ferrara N. Angiogenic inhibitors: A new therapeutic strategy in oncology. NatClin Pract Oncol 2:562-577, 2005.
55. Albain KS, de la Garza Salazar J, Pienkowski T, Aapro M, Bergh J, Caleffi M, Coleman R, Eiermann W, Icli F,
Pegram M, Piccart M, Snyder R, Toi M, Hortobagyi GN. Reducing the global breast cancer burden: The
4

importance of patterns of care research. Clin Breast Cancer 6:412-420, 2005.
56. Saji S, Hirose M, Toi M. Clinical significance of estrogen receptor beta in breast cancer. Cancer ChemotherPharmacol 56 Suppl 1:21-26, 2005.
57. Toi M, Horiguchi K, Bando H, Saji S, Chow LW. Trastuzumab: Updates and future issues.
Pharmacol 56 Suppl 1:94-99, 2005.

Cancer Chemother

58. Toi M, Takebayashi Y, Chow LW. Translational research in breast cancer. Breast Cancer 12:86-90, 2005.
59. Toi M, Rahman MA, Bando H, Chow WC. Role of thymidine phosphorylase /PD-ECGF in cancer biology andtreatment. Lancet Oncol 6:158-166, 2005.
60. Kuroi K, Toi M, Tsuda H, Kurosumi M, Akiyama F. Unargued issues on the pathological assessment of response
in primary systemic therapy for breast cancer. Biomed Pharmacother Suppl 2: S387-392, 2005.
61. Dewan MZ, Terunuma H, Ahmed S, Ohba K, Takada M, Tanaka Y, Toi M, Yamamoto N. Natural killer cells inbreast cancer cell growth and metastasis in SCID mice. Biomed Pharmacother Suppl 2:S375-379, 2005.
62. Ueno T, Toi M, Linder S. Detection of epithelial cell death in the body by cytokeratin 18 measurement.
Biomed Pharmacother Suppl 2:S359-362, 2005.
63. Toi M, Bando H, Weich HA. Vascular endothelial growth factor and its relationships with endogenous inhibitors
in a breast cancer microenvironment manipulated by hormonal therapy: A hypothetical consideration. Biomed
Pharmacother Suppl 2:S344-347, 2005.
64. Chow LW, Loo WT, Toi M. Current directions for COX-2 inhibition in breast cancer. Biomed Pharmacother
Suppl 2:S281-284, 2005.
65. Chow LW, Toi M. Translational research in oncology comes timely. Biomed Pharmacother Suppl 2:S263, 2005.
66. Saji S, Hirose M, Toi M. Novel sensitizing agents: Potential contribution of COX-2 inhibitor for endocrine
therapy of breast cancer. Breast Cancer 11:129-133, 2004.
67. Toi M, Bando H, Chow WC. Novel insights in clinical trials with preoperative systemic therapy for primarybreast cancer. Biomed Pharmacother 58:531-535, 2004.
68. Kuwano M, Oda Y, Izumi H, Yang SJ, Uchiumi T, Iwamoto Y, Toi M, Fujii T, Yamana H, Kinoshita H,
Kamura T, Tsuneyoshi M, Yasumoto K, Kohno K. The role of nuclear Y-box binding protein 1 as a global
marker in drug resistance. Mol Cancer Ther 3:1485-1492, 2004.
69. Toi M, Takada M, Bando H, Toyama K, Yamashiro H, Horiguchi S, Saji S. Current status of antibody therapy forbreast cancer. Breast Cancer 11:10-14, 2004.
70. Rahman MA, Toi M. Anti-angiogenic therapy in breast cancer. Biomed Pharmacother 57:463-470, 2003.
71. Toi M, Bando H, Saji S. Decision tree and paradigms of primary breast cancer: Changes elicited by preoperative
therapy. Med Sci Monit 9:RA90-95, 2003.
72. Kuroi K, Bando H, Saji S, Toi M. Weekly schedule of docetaxel in breast cancer: Evaluation of response andtoxicity. Breast Cancer 10:10-14, 2003.
73. Saji S, Omoto Y, Shimizu C, Horiguchi S, Watanabe T, Funata N, Hayashi S, Gustafsson JA, Toi M. Clinicalimpact of assay of estrogen receptor beta cx in breast cancer. Breast Cancer 9:303-307, 2002.
74. Kumagai Y, Toi M, Inoue H. Dynamism of tumour vasculature in the early phase of cancer progression:
Outcomes from oesophageal cancer research. Lancet Oncol 3:604-610, 2002.
5

75. Toi M, Matsumoto T, Bando H. Vascular endothelial growth factor: Its prognostic, predictive, and therapeutic
implications. Lancet Oncol 2:667-673, 2001.
76. Saji S, Toi M. Aromatase inhibitors and other novel agents in breast cancer treatment.
Drugs 7:303-319, 2002.

Expert Opin Emerg

77. Umemura S, Sakamoto G, Sasano H, Tsuda H, Akiyama F, Kurosumi M, Tokuda Y, Watanabe T, Toi M,
Hasegawa T, Osamura RY. Evaluation of HER2 status: for the treatment of metastatic breast cancers byhumanized anti-HER2 Monoclonal antibody (trastuzumab) (Pathological committee for optimal use of
trastuzumab). Breast Cancer 8:316-320, 2001.
78. Toi M, Bando H, Saji S. Aromatase and aromatase inhibitors. Breast Cancer 8:329-332, 2001.
79. Kuroi K, Toi M. Circulating angiogenesis regulators in cancer patients. Int J Biol Markers 16:5-26, 2001.
80. Toi M, Bando H, Kuroi K. The predictive value of angiogenesis for adjuvant therapy in breast cancer. Breast
Cancer 7:311-314, 2000.
81. Nagai S, Toi M. Interleukin-4 and breast cancer. Breast Cancer 7:181-186, 2000.
82. Toi M, Ishigaki S, Tominaga T. Metalloproteinases and tissue inhibitors of metalloproteinases. Breast Cancer
Res Treat 52:113-124, 1998.
83. Iino Y, Toi M. Chemoendocrine therapy: Basic science and clinical aspects. Breast Cancer 5:344-346, 1998.
84. Toi M, Saji S, Suzuki A, Yamamoto Y, Tominaga T. MDM2 in breast cancer. Breast Cancer 4:264-268, 1997
85. Toi M, Taniguchi T, Yamamoto Y, Kurisaki T, Suzuki H, Tominaga T. Clinical significance of thedetermination of angiogenic factors. Eur J Cancer 32A: 2513-2519, 1996.
86. Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Viale G, Weidner N, Harris
AL, Dirix LY. Quantification of angiogenesis in solid human tumours: an international consensus on themethodology and criteria of evaluation. Eur J Cancer 32A:2474-2484, 1996.
87. Toi M. Endothelial growth factors: A target for antiangiogenesis. The Cancer J 8:315-319, 1995.
Original articles
1. Johnston SRD, Toi M, O'Shaughnessy J, Rastogi P, Campone M, Neven P, Huang CS, Huober J, Jaliffe GG, Cicin
I, Tolaney SM, Goetz MP, Rugo HS, Senkus E, Testa L, Del Mastro L, Shimizu C, Wei R, Shahir A, Munoz M,
San Antonio B, André V, Harbeck N, Martin M; monarchE Committee Members. Abemaciclib plus endocrine
therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE):results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2022:
S1470-2045(22)00694-5. doi:10.1016/S1470-2045(22)00694-5. Online ahead of print.
2. Takada M, Yoshimura M, Kotake T, Kawaguchi K, Uozumi R, Kataoka M, Kato H, Yoshibayashi H, Suwa H,
Tsuji W, Yamashiro H, Suzuki E, Torii M, Yamada Y, Kataoka T, Ishiguro H, Morita S, Toi M. Phase Ib/II study ofnivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative
metastatic breast cancer. Sci Rep. 2022;12:22397.
3. Najnin RA, Al Mahmud MR, Rahman MM, Takeda S, Sasanuma H, Tanaka H, Murakawa Y, Shimizu N, Akter
S, Takagi M, Sunada T, Akamatsu S, He G, Itou J, Toi M, Miyaji M, Tsutsui KM,11 Keeney S, Yamada S. ATM
suppresses c-Myc overexpression in the mammary epithelium in response to estrogen. Cell Reports 2023; 42,111909. doi.org/10.1016/j.celrep.2022.111909
6

4. Ota R, Kataoka M, Iima M, Honda M, Kishimoto AO, Miyake KK, Yamada Y, Takeuchi Y, Toi M, Nakamoto Y.
Evaluation of breast lesions based on modified BI-RADS using high-resolution readout-segmented
diffusion-weighted echo-planar imaging and T2/T1-weighted image. Magn Reson Imaging. 2023 Jan
3:S0730-725X(22)00240-5. doi: 10.1016/j.mri.2022.12.024.
5. Kawaguchi H, Yamamoto Y, Saji S, Masuda N, Nakayama T, Aogi K, Anan K, Ohtani S, Sato N, Takano T,
Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita T, Yotsumoto
D, Toi M, Ohno S. Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of
ER-positive/HER2-negative post-menopausal advanced breast cancer: an additional analysis of the JBCRG-C06
Safari study. Jpn J Clin Oncol. 2022 Dec 8:hyac184. doi: 10.1093/jjco/hyac184. Online ahead of print.
6. Nakayama Y, Hanada M, Koda H, Sugimoto M, Takada M, Toi M. Breast cancer detection using volatilecompound profiles in exhaled breath via selected ion-flow tube mass spectrometry. J Breath Res. 2022;17. doi:
10.1088/1752-7163/aca696.
7. Yuge S, Miyake KK, Ishimori T, Kataoka M, Matsumoto Y, Fujimoto K, Sugie T, Toi M, Nakamoto Y.
Reproducibility assessment of uptake on dedicated breast PET for noise discrimination. Ann Nucl Med. 2022 Nov
25. doi: 10.1007/s12149-022-01809-6.,
8. Shirakawa C, Koyasu S, Takada M, Toi M, Nakamoto Y. Unilateral Reduction of 18F-FDG Accumulation in
Brown Adipose Tissue by Sympathectomy for Hyperhidrosis. Clin Nucl Med. 2023 Jan 1;48(1):79-80. doi:
10.1097/RLU.0000000000004393.
9. Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G,
Armstrong AC, Arnedos M, Balmaña J, Bergh J, Bliss J, Delaloge S, Domchek SM, Eisen A, Elsafy F, Fein LE,
Fielding A, Ford JM, Friedman S, Gelmon KA, Gianni L, Gnant M, Hollingsworth SJ, Im SA, Jager A,
Jóhannsson ÓÞ, Lakhani SR, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas PC, Marmé F,
Martinez de Dueñas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma
P, Singer CF, Španić T, Stickeler E, Toi M, Traina TA, Viale G, Zoppoli G, Park YH, Yerushalmi R, Yang H, Pang
D, Jung KH, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke GS, Sun Q, Parton M, Colleoni MA, Schmidt
M, Brufsky AM, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt ANJ; OlympiA Clinical Trial Steering
Committee and Investigators. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with
germline pathogenic variants in BRCA1/2 and high risk, early breast cancer. Ann Oncol. 2022:1250-1268. doi:
10.1016/j.annonc.2022.09.159. Epub 2022 Oct 10.
10. Toi M, Boyle F, Im YH, Reinisch M, Molthrop D, Jiang Z, Wei R, Sapunar F, Grimes BR, Nabinger SC, Johnston
SRD. Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1.
Oncologist. 2022 Nov 7:oyac234. doi:10.1093/oncolo/oyac234. Online ahead of print.
11. Toi M, Huang CS, Im YH, Sohn J, Zhang W, Sakaguchi S, Haddad N, van Hal G, Sledge GW Jr. Abemaciclib plus
fulvestrant in East Asian women with HR+, HER2- advanced breast cancer: Overall survival from MONARCH 2.
Cancer Sci. 2022 Sep 28. doi: 10.1111/cas.15600.
12. Correction: Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from theMONARCH 2 Study of Abemaciclib plus Fulvestrant. Tolaney SM, Toi M, Neven P, Sohn J, Grischke EM,
Llombart-Cussac A, Soliman H, Wang H, Wijayawardana S, Jansen VM, Litchfield LM, Sledge GW. Clin Cancer
Res. 2022;28:4587.
13. Mori T, Okamoto Y, Mu A, Ide Y, Yoshimura A, Senda N, Inagaki-Kawata Y, Kawashima M, Kitao H, Tokunaga E,
Miyoshi Y, Ohsumi S, Tsugawa K, Ohta T, Katagiri T, Ohtsuru S, Koike K, Ogawa S, Toi M, Iwata H, Nakamura
S, Matsuo K, Takata M. Lack of impact of the ALDH2 rs671 variant on breast cancer development in Japanese
BRCA1/2-mutation carriers. Cancer Med. 2022 Nov 7. doi: 10.1002/cam4.5430.
714. Galactionova K, Loibl S, Salari P, Marmé F, Martin M, Untch M, Bonnefoi HR, Kim SB, Bear HD, McCarthy N,
Gelmon KA, García-Sáenz JA, Kelly CM, Reimer T, Toi M, Rugo HS, Gnant M, Makris A, Burchardi N,
Schwenkglenks M. Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse:
Results from the PENELOPE-B trial. Front Oncol. 2022;12:886831. doi: 10.3389/fonc.2022.886831.
15. Honda M, Iima M, Kataoka M, Fukushima Y, Ota R, Ohashi A, Toi M, Nakamoto Y. Biomarkers predictive ofdistant disease-free survival derived from diffusion-weighted imaging of breast cancer. Magn Reson Med Sci.
2022 Aug 3. doi:10.2463/mrms.mp.2022-0060.
16. Yamamoto Y, Iwata H, Taira N, Masuda N, Takahashi M, Yoshinami T, Ueno T, Toyama T, Yamanaka T, Takano T,
Kashiwaba M, Tsugawa K, Hasegawa Y, Tamura K, Tada H, Hara F, Fujisawa T, Niikura N, Saji S, Morita S, Toi
M, Ohno S. Pertuzumab retreatment for HER2-positive advanced breast cancer: a randomized, open-label phase
III study (PRECIOUS). Cancer Sci. 2022 Jun 26. doi: 10.1111/cas.15474.
17. Shimizu H, Saito S, Yoshikawa A, Sekiguchi H, Tsuge I, Morimoto N, Toi M. Three-dimensional visualization ofthoracodorsal artery perforators using photoacoustic imaging.J Plast Reconstr Aesthet Surg. 2022 Jun
17:S1748-6815(22)00332-1. doi: 10.1016/j.bjps.2022.06.016.
18. Honda M, Kataoka M, Iima M, Ota R, Ohashi A, Ohno-Kishimoto A, Miyake KK, Nickel MD, Yamada Y, Toi M,
Nakamoto Y. Visual Evaluation of Ultrafast MRI in the Assessment of Residual Breast Cancer after Neoadjuvant
Systemic Therapy: A Preliminary Study Association with Subtype. Tomography. 2022;8:1522-1533.
19. Ota R, Kataoka M, Iima M, Honda M, Ohashi A, Ohno-Kishimoto A, Miyake KK, Yamada Y, Takeuchi Y, Toi M,
Nakamoto Y. Evaluation of pathological complete response after neoadjuvant systemic treatment of invasive
breast cancer using diffusion-weighted imaging compared with dynamic contrast-enhanced based kinetic analysis.
Eur J Radiol. 2022;154:110372.
20. Saji S, Taira N, Kitada M, Takano T, Takada M, Ohtake T, Toyama T, Kikawa Y, Hasegawa Y, Fujisawa T,
Kashiwaba M, Ishida T, Nakamura R, Yamamoto Y, Toh U, Iwata H, Masuda N, Morita S, Ohno S, Toi M. Switch
maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastaticoestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial.
Lancet Oncol. 2022:S1470-2045(22)00196-6. doi: 10.1016/S1470-2045(22)00196-6.
21. Tolaney SM, Toi M, Neven P, Sohn J, Grischke EM, Llombart-Cussac A, Soliman H, Wang H, Wijayawardana S,
Jansen VM, Litchfield LM, Sledge GW. Clinical Significance of PIK3CA and ESR1 Mutations in circulatingtumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib Plus Fulvestrant. Clin Cancer Res. 2022 Feb
4:clincanres.3276.2021. doi: 10.1158/1078-0432.CCR-21-3276.
22. Kikawa Y, Kotake T, Tsuyuki S, Kang Y, Takahara S, Fujimoto Y, Yamashiro H, Yoshibayashi H, Takada M,
Yasuoka R, Nakatsukasa K, Yamagami K, Suwa H, Okuno T, Nakayama I, Kato T, Ogura N, Moriguchi Y,
Ishiguro H, Kagimura T, Taguchi T, Sugie T, Toi M. Effectiveness of eribulin as first-line or second-line
chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from themulti-institutional, prospective, observational KBCRN A001: E-SPEC study. Breast Cancer. 2022 Apr 23. doi:
10.1007/s12282-022-01357-x.
23. Yutaka Y, Kawashima M, Toshi M, Toi M, Date H. Indocyanine green-enhanced thoracoscopic localization ofparasternal lymph node: How to do it. Asian Cardiovasc Thorac Ann. 2022 Apr 26:2184923221097843. doi:
10.1177/02184923221097843.
24. Ueno T, Kitano S, Masuda N, Ikarashi D, Yamashita M, Chiba T, Kadoya T, Bando H, Yamanaka T, Ohtani S,
Nagai S, Nakayama T, Takahashi M, Saji S, Aogi K, Velaga R, Kawaguchi K, Morita S, Haga H, Ohno S, Toi M.
Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant
chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR. BMC Med.
2022;20:136. doi: 10.1186/s12916-022-02332-1.
8

25. Masuda N, Chen Y, Kawaguchi T, Dozono K, Toi M. Safety in Japanese Advanced Breast Cancer Patients Who
Received Abemaciclib in MONARCH 2 and MONARCH 3: Assessment of Treatment-Emergent Neutropenia,
Diarrhea, and Increased Alanine Aminotransferase and Aspartate Aminotransferase Levels. Cancer Manag Res.
2022;14:1179-1194. doi: 10.2147/CMAR.S348591. eCollection 2022.
26. Rugo HS, O'Shaughnessy J, Boyle F, Toi M, Broom R, Blancas I, Gumus M, Yamashita T, Im YH, Rastogi P,
Zagouri F, Song C, Campone M, San Antonio B, Shahir A, Hulstijn M, Brown J, Zimmermann A, Wei R, Johnston
S, Reinisch M, Tolaney SM; monarchE Committee Members. Adjuvant abemaciclib combined with endocrine
therapy for high risk early breast cancer: safety and patient-reported outcomes from the monarchE study. Ann
Oncol. 2022 Mar 22:S0923-7534(22)00383-0. doi:10.1016/j.annonc.2022.03.006.
27. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen inpremenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian
suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncol.
2022;23:382-392. doi: 10.1016/S1470-2045(21)00758-0. Epub 2022 Feb 3.
28. Early Breast Cancer Trialists’ Collaborative group (EBCTCG). Trastuzumab for early-stage, HER2-positive breast
cancer: a meta-analysis of 13 864 women in seven randomised trials.
Lancet Oncol. 2021;22:1139-1150. doi: 10.1016/S1470-2045(21)00288-6.
29. Harbeck N, Rastogi P, Martin M, Tolaney SM, Shao ZM, Fasching PA, Huang CS, Jaliffe GG, Tryakin A, Goetz
MP, Rugo HS, Senkus E, Testa L, Andersson M, Tamura K, Del Mastro L, Steger GG, Kreipe H, Hegg R, Sohn J,
Guarneri V, Cortés J, Hamilton E, André V, Wei R, Barriga S, Sherwood S, Forrester T, Munoz M, Shahir A, San
Antonio B, Nabinger SC, Toi M, Johnston SRD, O'Shaughnessy J; monarchE Committee Members. Adjuvant
abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67
analysis from the monarchE study. Ann Oncol. 2021;32:1571-1581. doi: 10.1016/j.annonc.2021.09.015.
30. Krop IE, Im SA, Barrios C, Bonnefoi H, Gralow J, Toi M, Ellis PA, Gianni L, Swain SM, Im YH, De Laurentiis
M, Nowecki Z, Huang CS, Fehrenbacher L, Ito Y, Shah J, Boulet T, Liu H, Macharia H, Trask P, Song C, Winer
EP, Harbeck N. Trastuzumab emtansine plus pertuzumab versus taxane plus trastuzumab plus pertuzumab after
anthracycline for high-risk human epidermal growth factor receptor 2-positive early breast cancer: The phase III
KAITLIN Study. J Clin Oncol. 2022;40:438-448. doi: 10.1200/JCO.21.00896. Epub 2021 Dec 10.
31. van Mackelenbergh MT, Seither F, Möbus V, O'Shaughnessy J, Martin M, Joensuu H, Untch M, Nitz U, Steger
GG, Miralles JJ, Barrios CH, Toi M, Bear HD, Muss H, Reimer T, Nekljudova V, Loibl S. Effects of capecitabine
as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13
randomised trials including 15,993 patients. Eur J Cancer. 2022;166:185-201. doi: 10.1016/j.ejca.2022.02.003.
32. Kawaguchi H, Yamamoto Y, Saji S, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Takano T,
Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita
T, Yotsumoto D, Toi M, Ohno S. Factors associated with overall survival after recurrence in patients with
ER-positive /HER2-negative postmenopausal breast cancer: an ad hoc analysis of the JBCRG-C06 Safari study.
Jpn J Clin Oncol. 2022;52:545-553. doi: 10.1093/jjco/hyac022.
33. Takahashi M, Tokunaga E, Mori J, Tanizawa Y, van der Walt JS, Kawaguchi T, Goetz MP, Toi M. Japanese
subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone
receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Breast Cancer.
2022; 29:174-184.. doi: 10.1007/s12282-021-01295-0.
34. Yotsumoto D, Sagara Y, Kumamaru H, Niikura N, Miyata H, Kanbayashi C, Tsuda H, Yamamoto Y, Aogi K, Kubo
M, Tamura K, Hayashi N, Miyashita M, Kadoya T, Saji S, Toi M, Imoto S, Jinno H. Trends in adjuvant therapy
after breast-conserving surgery for ductal carcinoma in situ of breast: a retrospective cohort study using the
National Breast Cancer Registry of Japan. Breast Cancer. 2021;29:1-8. doi: 10.1007/s12282-021-01307-z.
35. Fukada I, Ito Y, Kondo N, Ohtani S, Hattori M, Tokunaga E, Matsunami N, Mashino K, Kosaka T, Tanabe M,
Yotsumoto D, Yamanouchi K, Sawaki M, Kashiwaba M, Kawabata H, Kuroi K, Morita S, Ohno S, Toi M, Masuda
9

N. A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with
HER2-negative, locally advanced breast cancer (JBCRG-17). Breast Cancer Res Treat. 2021;190:425-434. doi:
10.1007/s10549-021-06396-0.
36. Tokunaga E, Masuda N, Yamamoto N, Iwata H, Bando H, Aruga T, Ohtani S, Fujisawa T, Takano T, Inoue K,
Suganuma N, Takada M, Aogi K, Sakurai K, Shigematsu H, Kuroi K, Haga H, Ohno S, Morita S, Toi M.
Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab
and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast
Cancer (Neo-Lath Study). Cancers (Basel). 2021;13:4008.
37. Neven P, Johnston SRD, Toi M, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H,
Grischke EM, Conte P, Lu Y, Haddad N, Hurt KC, Llombart-Cussac A, Sledge GW. MONARCH 2: subgroup
analysis of patients receiving abemaciclib plus fulvestrant as first-line and second-line therapy for HR+, HER2advanced breast cancer. Clin Cancer Res. 2021;27:5801-5809. doi:10.1158/1078-0432.CCR-20-4685. Epub 2021
Aug 10.
38. Neven P, Rugo HS, Tolaney SM, Iwata H, Toi M, Goetz MP, Kaufman PA, Lu Y, Haddad N, Hurt KC, Sledge GW
Jr. Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negativeadvanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial. Breast Cancer
Res. 2021;23:87.
39. Miyake KK, Kataoka M, Ishimori T, Matsumoto Y, Torii M, Takada M, Satoh Y, Kubota K, Satake H, Yakami M,
Isoda H, Ikeda DM, Toi M, Nakamoto Y. A proposed dedicated breast PET lexicon: Standardization of description
and reporting of radiotracer uptake in the breast. Diagnostics (Basel). 2021;11:1267.
40. Burstein HJ, Curigliano G, Thürlimann B, Weber WP, Poortmans P, Regan MM, Senn HJ, Winer EP, Gnant M;
Panelists of the St Gallen Consensus Conference. Customizing local and systemic therapies for women with earlybreast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann
Oncol. 2021;32:1216-1235.
41. Tsuge I, Yamanaka H, Seo S, Takada M, Katsube M, Sakamoto M, Toi M, Hatano E, Morimoto N. A novel
real-time navigation system for lymphaticovenular anastomosis using projection mapping with indocyanine green
fluorescence. Plast Reconstr Surg Glob Open. 2021;9:e3758.
42. Johnston S, O'Shaughnessy J, Martin M, Huober J, Toi M, Sohn J, André VAM, Martin HR, Hardebeck MC,
Goetz MP. Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic
subgroups. NPJ Breast Cancer. 2021;7:80. doi: 10.1038/s41523-021-00289-7.
43. Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A,
Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga
JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M,
Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR,
Yothers G, Campbell C, Geyer CE Jr; OlympiA Clinical Trial Steering Committee and Investigators. Adjuvant
olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384:2394-2405. doi:
10.1056/NEJMoa2105215.
44. Nakamura Y, Takada M, Imamura M, Higami A, Jiaxi H, Fujino M, Nakagawa R, Inagaki Y, Matsumoto Y,
Kawaguchi K, Kawashima M, Suzuki E, Toi M. Usefulness and prospects of sentinel lymph node biopsy forpatients with breast cancer using the medical imaging projection system. Front Oncol. 2021;11:674419. doi:
10.3389/fonc.2021.674419. eCollection 2021.
45. Senda N, Kawaguchi-Sakita N, Kawashima M, Inagaki-Kawata Y, Yoshida K, Takada M, Kataoka M, Torii M,
Nishimura T, Kawaguchi K, Suzuki E, Kataoka Y, Matsumoto Y, Yoshibayashi H, Yamagami K, Tsuyuki S,
Takahara S, Yamauchi A, Shinkura N, Kato H, Moriguchi Y, Okamura R, Kan N, Suwa H, Sakata S, Mashima S,
Yotsumoto F, Tachibana T, Tanaka M, Togashi K, Haga H, Yamada T, Kosugi S, Inamoto T, Sugimoto M, Ogawa
10

S, Toi M. Optimization of prediction methods for risk assessment of pathogenic germline variants in the Japanese
population. Cancer Sci. 2021;112:3338-3348. doi: 10.1111/cas.14986. Epub 2021 Jun 28.
46. Yamaguchi A, Honda M, Ishiguro H, Kataoka M, Kataoka TR, Shimizu H, Torii M, Mori Y, Kawaguchi-Sakita N,
Ueno K, Kawashima M, Takada M, Suzuki E, Nakamoto Y, Kawaguchi K, Toi M. Kinetic information fromdynamic contrast-enhanced MRI enables prediction of residual cancer burden and prognosis in triple-negative
breast cancer: a retrospective study. Sci Rep. 2021;11:10112. doi: 10.1038/s41598-021-89380-4.
47. Itou J, Nakamura A, Hokazono H, Toi M. Supplementation with Fermented Barley Extract Prevents Mammary
Epithelial Cell Invasion in an Early Breast Cancer Model. Acta Histochem Cytochem. 2021;54:73-78. doi:
10.1267/ahc.20-00029. Epub 2021 Feb 27.
48. Toi M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Shimizu A, Ikeda T, Haga H, Saeki T, Aogi
K, Sugie T, Ueno T, Kinoshita T, Kai Y, Kitada M, Sato Y, Jimbo K, Sato N, Ishiguro H, Takada M, Ohashi Y,
Ohno S. Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast
cancer: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol 2021;22:74-84.
49. Piccart M, Procter M, Fumagalli D, de Azambuja E, Clark E, Ewer MS, Restuccia E, Jerusalem G, Dent S, Reaby
L, Bonnefoi H, Krop I, Liu TW, Pieńkowski T, Toi M, Wilcken N, Andersson M, Im YH, Tseng LM, Lueck HJ,
Colleoni M, Monturus E, Sicoe M, Guillaume S, Bines J, Gelber RD, Viale G, Thomssen C; APHINITY Steering
Committee and Investigators. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the
APHINITY trial: 6 years' follow-up. J Clin Oncol 2021;39:1448-1457. doi: 10.1200/JCO.20.01204. Epub 2021
Feb 4.
50. Iwata H, Umeyama Y, Liu Y, Zhang Z, Schnell P, Mori Y, Fletcher O, Marshall JC, Johnson JG, Wood LS, Toi M,
Finn RS, Turner NC, Bartlett CH, Cristofanilli M. Evaluation of the association of polymorphisms withpalbociclib-induced neutropenia: pharmacogenetic analysis of PALOMA-2/-3. Oncologist 2021;26:e1143-e1155.
doi: 10.1002/onco.13811. Epub 2021 Jun 7..
51. Aogi K, Watanabe K, Kitada M, Sangai T, Ohtani S, Aruga T, Kawagichi H, Fujisawa T, Maeda S, Morimoto T,
Sato N, Takao S, Morita S, Masuda N, Toi M, Ohno S. Clinical usefulness of eribulin as first- or second-line
chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19). Int J Clin
Oncol. 2021;26:1229-1236. doi: 10.1007/s10147-021-01920-0. Epub 2021 Apr 23..
52. Iima M, Kataoka M, Honda M, Ohashi A, Ohno-Kishimoto A, Ota R, Uozumi R, Urushibata Y, Feiweier T, Toi M,
Nakamoto Y. The Rate of Apparent Diffusion Coefficient Change With Diffusion Time on Breast
Diffusion-Weighted Imaging Depends on Breast Tumor Types and Molecular Prognostic Biomarker Expression.
Invest Radiol 2021;56:501-508. doi: 10.1097/RLI.0000000000000766.
53. Toi M, Inoue K, Masuda N, Iwata H, Sohn J, Hae Park I, Im SA, Chen SC, Enatsu S, Turner PK, André VAM,
Hardebeck MC, Sakaguchi S, Goetz MP, Sledge GW Jr. Abemaciclib in combination with endocrine therapy for
East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials. Cancer Sci
2021;112:2381-2392. doi: 10.1111/cas.14877. Epub 2021 May 1.
54. Goetz MP, Okera M, Wildiers H, Campone M, Grischke EM, Manso L, André VAM, Chouaki N, San Antonio
B, Toi M, Sledge GW Jr. Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone
receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specificsubgroup analysis of MONARCH 2 and 3 trials. Breast Cancer Res Treat 2021;186:417-428. doi:
10.1007/s10549-020-06029-y. Online ahead of print.
55. Masuda N, Bando H, Yamanaka T, Kadoya T, Takahashi M, Nagai SE, Ohtani S, Aruga T, Suzuki E, Kikawa Y,
Yasojima H, Kasai H, Ishiguro H, Kawabata H, Morita S, Haga H, Kataoka TR, Uozumi R, Ohno S, Toi M.
Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous
recombination deficiency status: a multicenter randomized phase II clinical trial. Breast Cancer Res Treat
2021;188:117-131. Mar 25. doi: 10.1007/s10549-021-06184-w.
1156. Johnston SRD, Harbeck N, Toi M, Martin M, O'Shaughnessy J, Rastogi P. Reply to K. Hashimoto and A.
Shimomura. J Clin Oncol 2021 Feb 25: doi: 10.1200/JCO.20.03477. Online ahead of print.
57. Ohno-Kishimoto A, Kataoka M, Iima M, Honda M, Miyake KK, Ohashi A, Ota R, Kataoka T, Sakurai T, Toi M,
Togashi K. Evaluation of malignant breast lesions using high-resolution readout-segmented diffusion-weighted
echo-planar imaging: comparison with pathology. Magn Reson Med Sci 2021;20:204-215.
doi:10.2463/mrms.mp.2020-0021.
58. Loibl S, Marmé F, Martin M, Untch M, Bonnefoi H, Kim SB, Bear H, McCarthy N, Melé Olivé M, Gelmon K,
García-Sáenz J, Kelly CM, Reimer T, Toi M, Rugo HS, Denkert C, Gnant M, Makris A, Koehler M,
Huang-Bartelett C, Lechuga Frean MJ, Colleoni M, Werutsky G, Seiler S, Burchardi N, Nekljudova V, vonMinckwitz G. Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast
cancer-The Penelope-B trial. J Clin Oncol 2021;39:1518-1530. doi: 10.1200/JCO.20.03639.
59. Moreno-Aspitia A, Holmes EM, Jackisch C, de Azambuja E, Boyle F, Hillman DW, Korde L, Fumagalli D,
Izquierdo MA, McCullough AE, Wolff AC, Pritchard KI, Untch M, Guillaume S, Ewer MS, Shao Z, Sim SH, Aziz
Z, Demetriou G, Mehta AO, Andersson M, Toi M, Lang I, Xu B, Smith IE, Barrios CH, Baselga J, Gelber RD,
Piccart-Gebhart M; ALTTO Steering Committee and Investigators. Updated results from the international phase
III ALTTO trial (BIG 2-06/Alliance N063D). Eur J Cancer 2021;148:287-296. doi: 10.1016/j.ejca.2021.01.053.
60. Inoue K, Masuda N, Iwata H, Takahashi M, Ito Y, Miyoshi Y, Nakayama T, Mukai H, van der Walt JS, Mori J,
Sakaguchi S, Kawaguchi T, Tanizawa Y, Llombart-Cussac A, Sledge GW Jr, Toi M. Japanese subpopulation
analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone
receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine
therapy. Breast Cancer 2021;28:1038-1050. doi: 10.1007/s12282-021-01239-8.
61. Yamamoto Y, Yamashiro H, Toh U, Kondo N, Nakamura R, Kashiwaba M, Takahashi M, Tsugawa K, Ishikawa T,
Nakayama T, Ohtani S, Takano T, Fujisawa T, Toyama T, Kawaguchi H, Mashino K, Tanino Y, Morita S, Toi M,
Ohno S. Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line
chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study. Breast Cancer
2021;28:145-160. doi: 10.1007/s12282-020-01138-4.
62. Yamashita T, Kawaguchi H, Masuda N, Kitada M, Narui K, Hattori M, Yoshinami T, Matsunami N, Yanagihara K,
Kawasoe T, Nagashima T, Bando H, Yano H, Hasegawa Y, Nakamura R, Kashiwaba M, Morita S, Ohno S, Toi M.
Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor
receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03
study). Invest New Drugs 2021;39:217-225. doi: 10.1007/s10637-020-00991-6.
63. Nishie M, Suzuki E, Hattori M, Kawaguch K, Kataoka TR, Hirata M, Pu F, Kotake T, Tsuda M, Yamaguchi A,
Sugie T, Toi M. Downregulated ATP6V1B1 expression acidifies the intracellular environment of cancer cells
leading to resistance to antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother 2021;70:817-830..
doi: 10.1007/s00262-020-02732-3.
64. Inagaki-Kawata Y, Yoshida K, Kawaguchi-Sakita N, Kawashima M, Nishimura T, Senda N, Shiozawa Y, Takeuchi
Y, Inoue Y, Sato-Otsubo A, Fujii Y, Nannya Y, Suzuki E, Takada M, Tanaka H, Shiraishi Y, Chiba K, Kataoka Y,
Torii M, Yoshibayashi H, Yamagami K, Okamura R, Moriguchi Y, Kato H, Tsuyuki S, Yamauchi A, Suwa H,
Inamoto T, Miyano S, Ogawa S, Toi M. Genetic and clinical landscape of breast cancers with germline BRCA1/2
variants. Commun Biol 2020;3:578. doi: 10.1038/s42003-020-01301-9.
65. Masuda N, Mukai H, Inoue K, Rai Y, Ohno S, Ohtani S, Shimizu C, Hashigaki S, Muramatsu Y, Umeyama Y,
Iwata H, Toi M. Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/humanepidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine
therapy in PALOMA-2 and -3. Breast Cancer 2021;28:335-345.. doi: 10.1007/s12282-020-01162-4.
66. Tsuda M, Ishiguro H, Toriguchi N, Masuda N, Bando H, Ohgami M, Homma M, Morita S, Yamamoto N, Kuroi K,
Yanagita Y, Takano T, Shimizu S, Toi M. Overnight fasting before lapatinib administration to breast cancer
12patients leads to reduced toxicity compared with nighttime dosing: a retrospective cohort study from a randomized
clinical trial. Cancer Med 2020;9:9246-9255. doi: 10.1002/cam4.3528.
67. Sagara Y, Mori M, Yamamoto S, Eguchi K, Iwatani T, Naito Y, Kogawa T, Tanaka K, Kotani H, Yasojima H,
Ozaki Y, Noguchi E, Miyasita M, Kondo N, Niikura N, Toi M, Shien T, Iwata H. Current status of advance careplanning and end-of-life communication for patients with advanced and metastatic breast cancer. Oncologist
2021;26:e686-e693.. doi: 10.1002/onco.13640.
68. Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, Zhang QY, Martinez Rodriguez JL, Campone M,
Hamilton E, Sohn J, Guarneri V, Okada M, Boyle F, Neven P, Cortés J, Huober J, Wardley A, Tolaney SM, Cicin I,
Smith IC, Frenzel M, Headley D, Wei R, San Antonio B, Hulstijn M, Cox J, O'Shaughnessy J, Rastogi P;
monarchE Committee Members and Investigators. Abemaciclib combined with endocrine therapy for the adjuvant
treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol 2020;
38:3987-3998. doi: 10.1200/JCO.20.02514. Epub 2020 Sep 20.
69. Honda M, Kataoka M, Kawaguchi K, Iima M, Miyake KK, Ohno-Kishimoto A, Ota R, Ohashi A, Toi M,
Nakamoto Y. Subcategory classifications of breast imaging and data system (BI-RADS) category 4 lesions on
MRI. Jpn J Radiol 2021;39:56-65. doi: 10.1007/s11604-020-01029-w. Epub 2020 Sep 1.
70. Kawashima M, Bensaad K, Zois CE, Barberis A, Bridges E, Wigfield S, Lagerholm C, Dmitriev RI, Tokiwa
M, Toi M, Papkovsky DB, Buffa FM, Harris AL. Disruption of hypoxia-inducible fatty acid binding protein 7
induces beige fat-like differentiation and thermogenesis in breast cancer cells. Cancer Metab 2020;8:13. doi:
10.1186/s40170-020-00219-4. eCollection 2020.. eCollection 2020. correction Cancer Metab 2020 Aug 10;8:18
71. Yamamoto Y, Yamashiro H, Toh U, Kondo N, Nakamura R, Kashiwaba M, Takahashi M, Tsugawa K, Ishikawa T,
Nakayama T, Ohtani S, Takano T, Fujisawa T, Toyama T, Kawaguchi H, Mashino K, Tanino Y, Morita S, Toi M,
Ohno S. Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line
chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study. Breast Cancer
2021;28:145-160. doi: 10.1007/s12282-020-01138-4. Epub 2020 Jul 26.
72. Kawashima M, Tokiwa M, Nishimura T, Kawata Y, Sugimoto M, Kataoka TR, Sakurai T, Iwaisako K, Suzuki E,
Hagiwara M, Harris AL, Toi M. High-resolution imaging mass spectrometry combined with transcriptomic
analysis identified a link between fatty acid composition of phosphatidylinositols and the immune checkpoint
pathway at the primary tumour site of breast cancer. Br J Cancer 122:245-257, 2020. Epub 2019 Dec 10.
73. Ohno-Kishimoto A, Kataoka M, Iima M, Honda M, Miyake KK, Ohashi A, Ota R, Kataoka T, Sakurai T, Toi M,
Togashi K. Evaluation of malignant breast lesions using high-resolution readout-segmented diffusion-weighted
echo-planar imaging: comparison with pathology. Magn Reson Med Sci 2021;20:204-215. doi:
10.2463/mrms.mp.2020-0021. Epub 2020 Jul 2.
74. Tsuge I, Saito S, Yamamoto G, Sekiguchi H, Yoshikawa A, Matsumoto Y, Suzuki S, Toi M. Preoperative vascularmapping for anterolateral thigh flap surgeries: A clinical trial of photoacoustic tomography imaging. Microsurgery
40:324-330, 2020. Epub 2019 Nov 12.
75. Goetz MP, Martin M, Tokunaga E, Park IH, Huober J, Toi M, Stoffregen C, Shekarriz S, Andre V, Gainford MC,
Price GL, Johnston S. Health-related quality of life in MONARCH 3: Abemaciclib plus an aromatase inhibitor as
initial therapy in HR+, HER2- advanced breast cancer. Oncologist 25:e1346-e1354, 2020.
76. Lin X, Matsumoto Y, Nakakimura T, Ono K, Umeoka S, Torii M, Yoshibayashi H, Toi M. Invasive solid papillarycarcinoma with neuroendocrine differentiation of the breast: a case report and literature review. Surg Case Rep
6:143, 2020.
77. Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E,
Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yamamoto
Y, Yotsumoto D, Toi M, Ohno S. Factors associated with prolonged overall survival in patients with
postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of
the JBCRG-C06 Safari study. Breast Cancer 27:389-398, 2020. Epub 2019 Dec 6.
13

78. Shibata T, Watari K, Kawahara A, Sudo T, Hattori S, Murakami Y, Izumi H, Itou J, Toi M, Akiba J, Akagi Y,
Tanaka M, Kuwano M, Ono M., Targeting Phosphorylation of Y-Box-Binding Protein YBX1 by TAS0612 andEverolimus in Overcoming Antiestrogen Resistance. Mol Cancer Ther 19:882-894, 2020. Epub 2019 Dec 26.
79. Itou J, Takahashi R, Sasanuma H, Tsuda M, Morimoto S, Matsumoto Y, Ishii T, Sato F, Takeda S, Toi M. Estrogen
induces mammary ductal dysplasia via the upregulation of myc expression in a DNA-repair-deficient condition.
iScience 23: 100821, 2020. Epub 2020 Jan 9.
80. Masuda N, Ohtani S, Takano T, Inoue K, Suzuki E, Nakamura R, Bando H, Ito Y, Ishida K, Yamanaka T, Kuroi K,
Yasojima H, Kasai H, Takasuka T, Sakurai T, Kataoka TR, Morita S, Ohno S, Toi M. A randomized, 3-arm,neoadjuvant, phase 2 study comparing docetaxel+carboplatin+trastuzumab+pertuzumab (TCbHP), TCbHP
followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast
cancer. Breast Cancer Res Treat 180:135-146, 2020. Epub 2020 Jan 17.
81. Ueno T, Masuda N, Sato N, Ohtani S, Yamamura J, Matsunami N, Kashiwaba M, Takano T, Takahashi M, Kaneko
K, Ohno S, Morita S, Toi M. Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide
and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study. Jpn J Clin Oncol 50:3-11, 2020.
82. Yamashiro H, Iwata H, Masuda N, Yamamoto N, Nishimura R, Ohtani S, Sato N, Takahashi M, Kamio T,
Yamazaki K, Saito T, Kato M, Lee T, Kuroi K, Takano T, Yasuno S, Morita S, Ohno S, Toi M. JBCRG-C01
Collaborative Group. Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended
follow-up of JBCRG-cohort study 01. Breast Cancer 2020;27:631-641. doi: 10.1007/s12282-020-01057-4. Epub2020 Feb 14.
83. Poudel S, Hirano S, Kurashima Y, Stefanidis D, Akiyama H, Eguchi S, Fukui T, Hagiwara M, Hashimoto D, Hida
K, Izaki T, Iwase H, Kawamoto S, Otomo Y, Nagai E, Saito M, Takami H, Takeda Y, Toi M, Yamaue H, Yoshida
M, Yoshida S, Kodera Y. Japan Surgical Society Residency Curriculum Review Working Group; Japan SurgicalSociety Education Committee. Are graduating residents sufficiently competent? Results of a national gap analysis
survey of program directors and graduating residents in Japan. Surg Today 2020;50:995-1001. doi:
10.1007/s00595-020-01981-0. Epub 2020 Mar 3.
84. Ishiguro H, Masuda N, Sato N, Higaki K, Morimoto T, Yanagita Y, Mizutani M, Ohtani S, Kaneko K, Fujisawa T,
Takahashi M, Kadoya T, Matsunami N, Yamamoto Y, Ohno S, Takano T, Morita S, Tanaka-Mizuno S, Toi M. A
randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide(FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative
primary breast cancer. Breast Cancer Res Treat 180:715-724, 2020. Epub 2020 Mar 13.
85. Tanaka S, Ishii T, Sato F, Toi M, Itou J. Eribulin mesylate-induced c-Fos upregulation enhances cell survival inbreast cancer cell lines. Biochem Biophys Res Commun 526:154-157, 2020. Epub 2020 Mar 19.
86. Al Mahmud MR, Ishii K, Bernal-Lozano C, Delgado-Sainz I, Toi M, Akamatsu S, Fukumoto M, Watanabe M,
Takeda S, Cortes-Ledesma F, Sasanuma H. TDP2 suppresses genomic instability induced by androgens in theepithelial cells of prostate glands. Genes Cells 2020;25:450-465. doi: 10.1111/gtc.12770. Epub 2020 May 5.
87. Ohashi A, Kataoka M, Iima M, Kanao S, Honda M, Urushibata Y, Nickel MD, Ohno-Kishimoto A, Ota R, Toi M,
Togashi K. A multiparametric approach to diagnosing breast lesions using diffusion-weighted imaging andultrafast dynamic contrast-enhanced MRI. Magn Reson Imaging 2020;71:154-160. doi:
10.1016/j.mri.2020.04.008. Epub 2020 Apr 14.
88. Honda M, Kataoka M, Iima M, Miyake KK, Ohashi A, Ohno-Kishimoto A, Ota R, Nickel MD, Toi M, Togashi K.
Background parenchymal enhancement and its effect on lesion detectability in ultrafast dynamic
contrast-enhanced MRI. Eur J Radiol 2020;129:108984. doi: 10.1016/j.ejrad.2020.108984. Epub 2020 Apr 18.
89. Ohno-Kishimoto A, Kataoka M, Iima M, Honda M, Miyake KK, Ohashi A, Ota R, Kataoka T, Sakurai T, Toi M,
Togashi K. The comparison of high-resolution diffusion weighted imaging (DWI) with high-resolution
contrast-enhanced MRI in the evaluation of breast cancers. Magn Reson Imaging 2020;71:161-169. doi:14

10.1016/j.mri.2020.03.007. Epub 2020 Apr 19..
90. Takahashi M, Masuda N, Nishimura R, Inoue K, Ohno S, Iwata H, Hashigaki S, Muramatsu Y, Umeyama Y, Toi
M. Palbociclib-letrozole as first-line treatment for advanced breast cancer: Updated results from a Japanese phase2 study. Cancer Med 2020;9:4929-4940. doi: 10.1002/cam4.3091. Epub 2020 May 18.
91. Hashimoto D, Poudel S, Hirano S, Kurashima Y, Akiyama H, Eguchi S, Fukui T, Hagiwara M, Hida K, Izaki T,
Iwase H, Kawamoto S, Otomo Y, Nagai E, Saito M, Takami H, Takeda Y, Toi M, Yamaue H, Yoshida M, Yoshida
S, Ohki T, Kodera Y. Japan Surgical Society Residency Curriculum Review Working Group, Japan SurgicalSociety Education Committee. Is there disparity between regions and facilities in surgical resident training inJapan? Insights from a national survey. Surg Today 2020;50:1585-1593. doi: 10.1007/s00595-020-02037-z. Epub2020 Jun 2.
92. Im SA, Mukai H, Park IH, Masuda N, Shimizu C, Kim SB, Im YH, Ohtani S, Huang Bartlett C, Lu DR, Iyer S,
Mori Y, Mori A, Gauthier E, Finn RS, Toi M. Palbociclib plus letrozole as first-line therapy in postmenopausal
Asian women with metastatic breast cancer: results from the phase III, randomized PALOMA-2 study. J Glob
Oncol 2019;5:1-19. doi: 10.1200/JGO.18.00173.
93. Poudel S, Hirano S, Kurashima Y, Stefanidis D, Akiyama H, Eguchi S, Fukui T, Hagiwara M, Hashimoto D, Hida
K, Izaki T, Iwase H, Kawamoto S, Otomo Y, Nagai E, Saito M, Takami H, Takeda Y, Toi M, Yamaue H, Yoshida
M, Yoshida S, Kodera Y. A snapshot of surgical resident training in Japan: results of a national-level needs
assessment survey. Surg Today 49:870-876, 2019. Epub 2019 May 17.
94. Sakaguchi R, Kataoka M, Kanao S, Miyake KK, Nakamoto Y, Sugie T, Toi M, Mikami Y, Togashi K., Distribution
pattern of FDG uptake using ring-type dedicated breast PET in comparison to whole-body PET/CT scanning ininvasive breast cancer. Ann Nucl Med 33:570-578, 2019. Epub 2019 May 21.
95. Masuda N, Mukai H, Inoue K, Rai Y, Ohno S, Mori Y, Hashigaki S, Muramatsu Y, Umeyama Y, Iwata H, Toi M.
Neutropenia management with palbociclib in Japanese patients with advanced breast cancer. Breast Cancer
26:637-650, 2019. Epub 2019 May 24.
96. Perez EA, de Haas SL, Eiermann W, Barrios CH, Toi M, Im YH, Conte PF, Martin M, Pienkowski T, Pivot XB,
Burris HA 3rd, Stanzel S, Patre M, Ellis PA., Relationship between tumor biomarkers and efficacy in
MARIANNE, a phase III study of trastuzumab emtansine ±pertuzumab versus trastuzumab plus taxane in
HER2-positive advanced breast cancer. BMC Cancer 19:517, 2019.
97. Ohashi A, Kataoka M, Kanao S, Iima M, Murata K, Weiland E, Onishi N, Kawai M, Toi M, Togashi K.,
Diagnostic performance of maximum slope: A kinetic parameter obtained from ultrafast dynamic
contrast-enhanced magnetic resonance imaging of the breast using k-space weighted image contrast (KWIC). Eur
J Radiol 2019; 118:285-292.Epub 2019 Jun 12.
98. Honda M, Kataoka M, Onishi N, Iima M, Ohashi A, Kanao S, Nickel MD, Toi M, Togashi K., New parameters ofultrafast dynamic contrast-enhanced breast MRI using compressed sensing. J Magn Reson Imaging 51:164-174,
2020. Epub 2019 Jun 18.
99. Ono Y, Yoshimura M, Hirata K, Yamauchi C, Toi M, Suzuki E, Takada M, Hiraoka M, Mizowaki T., The impactof age on the risk of ipsilateral breast tumor recurrence after breast-conserving therapy in breast cancer patientswith a >5 mm margin treated without boost irradiation. Radiat Oncol 14:121, 2019.
100.
Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot XB, Burris HA
3rd, Petersen JA, De Haas S, Hoersch S, Patre M, Ellis PA., Trastuzumab emtansine with or without pertuzumab
versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer:
Final results from MARIANNE. Cancer 125:3974-3984, 2019. Epub 2019 Jul 18.
101.
Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita
S, Ohno S, Toi M. Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored byclinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor-positive breast15

cancer: A multicenter, open-label, phase II study. Cancer Med 8:5468-5481, 2019. Epub 2019 Jul 30.
102.
Tanaka S, Senda N, Iida A, Sehara-Fujisawa A, Ishii T, Sato F, Toi M, Itou J. In silico analysis-based
identification of the target residue of integrin α6 for metastasis inhibition of basal-like breast cancer. Genes Cells
24:596-607, 2019. Epub 2019 Aug 5.
103.
Kinoshita T, Nakayama T, Fukuma E, Inokuchi M, Ishiguro H, Ogo E, Kikuchi M, Jinno H, Yamazaki N,
Toi M. Efficacy of scalp cooling in preventing and recovering from chemotherapy-induced alopecia in breast
cancer patients: The HOPE study. Front Oncol 2019;9:733.
104.
Masuda N, Mukai H, Inoue K, Rai Y, Ohno S, Mori Y, Hashigaki S, Muramatsu Y, Umeyama Y, Iwata H,
Toi M. Correction to: Neutropenia management with palbociclib in Japanese patients with advanced breast cancer.
Breast Cancer 2019;26:651.
105.
Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA,
Koh H, Grischke EM, Conte P, Lu Y, Barriga S, Hurt K, Frenzel M, Johnston S, Llombart-Cussac A. The effect of
abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that
progressed on endocrine therapy-MONARCH 2: A randomized clinical trial. JAMA Oncol 29:116-24, 2019.
106.
Kaufman PA, Toi M, Neven P, Sohn J, Grischke EM, Andre V, Stoffregen C, Shekarriz S, Price GL, Carter
GC, Sledge GW Jr. Health-Related Quality of Life in MONARCH 2: Abemaciclib plus fulvestrant in hormone
receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. Oncologist 25:e243-e251, 2020.
Epub 2019 Oct 24.
107.
Ueno T, Saji S, Masuda N, Iwata H, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H,
Hisamatsu K, Aogi K, Sasano H, Toi M. Changes in Recurrence Score by neoadjuvant endocrine therapy of breast
cancer and their prognostic implication. ESMO Open 2019;4:e000476.
108.
Sasanuma H, Tsuda M, Morimoto S, Saha LK, Rahman MM, Kiyooka Y, Fujiike H, Cherniack AD, Itou J,
Callen Moreu E, Toi M, Nakada S, Tanaka H, Tsutsui K, Yamada S, Nussenzweig A, Takeda S. BRCA1 ensures
genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes. Proc Natl Acad
Sci USA 2018;115:E10642-E10651. doi: 10.1073/pnas.1803177115. Epub 2018 Oct 23.
109.
Fukui Y, Kawashima M, Kawaguchi K, Takeuchi M, Hirata M, Kataoka TR, Sakurai T, Kataoka M, Kanao
S, Nakamoto Y, Hirata K, Yoshimura M, Yoshikawa K, Ishiguro H, Toi M. Granulocyte-colony-stimulating
factor-producing metaplastic carcinoma of the breast with significant elevation of serum interleukin-17 andvascular endothelial growth factor levels. Int Cancer Conf J 7:107-113, 2018.
110.
Nagae K, Asao Y, Sudo Y, Murayama N, Tanaka Y, Ohira K, Ishida Y, Otsuka A, Matsumoto Y, Saito S,
Furu M, Murata K, Sekiguchi H, Kataoka M, Yoshikawa A, Ishii T, Togashi K, Shiina T, Kabashima K, Toi M,
Yagi T. Real-time 3D photoacoustic visualization system with a wide field of view for imaging human limbs.
F1000Res 2018; 7:1813. doi: 10.12688/f1000research.16743.1. eCollection 2018.
111.
Mukai H, Shimizu C, Masuda N, Ohtani S, Ohno S, Takahashi M, Yamamoto Y, Nishimura R, Sato N,
Ohsumi S, Iwata H, Mori Y, Hashigaki S, Muramatsu Y, Nagasawa T, Umeyama Y, Lu DR, Toi M. Palbociclib in
combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor
2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. Int J Clin Oncol
24:274-287, 2019. doi: 10.1007/s10147-018-1353-9. Epub 2018 Dec 4112.
Sagawa H, Kataoka M, Kanao S, Onishi N, Nickel MD, Toi M, Togashi K. Impact of the number ofinteractions in compressed sensing reconstruction on ultrafast dynamic contrast-enhanced breast MR imaging.
Magn Reson Med Sci 2019;18:200-207. doi: 10.2463/mrms.mp.2018-0015. Epub 2018 Nov 9.
113.
Shibata T, Tokunaga E, Hattori S, Watari K, Murakami Y, Yamashita N, Oki E, Itou J, Toi M, Maehara Y,
Kuwano M, Ono M. Y-box binding protein YBX1 and its correlated genes as biomarkers for poor outcomes inpatients with breast cancer. Oncotarget 9:37216-37228, 2018. doi: 10.18632/oncotarget.26469. eCollection 2018
Dec 14.
16

114.
Johnston S, Martin M, Di Leo A, Im SA, Awada A, Forrester T, Frenzel M, Hardebeck MC, Cox J, Barriga
S, Toi M, Iwata H, Goetz MP. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy foradvanced breast cancer. NPJ Breast Cancer 2019; 5:5. doi: 10.1038/s41523-018-0097-z. eCollection 2019.
115.
Kitada K, Pu F, Toi M. Occurrence of senescence-escaping cells in doxorubicin-induced senescence isenhanced by PD0332991, a cyclin-dependent kinase 4/6 inhibitor, in colon cancer HCT116 cells. Oncol Lett
17:1153-1159, 2019. doi: 10.3892/ol.2018.9657. Epub 2018 Nov 1.
116.
Kawaguchi K, Sakurai M, Yamamoto Y, Suzuki E, Tsuda M, Kataoka TR, Hirata M, Nishie M, Nojiri T,
Kumazoe M, Saito K, Toi M. Alteration of specific cytokine expression patterns in patients with breast cancer. Sci
Rep 9:2924, 2019. doi: 10.1038/s41598-019-39476-9.
117.
Ueno T, Saji S, Chiba T, Kamma H, Isaka H, Itoh H, Imi K, Miyamoto K, Tada M, Sasano H, Toi M,
Imoto S. Progesterone receptor expression in proliferating cancer cells of hormone-receptor-positive breast cancer.
Tumour Biol 2018;40: 1010428318811025. doi: 10.1177/1010428318811025.
118.
Ueno T, Masuda N, Kamigaki S, Morimoto T, Saji S, Imoto S, Sasano H, Toi M. Differential involvementof autophagy and apoptosis in response to chemoendocrine and endocrine therapy in breast cancer: JBCRG-07TR.
Int J Mol Sci 2019;20. pii: E984. doi: 10.3390/ijms20040984.
119.
Ishiguro H, Ohno S, Yamamoto Y, Takao S, Sato N, Fujisawa T, Kadoya T, Kuroi K, Bando H, Teramura
Y, Iwata H, Tanaka S, Toi M. Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulatorswith intra-patient dose escalation in breast cancer. Breast Cancer 2019;26:535-543. doi:
10.1007/s12282-019-00952-9. Epub 2019 Feb 7.
120.
Kikawa Y, Kotake T, Kajiwara Y, Hashimoto K, Yamashiro H, Ohtani S, Takao S, Toi M. ClinicalPredictive Factors for the Efficacy of Everolimus in Patients With Hormone Receptor-Positive, HER2-Negative
Advanced Breast Cancer: A Multicenter Retrospective Cohort Study in Japan. Breast Cancer (Auckl)
2019;13:1178223418825135. doi: 10.1177/1178223418825135. eCollection 2019.
121.
Saito S, Bise R, Yoshikawa A, Sekiguchi H, Tsuge I, Toi M. Digital artery deformation on movement of
the proximal interphalangeal joint. J Hand Surg Eur 2019 ;44:187-195. doi: 10.1177/1753193418807833. Epub
2018 Oct 18.
122.
Suzuki E, Sugimoto M, Kawaguchi K, Pu F, Uozumi R, Yamaguchi A, Nishie M, Tsuda M, Kotake T,
Morita S, Toi M. Gene expression profile of peripheral blood mononuclear cells may contribute to theidentification and immunological classification of breast cancer patients. Breast Cancer 2019;26:282-289. doi:
10.1007/s12282-018-0920-2. Epub 2018 Oct 13.
123.
Matsumoto Y, Asao Y, Sekiguchi H, Yoshikawa A, Ishii T, Nagae KI, Kobayashi S, Tsuge I, Saito S,
Takada M, Ishida Y, Kataoka M, Sakurai T, Yagi T, Kabashima K, Suzuki S, Togashi K, Shiina T, Toi M.
Visualising peripheral arterioles and venules through high-resolution and large-area photoacoustic imaging. Sci
Rep 8:14930, 2018. doi: 10.1038/s41598-018-33255-8.
124.
Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita
S, Ohno S, Toi M. Neoadjuvant endocrine therapy with exemestane followed by response-guided combination
therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast
cancer: A multicenter, open-label, phase II study. Cancer Med 2018;7:3044-3056. doi: 10.1002/cam4.1600. Epub
2018 Jun 14.
125.
Sagara Y, Takada M, Ohi Y, Ohtani S, Kurozumi S, Inoue K, Kosaka Y, Hattori M, Yamashita T, Takao S,
Sato N, Iwata H, Kurosumi M, Toi M. Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal
HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group(JBCRG)-C03. Breast Cancer Res Treat 171:675-683, 2018. doi: 10.1007/s10549-018-4873-0. Epub 2018 Jul 3.

17

126.
Hanai A, Ishiguro H, Sozu T, Tsuda M, Yano I, Nakagawa T, Imai S, Hamabe Y, Toi M, Arai H,
Tsuboyama T. Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy:
Prospective Self-Controlled Trial. J Natl Cancer Inst 110:141-148, 2018. doi: 10.1093/jnci/djx178.
127.
Kiso M, Tanaka S, Saji S, Toi M, Sato F. Long isoform of VEGF stimulates cell migration of breast cancer
by filopodia formation via NRP1/ARHGAP17/Cdc42 regulatory network. Int J Cancer 2018;143:2905-2918. doi:
10.1002/ijc.31645. Epub 2018 Oct 9.
128.
Yamaga I, Kawaguchi-Sakita N, Asao Y, Matsumoto Y, Yoshikawa A, Fukui T, Takada M, Kataoka M,
Kawashima M, Fakhrejahani E, Kanao S, Nakayama Y, Tokiwa M, Torii M, Yagi T, Sakurai T, Haga H, Togashi
K, Shiina T, Toi M. Vascular branching point counts using photoacoustic imaging in the superficial layer of thebreast: A potential biomarker for breast cancer. Photoacoustics 2018;11:6-13. doi: 10.1016/j.pacs.2018.06.002.
eCollection 2018 Sep.
129.
Yamashiro H, Sawaki M, Masuda N, Okumura Y, Takano T, Tokunaga E, Saito T, Sagara Y, Yamazaki K,
Kawaguchi Y, Lee T, Ozaki S, Yamagami K, Yamamoto N, Kuroi K, Suwa H, Ohtani S, Ito T, Yasuno S, Morita
S, Ohno S, Toi M. Survival outcomes of retreatment with trastuzumab and cytotoxic chemotherapy for
HER2-positive recurrent patients with breast cancer who had been treated with neo/adjuvant trastuzumab plus
multidrug chemotherapy: A Japanese multicenter observational study. Breast Cancer (Auckl) 2018;12:1178223418786243. doi: 10.1177/1178223418786243. eCollection 2018.
130.
Yamamoto Y, Iwata H, Ueno T, Taira N, Kashiwaba M, Takahashi M, Tada H, Tsugawa K, Toyama T,
Niikura N, Hara F, Fujisawa T, Yoshinami T, Saji S, Takano T, Masuda N, Morita S, Toi M, Ohno S. A
randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic
breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast
Cancer Research Group-M05 PRECIOUS study. Jpn J Clin Oncol 48:855-859, 2018. doi: 10.1093/jjco/hyy097.
131.
Takada M, Sugimoto M, Masuda N, Iwata H, Kuroi K, Yamashiro H, Ohno S, Ishiguro H, Inamoto T, Toi
M. Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patientstreated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm. Breast Cancer Res
Treat 2018;172:611-618. doi: 10.1007/s10549-018-4958-9. Epub 2018 Sep 7.
132.
Mackenzie LJ, Carey ML, Suzuki E, Sanson-Fisher RW, Asada H, Ogura M, D'Este C, Yoshimura M, Toi
M. Agreement between patients' and radiation oncologists' cancer diagnosis and prognosis perceptions: A crosssectional study in Japan. PLoS One 2018;13:e0198437. doi: 10.1371/journal.pone.0198437.
133.
Takada M, Takeuchi M, Suzuki E, Sato F, Matsumoto Y, Torii M, Kawaguchi-Sakita N, Nishino H, Seo S,
Hatano E, Toi M. Real-time navigation system for sentinel lymph node biopsy in breast cancer patients using
projection mapping with indocyanine green fluorescence. Breast Cancer 2018;25:650-655. doi:
10.1007/s12282-018-0868-2. Epub 2018 May 9.
134.
Ueno T, Masuda N, Kamigaki S, Morimoto T, Akiyama F, Kurosumi M, Tsuda H, Mikami Y, Tanaka S,
Morita S, Toi M. A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in
postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy andclinical implications of circulating endothelial cells. Cancer Med 7:2442-2451, 2018. doi: 10.1002/cam4.1516.
Epub 2018 May 7.
135.
Tsuge I, Saito S, Sekiguchi H, Yoshikawa A, Matsumoto Y, Toi M, Suzuki S. Photoacoustic tomographyshows the branching pattern of anterolateral thigh perforators in vivo. Plast Reconstr Surg 141:1288-1292, 2018.
doi: 10.1097/PRS.0000000000004328.
136.
Miyake O, Murata K, Tanaka S, Ishiguro H, Toi M, Tamura K, Kawakami K. Costs associated with febrileneutropenia in Japanese patients with primary breast cancer: post-hoc analysis of a randomized clinical trial. Jpn J
Clin Oncol 48:410-416, 2018. doi: 10.1093/jjco/hyy030.
137.
Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J,
Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J,
18

Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J,
Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry
JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade
MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW,
Loibl S, Latouche A, Pierga JY, Pantel K. Circulating Tumor Cells in Breast Cancer Patients Treated by
Neoadjuvant Chemotherapy: A Meta-analysis. J Natl Cancer Inst 110:560-567, 2018. doi: 10.1093/jnci/djy018.
138.
Mackenzie L, Carey M, Suzuki E, Yoshimura M, Toi M, D'Este C, Sanson-Fisher R. A cross-sectional
study of agreement between the Hospital Anxiety and Depression Scale and patient- and radiation
oncologist-reported single-item assessment of depression and anxiety. Psychooncology 1840-1846, 2018. doi:
10.1002/pon.4736. Epub 2018 May 16.
139.
Kanao S, Kataoka M, Iima M, Ikeda DM, Toi M, Togashi K. Differentiating benign and malignant
inflammatory breast lesions: Value of T2 weighted and diffusion weighted MR images. Magn Reson Imaging
2018;50:38-44. doi: 10.1016/j.mri.2018.03.012. Epub 2018 Mar 12.
140.
Ueno T, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K,
Aogi K, Iwata H, Yamanaka T, Sasano H, Toi M. Impact of clinical response to neoadjuvant endocrine therapy on
patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial. ESMOOpen 2018;3:e000314. doi: 10.1136/esmoopen-2017-000314. eCollection 2018.
141.
Miyake KK, Nakamoto Y, Saji S, Sugie T, Kurihara K, Kanao S, Ikeda DM, Toi M, Togashi K. Impact ofphysiological hormonal fluctuations on 18F-fluorodeoxyglucose uptake in breast cancer. Breast Cancer Res Treat
169:437-446, 2018. doi: 10.1007/s10549-018-4711-4. Epub 2018 Feb 8.
142.
Förnvik D, Kataoka M, Iima M, Ohashi A, Kanao S, Toi M, Togashi K. The role of breast tomosynthesis ina predominantly dense breast population at a tertiary breast centre: breast density assessment and diagnostic
performance in comparison with MRI. Eur Radiol 28:3194-3203, 2018. doi: 10.1007/s00330-017-5297-7. Epub
2018 Feb 19.
143.
Itou J, Li W, Ito S, Tanaka S, Matsumoto Y, Sato F, Toi M. Sal-like 4 protein levels in breast cancer cells
are post-translationally down-regulated by tripartite motif-containing 21. J Biol Chem 293:6556-6564, 2018. doi:
10.1074/jbc.RA117.000245. Epub 2018 Mar 6.
144.
Filipits M, Dafni U, Gnant M, Polydoropoulou V, Hills M, Kiermaier A, de Azambuja E, Larsimont D,
Rojo F, Viale G, Toi M, Harbeck N, Prichard KI, Gelber RD, Dinh P, Zardavas D, Leyland-Jones B,
Piccart-Gebhart MJ, Dowsett M; TransHERA investigators. Association of p27 and cyclin D1 expression andbenefit from adjuvant trastuzumab treatment in HER2-positive early breast cancer: A TransHERA study. Clin
Cancer Res 24:3079-3086, 2018. doi: 10.1158/1078-0432.CCR-17-3473. Epub 2018 Mar 12.
145.
Iima M, Kataoka M, Kanao S, Onishi N, Kawai M, Ohashi A, Sakaguchi R, Toi M, Togashi K. Intravoxel
Incoherent Motion and Quantitative Non-Gaussian Diffusion MR Imaging: Evaluation of the Diagnostic andPrognostic Value of Several Markers of Malignant and Benign Breast Lesions. Radiology 2017:162853. doi:
10.1148/radiol.2017162853. [Epub ahead of print.
146.
Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M,
Hayes DF; EBCTCG. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 Years. N Engl
J Med 2017;377:1836-1846. doi: 10.1056/NEJMoa1701830.
147.
Kawai M, Kataoka M, Kanao S, Iima M, Onishi N, Ohashi A, Sakaguchi R, Toi M, Togashi K. The valueof lesion size as an adjunct to the BI-RADS-MRI 2013 Descriptors in the diagnosis of solitary breast masses. Magn
Reson Med Sci 2018;17:203-210. doi: 10.2463/mrms.mp.2017-0024.
148.
Matsumoto Y, Asao Y, Yoshikawa A, Sekiguchi H, Takada M, Furu M, Saito S, Kataoka M, Abe H, Yagi
T, Togashi K, Toi M. Label-free photoacoustic imaging of human palmar vessels: a structural morphologicalanalysis. Sci Rep 2018;8:786. doi: 10.1038/s41598-018-19161-z.
19

149.
Masuda N, Nishimura R, Takahashi M, Inoue K, Ohno S, Iwata H, Mori Y, Hashigaki S, Muramatsu Y,
Nagasawa T, Umeyama Y, Toi M. Palbociclib in combination with letrozole as first-line treatment for advanced
breast cancer: a Japanese phase II study. Cancer Sci 2018;109:803-813. doi: 10.1111/cas.13507. Epub 2018 Feb
22.
150.
Matsumoto Y, Itou J, Sato F, Toi M. SALL4 - KHDRBS3 network enhances stemness by modulating CD44
splicing in basal-like breast cancer. Cancer Med 7:454-462, 2018. doi: 10.1002/cam4.1296. Epub 2018 Jan 22.
151.
Itou J, Tsukihara H, Nukatsuka M, Toi M, Takechi T. 5-Chloro-2,4-dihydroxypyridine, CDHP, preventslung metastasis of basal-like breast cancer cells by reducing nascent adhesion formation. Cancer Med 7:463-470,
2018. doi: 10.1002/cam4.1265. Epub 2018 Jan 22.
152.
Masuda N, Toi M, Yamamoto N, Iwata H, Kuroi K, Bando H, Ohtani S, Takano T, Inoue K, Yanagita Y,
Kasai H, Morita S, Sakurai T, Ohno S. Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant
treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for
HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial. Breast Cancer
2018;25:407-415. doi: 10.1007/s12282-018-0839-7. Epub 2018 Feb 14.
153.
Dubsky P, Curigliano G, Burstein HJ, Winer EP, Gnant M, Loibl S, Colleoni M, Regan MM,
Piccart-Gebhart M, Senn HJ, Thürlimann B; Panel Members of the St Gallen International Expert Consensus on
the Primary Therapy of Early Breast Cancer 2017, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso
F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu
B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M,
Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V,
Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B. Reply to 'The St Gallen International
Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panelof Experts in Radiation Oncology' by Kirova et al. Ann Oncol 29:281-282, 2018. doi: 10.1093/annonc/mdx543.
154.
Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas MP, Simoncini
E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, Marth C, Müller B, O'Reilly S, Di Lauro V, Gombos A,
Ruhstaller T, Burstein H, Ribi K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber RD, Coates AS, Di
Leo A, Regan MM, Goldhirsch A; SOLE Investigators. Extended adjuvant intermittent letrozole versus continuous
letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-labell, randomised, phase 3
trial. Lancet Oncol 19:127-138, 2018. doi: 10.1016/S1470-2045(17)30715-5. Epub 2017 Nov 17.
155.
Chow LWC, Morita S, Chow CYC, Ng WK, Toi M. Neoadjuvant palbociclib on ER+ breast cancer (N007):
clinical response and EndoPredict's value. Endocr Relat Cancer 25:123-130, 2018. doi: 10.1530/ERC-17-0396.
Epub 2017 Nov 20.
156.
Tanaka Y, Murata-Hirai K, Iwasaki M, Matsumoto K, Hayashi K, Kumagai A, Nada MH, Wang H,
Kobayashi H, Kamitakahara H, Okamura H, Sugie T, Minato N, Toi M, Morita CT. Expansion of human γδ T
cells for adoptive immunotherapy using a bisphosphonate prodrug. Cancer Sci 2018;109(3):587-599. doi:
10.1111/cas.13491. Epub 2018 Feb 4.
157.
Sugie T, Suzuki E, Yamauchi A, Yamagami K, Masuda N, Gondo N, Sumi E, Ikeda T, Tada H, Uozumi R,
Kanao S, Tanaka Y, Hamazaki Y, Minato N, Toi M. Combined effects of neoadjuvant letrozole and zoledronic
acid on γδT cells in postmenopausal women with early-stage breast cancer. Breast 38:114-119, 2018. doi:
10.1016/j.breast.2017.12.017. [Epub ahead of print]
158.
Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T,
Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H,
Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S. Factors associated with prolonged time to treatment
failure with fulvestrant 500 mg in patients with postmenopausal estrogen receptor-positive advanced breast
cancer: a subgroup analysis of the JBCRG-C06 Safari study. Curr Med Res Opin 2018;34:49-54. doi:
10.1080/03007995.2017.1400426. Epub 2017 Nov 21.

20

159.
Tanaka S, Ueno T, Ishiguro H, Morita S, Toi M. The lack of increases in circulating endothelial progenitor
cell as a negative predictor for pathological response to neoadjuvant chemotherapy in breast cancer patients. NPJ
Precis Oncol 1:6, 2017. doi: 10.1038/s41698-017-0006-1. eCollection 2017.
160.
Ishiguro H, Saji S, Nomura S, Tanaka S, Ueno T, Onoue M, Iwata H, Yamanaka T, Sasaki Y, Toi M. A
phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S-1 for recurrent/metastatic
breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study). Cancer Med 6:2909-2917,
2017. doi: 10.1002/cam4.1258. Epub 2017 Nov 13.
161.
Sugie T, Toi M. Comparison of the indocyanine green fluorescence and blue dye methods for the detectionof sentinel lymph nodes in early-stage breast cancer: A reply. Ann Surg Oncol 2017;24(Suppl 3):583-584. doi:
10.1245/s10434-017-6187-6. Epub 2017 Nov 1.
162.
Curigliano G, et al. Reply to "The St. Gallen International Expert Consensus on the Primary Therapy of
Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology" by
Kirova et al. Ann Oncol 2017 Sep 25. doi: 10.1093/annonc/mdx543. [Epub ahead of print] No abstract available.
163.
Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM,
Piccart-Gebhart M, Senn HJ, Thürlimann B; St. Gallen International Expert Consensus on the Primary Therapy of
Early Breast Cancer 2017, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E,
Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck
N, Hayes DF, Huang CS, Huober J, Hussein K, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne
KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi
M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B. De-escalating and escalating treatments for early-stage breast
cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer
2017. Ann Oncol. 2017;28:1700-1712. doi: 10.1093/annonc/mdx308.
164.
Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Trédan O, Chen SC, Manso
L, Freedman OC, Garnica Jaliffe G, Forrester T, Frenzel M, Barriga S, Smith IC, Bourayou N, Di Leo A.
MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 2017;35(32):3638-3646.
doi: 10.1200/JCO.2017.75.6155. Epub 2017 Oct 2.
165.
Torii M, Fukui T, Inoue M, Kanao S, Umetani K, Shirai M, Inagaki T, Tsuchimochi H, Pearson JT, Toi M.
Analysis of the microvascular morphology and hemodynamics of breast cancer in mice using SPring-8
synchrotron radiation microangiography. J Synchrotron Radiat 2017;24(Pt 5):1039-1047. doi:
10.1107/S1600577517008372. Epub 2017 Aug 2.
166.
Toi M, Masuda N, Ohashi Y. Adjuvant Capecitabine for Breast Cancer. N Engl J Med 377:791-2, 2017.
doi: 10.1056/NEJMc1708487. No abstract available.
167.
Spraggs CF, Parham LR, Briley LP, Warren L, Williams LS, Fraser DJ, Jiang Z, Aziz Z, Ahmed S,
Demetriou G, Mehta A, Jackson N, Byrne J, Andersson M, Toi M, Harris L, Gralow J, Zujewski JA, Crescenzo R,
Armour A, Perez E, Piccart M. Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver
toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or
taxanes. Pharmacogenomics J 2018;18:480-486. doi: 10.1038/tpj.2017.39. Epub 2017 Aug 8.
168.
Tanaka Y, Iwasaki M, Murata-Hirai K, Matsumoto K, Hayashi K, Okamura H, Sugie T, Minato N, Morita
CT, Toi M. Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug. Sci Rep 7:5987,
2017. doi: 10.1038/s41598-017-05553-0.
169.
Ohgami M, Bando H, Ishiguro H, Tsuda M, Toriguchi N, Aogi K, Toi M, Masuda N, Mitsuhashi S,
Kurosawa A, Homma M. Effect of dose timing on the blood concentration of lapatinib in patients with breast cancer.
Ann Oncol 2017;28:2888-2889. doi: 10.1093/annonc/mdx328.

21

170.
Nishimatsu K, Nakamoto Y, Miyake KK, Ishimori T, Kanao S, Toi M, Togashi K. Higher breast cancer
conspicuity on dbPET compared to WB-PET/CT. Eur J Radiol 90:138-145, 2017. doi:
10.1016/j.ejrad.2017.02.046. Epub 2017 Mar 1.
171.
von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A,
Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY
Steering Committee and Investigators. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast
cancer. N Engl J Med 377:122-131, 2017. doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5. Erratum in: N Engl J
Med. 2017 Aug 17;377(7):702.
172.
Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA,
Koh H, Grischke EM, Frenzel M, Lin Y, Barriga S, Smith IC, Bourayou N, Llombart-Cussac A. MONARCH 2:
Abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had
progressed while receiving endocwine therapy. J Clin Oncol 35:2875-2884, 2017. doi: 10.1200/JCO.2017.73.7585.
Epub 2017 Jun 3.
173.
Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, Yanagita Y,
Ohno S, Takao S, Aogi K, Iwata H, Jeong J, Kim A, Park KH, Sasano H, Ohashi Y, Toi M. Adjuvant
Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med 376:2147-2159, 2017. doi:
10.1056/NEJMoa1612645.
174.
Onishi N, Kataoka M, Kanao S, Sagawa H, Iima M, Nickel MD, Toi M, Togashi K. Ultrafast dynamic
contrast-enhanced mri of the breast using compressed sensing: breast cancer diagnosis based on separate
visualization of breast arteries and veins. J Magn Reson Imaging 2018;47:97-104. doi: 10.1002/jmri.25747. Epub
2017 May 28.
175.
Kawaguchi K, Suzuki E, Nishie M, Kii I, Kataoka TR, Hirata M, Inoue M, Pu F, Iwaisako K, Tsuda M,
Yamaguchi A, Haga H, Hagiwara M, Toi M. Downregulation of neuropilin-1 on macrophages modulates
antibody-mediated tumoricidal activity. Cancer Immunol Immunother 2017;66(9):1131-1142. doi:
10.1007/s00262-017-2002-2. Epub 2017 Apr 21.
176.
Toi M, Shao Z, Hurvitz S, Tseng LM, Zhang Q, Shen K, Liu D, Feng J, Xu B, Wang X, Lee KS, Ng TY,
Ridolfi A, Noel-Baron F, Ringeisen F, Jiang Z. Efficacy and safety of everolimus in combination withtrastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1. Breast Cancer
Res 19:47, 2017. doi: 10.1186/s13058-017-0839-0.
177.
Sonnenblick A, Agbor-Tarh D, Bradbury I, Di Cosimo S, Azim HA Jr, Fumagalli D, Sarp S, Wolff AC,
Andersson M, Kroep J, Cufer T, Simon SD, Salman P, Toi M, Harris L, Gralow J, Keane M, Moreno-Aspitia A,
Piccart-Gebhart M, de Azambuja E. Impact of diabetes, insulin, and metformin use on the outcome of patientswith human epidermal growth factor receptor 2-positive primary breast cancer: Analysis from the ALTTO phase
III randomized trial. J Clin Oncol 35:1421-1429, 2017. doi: 10.1200/JCO.2016.69.7722. Epub 2017 Mar 13.
178.
Chow LW, Biganzoli L, Leo AD, Kuroi K, Han HS, Patel J, Huang CS, Lu YS, Zhu L, Chow CY, Loo WT,Glück S, Toi M. Toxicity profile differences of adjuvant docetaxel/ cyclophosphamide (TC) between Asian and
Caucasian breast cancer patients. Asia Pac J Clin Oncol 2017;13(6):372-378. doi: 10.1111/ajco.12682. Epub 2017
Mar 28.
179.
Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Tokunaga E,
Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita T, Yamamoto Y, Ohno
S, Toi M. Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective
multicenter cohort study (JBCRG-C06; Safari). Breast Cancer Res Treat 163:545-554, 2017. doi:
10.1007/s10549-017-4212-x. Epub 2017 Mar 23.
180.
Nakamoto R, Nakamoto Y, Ishimori T, Nishimatsu K, Miyake KK, Kanao S, Iima M, Toi M, Togashi K.
Diagnostic performance of a novel dedicated breast PET scanner with C-shaped ring detectors. Nucl Med
Commun 38:388-395, 2017. doi: 10.1097/MNM.0000000000000661.
22

181.
Toi M, Asao Y, Matsumoto Y, Sekiguchi H, Yoshikawa A, Takada M, Kataoka M, Endo T,
Kawaguchi-Sakita N, Kawashima M, Fakhrejahani E, Kanao S, Yamaga I, Nakayama Y, Tokiwa M, Torii M, Yagi
T, Sakurai T, Togashi K, Shiina T. Visualization of tumor-related blood vessels in human breast by photoacoustic
imaging system with a hemispherical detector array. Sci Rep 7:41970, 2017. doi: 10.1038/srep41970.
182.
Bell R, Brown J, Parmar M, Toi M, Suter T, Steger GG, Pivot X, Mackey J, Jackisch C, Dent R, Hall P, Xu
N, Morales L, Provencher L, Hegg R, Vanlemmens L, Kirsch A, Schneeweiss A, Masuda N, Overkamp F,
Cameron D. Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating
adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. Ann Oncol 2017;28(4):754-760.
doi: 10.1093/annonc/mdw665.
183.
Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot X, Burris H
3rd, Petersen JA, Stanzel S, Strasak A, Patre M, Ellis P. Trastuzumab Emtansine with or without Pertuzumab
versus Trastuzumab Plus Taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer:
primary results from the phase III MARIANNE Study. J Clin Oncol 35:141-148, 2017.
184.
Uehiro N, Sato F, Pu F, Tanaka S, Kawashima M, Kawaguchi K, Sugimoto M, Saji S, Toi M. Circulatingcell-free DNA-based epigenetic assay can detect early breast cancer. Breast Cancer Res 18:129, 2016
185.
Hayakawa Y, Kawada M, Nishikawa H, Ochiya T, Saya H, Seimiya H, Yao R, Hayashi M, Kai C, Matsuda
A, Naoe T, Ohtsu A, Okazaki T, Saji H, Sata M, Sugimura H, Sugiyama Y, Toi M, Irimura T. Report on the useof non-clinical studies in the regulatory evaluation of oncology drugs. Cancer Sci 107:189-202, 2016. doi:
10.1111/cas.12857
186.
Asao Y, Hashizume Y, Suita T, Nagae KI, Fukutani K, Sudo Y, Matsushita T, Kobayashi S, Tokiwa M,
Yamaga I, Fakhrejahani E, Torii M, Kawashima M, Takada M, Kanao S, Kataoka M, Shiina T, Toi M.
Photoacoustic mammography capable of simultaneously acquiring photoacoustic and ultrasound images. J
Biomed Opt 2016;21:116009.
187.
Ikeda T, Sugie T, Shimizu A, Toi M. Patterns of clinical practice for sentinel lymph node biopsy in womenwith node-negative breast cancer: the results of a national survey in Japan. Breast Cancer 2017;24:341-344. doi:
10.1007/s12282-016-0720-5. Epub 2016 Aug 27.
188.
André F, Hurvitz S, Fasolo A, Tseng LM, Jerusalem G, Wilks S, O'Regan R, Isaacs C, Toi M, Burris H, He
W, Robinson D, Riester M, Taran T, Chen D, Slamon D. Molecular alterations and everolimus efficacy in humanepidermal growth factor receptor 2-overexpressing metastatic breast cancers: Combined exploratory biomarker
analysis from BOLERO-1 and BOLERO-3. J Clin Oncol 34:2115-24, 2016. doi: 10.1200/JCO.2015.63.9161.
Epub 2016 Apr 18
189.
Itou J, Tanaka S, Li W, Iida A, Sehara-Fujisawa A, Sato F, Toi M. The Sal-like 4 - integrin α6β1 network
promotes cell migration for metastasis via activation of focal adhesion dynamics in basal-like breast cancer cells.
Biochim Biophys Acta 1864:76-88, 2017.
190.
Hirata K, Yoshimura M, Inoue M, Yamauchi C, Ogura M, Toi M, Suzuki E, Takeuchi M, Takada M,
Hiraoka M. Regional recurrence in breast cancer patients with one to three positive axillary lymph nodes treatedwith breast-conserving surgery and whole breast irradiation. J Radiat Res 2017;58:79-85. doi: 10.1093/jrr/rrw071.
Epub 2016 Jul 15.
191.
Lee ES, Han W, Shin HC, Takada M, Ryu HS, Cho N, Kim MK, Kim J, Yoo TK, Moon HG, Toi M, Moon
WK, Park IA, Noh DY. Clinical benefit of nomogram for predicting positive resection margins in breast conserving
surgery. Eur J Surg Oncol 2016;42:1169-75. doi: 10.1016/j.ejso.2016.04.058. Epub 2016 May 25.
192.
Li W, Itou J, Tanaka S, Nishimura T, Sato F, Toi M. A homeobox protein, NKX6.1, up-regulatesinterleukin-6 expression for cell growth in basal-like breast cancer cells. Exp Cell Res 343:177-89, 2016. doi:
10.1016/j.yexcr.2016.03.023. Epub 2016 Mar 28.

23

193.
Kawaguchi K, Suzuki E, Yamaguchi A, Yamamoto M, Morita S, Toi M. Altered expression of major
immune regulatory molecules in peripheral blood immune cells associated with breast cancer. Breast Cancer
2017;24(1):111-120. doi: 10.1007/s12282-016-0682-7. Epub 2016 Mar 4.
194.
Shi G, Yoshida Y, Yuki K, Nishimura T, Kawata Y, Kawashima M, Iwaisako K, Yoshikawa K, Kurebayashi
J, Toi M, Noda M. Pattern of RECK CpG methylation as a potential marker for predicting breast cancer prognosis
and drug-sensitivity. Oncotarget 2016;7(50):82158-82169. doi: 10.18632/oncotarget.8620.
195.
Itou J, Tanaka S, Li W, Matsumoto Y, Sato F, Toi M. Data of a fluorescent imaging-based analysis ofanti-cancer drug effects on three-dimensional cultures of breast cancer cells. Data Brief 5:429-33, 2015. doi:
10.1016/j.dib.2015.09.037. eCollection 2015 Dec.
196.
Ueno T, Saji S, Sugimoto M, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H,
Hisamatsu K, Aogi K, Iwata H, Imoto S, Sasano H, Toi M. Clinical significance of the expression of
autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy. BMC
Cancer 16:230, 2016. doi: 10.1186/s12885-016-2270-9.
197.
Kawaguchi-Sakita N, Kaneshiro-Nakagawa K, Kawashima M, Sugimoto M, Tokiwa M, Suzuki E, Kajihara
S, Fujita Y, Iwamoto S, Tanaka K, Toi M. Serum immunoglobulin G Fc region N-glycosylation profiling by
matrix-assisted laser desorption/ionization mass spectrometry can distinguish breast cancer patients fromcancer-free controls. Biochem Biophys Res Commun 469:1140-5, 2016. doi: 10.1016/j.bbrc.2015.12.114. Epub2015 Dec 29.
198.
Onishi N, Kataoka M, Kanao S, Kawai M, Iima M, Ohashi A, Toi M, Togashi K. A pilot study to determine
the diagnostic criteria of spiculated masses for BI-RADS MRI category 5: when to perform re-biopsy after
discordant pathologic result? Breast Cancer 2017;24:69-78. doi: 10.1007/s12282-016-0668-5. Epub 2016 Feb 1.
199.
Fakhrejahani E, Torii M, Kitai T, Kanao S, Asao Y, Hashizume Y, Mikami Y, Yamaga I, Kataoka M, Sugie
T, Takada M, Haga H, Togashi K, Shiina T, Toi M. Clinical report on the first prototype of a photoacoustic
tomography system with dual illumination for breast cancer imaging. PLoS One 10:e0139113, 2015. doi:
10.1371/journal.pone.0139113. eCollection 2015.
200.
Sugie T, Kinoshita T, Masuda N, Sawada T, Yamauchi A, Kuroi K, Taguchi T, Bando H, Yamashiro H, Lee
T, Shinkura N, Kato H, Ikeda T, Yoshimura K, Ueyama H, Toi M. Evaluation of the Clinical utility of the ICG
fluorescence method compared with the radioisotope method for sentinel lymph node biopsy in breast cancer. Ann
Surg Oncol 23:44-50, 2016. doi: 10.1245/s10434-015-4809-4. Epub 2015 Aug 15
201.
Suzuki E, Mackenzie L, Sanson-Fisher R, Carey M, D'Este C, Asada H, Toi M. Acceptability of a touch
screen tablet psychosocial survey administered to radiation therapy patients in Japan. Int J Behav Med
2016;23:485-91. doi: 10.1007/s12529-015-9502-2.
202.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Dowsett M, Forbes JF, Bradley R, Ingle J,
Aihara T, Bliss J, Boccardo F, Coates A, Coombes RC, Cuzick J, Dubsky P, Gnant M, Kaufmann M, Kilburn L,
Perrone F, Rea D, Thürlimann B, van de Velde C, Pan H, Peto R, Davies C, Gray R. Aromatase inhibitors versus
tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386(10001):1341-52,
2015.
203.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Coleman R, Powles T, Paterson A, Gnant
M, Anderson S, Diel I, Gralow J, von Minckwitz G, Moebus V, Bergh J, Pritchard KI, Bliss J, Cameron D, Evans
V, Pan H, Peto R, Bradley R, Gray R. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses ofindividual patient data from randomised trials. Lancet 386(10001):1353-61, 2015. doi:
10.1016/S0140-6736(15)60908-4. Epub 2015 Jul 23. Erratum in: Lancet. 2016 Jan 2;387(10013):30.
204.
Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ;
Panel Members. -Tailoring therapies-improving the management of early breast cancer: St Gallen International
Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 26:1533-46, 2015. doi:
10.1093/annonc/mdv221. Epub 2015 May 4.
24

205.
Toi M, Winer EP, Benson JR, Inamoto T, Forbes JF, von Minckwitz G, Robertson JF, Grobmyer SR, Jatoi I,
Sasano H, Kunkler I, Ho AY, Yamauchi C, Chow LW, Huang CS, Han W, Noguchi S, Pegram MD, Yamauchi H,
Lee ES, Larionov AA, Bevilacqua JL, Yoshimura M, Sugie T, Yamauchi A, Krop IE, Noh DY, Klimberg VS; 2014
Kyoto Breast Cancer Consensus Conference. Personalization of loco-regional care for primary breast cancer
patients (part 2). Future Oncol 11:1301-5, 2015. doi: 10.2217/fon.15.66.
206.
Kuroi K, Toi M, Ohno S, Nakamura S, Iwata H, Masuda N, Sato N, Tsuda H, Kurosumi M, Akiyama F.
Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysisof three prospective neoadjuvant studies of JBCRG. Breast Cancer 22:586-95, 2015. doi:
10.1007/s12282-014-0524-4. Epub 2014 Feb 27.
207.
Suzuki E, Kataoka TR, Hirata M, Kawaguchi K, Nishie M, Haga H, Toi M. Trogocytosis-mediatedexpression of HER2 on immune cells may be associated with a pathological complete response to
trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients. BMC Cancer 15:39,
2015. [Epub ahead of print]
208.
Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, Tseng LM, Zhang Q, Shen K, Liu D,
Dreosti LM, Burris HA, Toi M, Buyse ME, Cabaribere D, Lindsay MA, Rao S, Pacaud LB, Taran T, Slamon D.
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with
HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Lancet Oncol 16:816-29, 2015. doi: 10.1016/S1470-2045(15)00051-0. Epub 2015 Jun 16.
209.
Mukai H, Masuda N, Ishiguro H, Mitsuma A, Shibata T, Yamamura J, Toi M, Watabe A, Sarashina A,
Uttenreuther-Fischer M, Ando Y. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced
solid tumors, including breast cancer. Cancer Chemother Pharmacol 76:739-50, 2015. doi:
10.1007/s00280-015-2826-4. Epub 2015 Aug 8
210.
Ueno T, Utsumi J, Toi M, Shimizu K. Characteristic gene expression profiles of human fibroblasts andbreast cancer cells in a newly developed bilateral coculture system. Biomed Res Int 2015;2015:960840. doi:
10.1155/2015/960840. Epub 2015 Jun 11.
211.
Sugimoto M, Takada M, Toi M. Development of web tools to predict axillary lymph node metastasis andpathological response to neoadjuvant chemotherapy in breast cancer patients. Int J Biol Markers 29:e372-9, 2014.
doi: 10.5301/jbm.5000103.

212.
Sumi E, Sugie T, Yoshimura K, Tada H, Ikeda T, Suzuki E, Tanaka Y, Teramukai S, Shimizu A, Toi M,
Minato N. Effects of zoledronic acid and the association between its efficacy and γδT cells in postmenopausal
women with breast cancer treated with preoperative hormonal therapy: a study protocol. J Transl Med 12:310,
2014. doi: 10.1186/s12967-014-0310-2.
213.
Goto Y, Zeng L, Yeom CJ, Zhu Y, Morinibu A, Shinomiya K, Kobayashi M, Hirota K, Itasaka S,
Yoshimura M, Tanimoto K, Torii M, Sowa T, Menju T, Sonobe M, Kakeya H, Toi M, Date H, Hammond EM,
Hiraoka M, Harada H. UCHL1 provides diagnostic and antimetastatic strategies due to its deubiquitinating effecton HIF-1α. Nat Commun 6:6153, 2015. doi: 10.1038/ncomms7153.
214.
Ueshima C, Kataoka TR, Hirata M, Furuhata A, Suzuki E, Toi M, Tsuruyama T, Okayama Y, Haga H. The
killer cell Ig-like receptor 2DL4 expression in human mast cells and its potential role in breast cancer invasion.
Cancer Immunol Res 2015s;3:871-80. doi: 10.1158/2326-6066.CIR-14-0199. Epub 2015 Mar 3.
215.
Yamshiro H, Iwata H, Masuda N, Yamamoto N, Nishimura R, Ohtani S, Sato N, Takahashi M, Kamio T,
Yamazaki K, Saito T, Kato M, Lee T, Ohno S, Kuroi K, Takano T, Takada M, Yasuno S, Morita S, Toi M.
Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients. Int J Clin Oncol 2015;20:709-22.
doi: 10.1007/s10147-015-0785-8. Epub 2015 Feb 10. Erratum in: Int J Clin Oncol. 2015;20:723-4. Sato, Nobuki[corrected to Sato, Nobuaki].
25

216.
Itou J, Tanaka S, Sato F, Akiyama R, Kawakami Y, Toi M. An optical labeling-based proliferation assay
system reveals the paracrine effect of interleukin-6 in breast cancer. Biochim Biophys Acta 1853:27-40, 2014.
doi: 10.1016/j.bbamcr.2014.10.004.
217.
Sugimoto M, Takada M, Toi M. Development of Web tools to predict axillary lymph node metastasis andpathological response to neoadjuvant chemotherapy in breast cancer patients. Int J Biol Markers
2014;29(4):e372-9. doi: 10.5301/jbm.5000103.
218.
EBCTCG (Early Breast Cancer Trialists' Collaborative Group), McGale P, Taylor C, Correa C, Cutter D,
Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, Wang Y, Wang Z, Darby S. Effect of radiotherapy
after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis ofindividual patient data for 8135 women in 22 randomised trials. Lancet 383(9935):2127-35, 2014. doi:
10.1016/S0140-6736(14)60488-8. Epub 2014 Mar 19. Erratum in: Lancet 2014 Nov 22;384(9957):1848.
219.
Mukai H, Noguchi S, Akiyama F, Inaji H, Iwase H, Horiguchi J, Kurebayashi J, Hirata K, Toi M,
Kurosumi M, Kohno N, Nishimura R, Nakamura S, Imoto S, Iwase T, Endo T, Saeki T, Ogawa Y, Ito Y, Tokuda
Y, Ikeda T. 2013 clinical practice guidelines (The Japanese Breast Cancer Society): history, policy and mission.
Breast Cancer 2015;22:1-4. doi: 10.1007/s12282-014-0550-2. Epub 2014 Jul 24.
220.
Miyake KK, Nakamoto Y, Kanao S, Tanaka S, Sugie T, Mikami Y, Toi M, Togashi K. Journal Club:
Diagnostic value of (18)F-FDG PET/CT and MRI in predicting the clinicopathologic subtypes of invasive breast
cancer. Journal Club: Diagnostic value of (18)F-FDG PET/CT and MRI in predicting the clinicopathologic
subtypes of invasive breast cancer. AJR Am J Roentgenol 203:272-9, 2014. doi: 10.2214/AJR.13.11971.
221.
Masuda N, Higaki K, Takano T, Matsunami N, Morimoto T, Ohtani S, Mizutani M, Miyamoto T, Kuroi K,
Ohno S, Morita S, Toi M. A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by
5-fluorouracil/ epirubicin/ cyclophosphamide as preoperative chemotherapy for triple-negative or low
hormone receptor expressing/HER2-negative primary breast cancer. Cancer Chemother Pharmacol 74:229-38,
2014. doi: 10.1007/s00280-014-2492-y. Epub 2014 May 29.
222.
André F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, Masuda N, Wilks S, Arena F, Isaacs C,
Yap YS, Papai Z, Lang I, Armstrong A, Lerzo G, White M, Shen K, Litton J, Chen D, Zhang Y, Ali S, Taran T, etal. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a
randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15:580-91, 2014. doi:
10.1016/S1470-2045(14)70138-X. Epub 2014 Apr 14.
223.
Takada M, Ishiguro H, Nagai S, Ohtani S, Kawabata H, Yanagita Y, Hozumi Y, Shimizu C, Takao S, Sato
N, Kosaka Y, Sagara Y, Iwata H, Ohno S, Kuroi K, Masuda N, Yamashiro H, Sugimoto M, Kondo M, Naito Y,
Sasano H, Inamoto T, Morita S, Toi M. Survival of HER2-positive primary breast cancer patients treated byneoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study).
Breast Cancer Res Treat 145:143-53, 2014. doi: 10.1007/s10549-014-2907-9. Epub 2014 Mar 30.
224.
Onishi N, Kanao S, Kataoka M, Iima M, Sakaguchi R, Kawai M, Kataoka TR, Mikami Y, Toi M, Togashi
K. Apparent diffusion coefficient as a potential surrogate marker for Ki-67 index in mucinous breast carcinoma. J
Magn Reson Imaging 2015;41:610-5. doi: 10.1002/jmri.24615. Epub 2014 Mar 4.
225.
Itou J, Matsumoto Y, Yoshikawa K, Toi M. Sal-like 4 (SALL4) suppresses CDH1 expression andmaintains cell dispersion in basal-like breast cancer. FEBS Lett 587:3115-21, 2013. doi:
10.1016/j.febslet.2013.07.049. Epub 2013 Aug 14.
226.
Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, Steger GG, Suter TM, Toi M, Parmar M,
Laeufle R, Im YH, Romieu G, Harvey V, Lipatov O, Pienkowski T, Cottu P, Chan A, Im SA, Hall PS,
Bubuteishvili-Pacaud L, Henschel V, Deurloo RJ, Pallaud C, Bell R. Adjuvant bevacizumab-containing therapy intriple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol
14:933-42, 2013. doi: 10.1016/S1470-2045(13)70335-8. Epub 2013 Aug 7.

26

227.
Kawashima M, Iwamoto N, Kawaguchi-Sakita N, Sugimoto M, Ueno T, Mikami Y, Terasawa K, Sato TA,
Tanaka K, Shimizu K, Toi M. High-resolution imaging mass spectrometry reveals detailed spatial distribution ofphosphatidylinositols in human breast cancer. Cancer Sci 2013;104:1372-9. doi: 10.1111/cas.12229. Epub 2013
Aug 6.
228.
Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ; Panelmembers. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International
Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24:2206-23, 2013. doi:
10.1093/annonc/mdt303. Epub 2013 Aug 4.
229.
Ohno S, Chow LW, Sato N, Masuda N, Sasano H, Takahashi F, Bando H, Iwata H, Morimoto T, Kamigaki
S, Nakayama T, Nakamura S, Kuroi K, Aogi K, Kashiwaba M, Yamashita H, Hisamatsu K, Ito Y, Yamamoto Y,
Ueno T, Fakhrejahani E, Yoshida N, Toi M. Randomized trial of preoperative docetaxel with or without
capecitabine after 4 cycles of 5-fluorouracil– epirubicin–cyclophosphamide (FEC) in early-stage breast cancer:
exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy. Breast
Cancer Res Treat 2013;142:69-80. doi:10.1007/s10549-013-2691-y.
230.
Kuroi K, Toi M, Ohno S, Nakamura S, Iwata H, Masuda N, Sato N, Tsuda H, Kurosumi M, Akiyama F.
Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis ofprospective neoadjuvant studies of JBCRG. Breast Cancer 2015;22:486-95. doi: 10.1007/s12282-013-0511-1.
Epub 2013 Dec 14.
231.
Toi M, Hirota S, Tomotaki A, Sato N, Hozumi Y, Anan K, Nagashima T, Tokuda Y, Masuda N, Ohsumi S,
Ohno S, Takahashi M, Hayashi H, Yamamoto S, Ohashi Y. Probiotic beverage with soy isoflavone consumption
for breast cancer prevention: a case-control study. Curr Nutr Food Sci 2013;9:194-200. doi:
10.2174/15734013113099990001.
232.
Kaga C, Takagi A, Kano M, Kado S, Kato I, Sakai M, Miyazaki K, Nanno M, Ishikawa F, Ohashi Y, Toi
M. Lactobacillus casei Shirota enhances the preventive efficacy of soymilk in chemically induced breast cancer.
Cancer Sci 2013;104(11):1508-14. doi: 10.1111/cas.12268. Epub 2013 Oct 20.
233.
Ueno T, Masuda N, Yamanaka T, Saji S, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H,
Hisamatsu K, Aogi K, Iwata H, Sasano H, Toi M. Evaluating the 21-gene assay Recurrence Score® as a predictorof clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer. Int J Clin
Oncol 2014;19(4):607-13. doi: 10.1007/s10147-013-0614-x. Epub 2013 Oct 8.
234.
Yamashiro H, Takada M, Nakatani E, Imai S, Yamauchi A, Tsuyuki S, Matsutani Y, Sakata S, Wada Y,
Okamura R, Harada T, Tanaka F, Moriguchi Y, Kato H, Higashide S, Kan N, Yoshibayashi H, Suwa H, Okino T,
Nakayama I, Ichinose Y, Yamagami K, Hashimoto T, Inamoto T, Toi M. Prevalence and risk factors of bonemetastasis and skeletal related events in patients with primary breast cancer in Japan. Int J Clin Oncol
2014;19(5):852-62. doi: 10.1007/s10147-013-0643-5. Epub 2013 Nov 29.
235.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A,
Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M,
Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F,
Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R;
Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing
adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast
cancer: ATLAS, a randomised trial. Lancet 2013;381(9869):805-16. Erratum in: Lancet 2013;381(9869):804.
236.
Hamada S, Hinotsu S, Ishiguro H, Toi M, Kawakami K. Cross-national comparison of medical costs sharedby payers and patients: a study of postmenopausal women with early-stage breast cancer based on assumption
case scenarios and reimbursement fees. Breast Care (Basel) 2013;8:282-8. doi: 10.1159/000354249.
237.
Mikami Y, Ueno T, Yoshimura K, Tsuda H, Kurosumi M, Masuda S, Horii R, Toi M, Sasano H.
Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67
Ring Study. Cancer Sci 2013;104(11):1539-43. doi: 10.1111/cas.12245. Epub 2013 Sep 6.
27

238.
Tsuji W, Ishiguro H, Tanaka S, Takeuchi M, Ueno T, Toi M. Orally administered S-1 suppresses
circulating endothelial cell counts in metastatic breast cancer patients. Int J Clin Oncol 2014;19(3):452-9. doi:
10.1007/s10147-013-0570-5. Epub 2013 Jun 6.
239.
Komuro M, Suzuki K, Kanebako M, Kawahara T, Otoi T, Kitazato K, Inagi T, Makino K, Toi M, Terada H.
Novel iontophoretic administration method for local therapy of breast cancer. J Control Release 168:298-306,
2013.
240.
Idrees AS, Sugie T, Inoue C, Murata-Hirai K, Okamura H, Morita CT, Minato N, Toi M, Tanaka Y.
Comparison of γδ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated withzoledronic acid. Cancer Sci 104:536-42, 2013.
241.
Sugie T, Sawada T, Tagaya N, Kinoshita T, Yamagami K, Suwa H, Ikeda T, Yoshimura K, Niimi M,
Shimizu A, Toi M. Comparison of the indocyanine green fluorescence and blue dye methods in detection ofsentinel lymph nodes in early-stage breast cancer. Ann Surg Oncol 20:2213-8, 2013. doi:
10.1245/s10434-013-2890-0. Epub 2013 Feb 21.
242.
Chow LW, Tung SY, Ng TY, Im SA, Lee MH, Yip AY, Toi M, Glück S. Concurrent celecoxib with
5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: theOOTR-N001 study. Expert Opin Investig Drugs 22:299-307,2013.
243.
Chan MS, Wang L, Felizola SJ, Ueno T, Toi M, Loo W, Chow LW, Suzuki T, Sasano H. Changes of tumor
infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive
breast cancer patients--an immunohistochemical study of Cd8+ and Foxp3+ using double immunostaining withcorrelation to the pathobiological response of the patients. Int J Biol Markers 27;27:e295-304, 2012.
244.
Gasparini G, Torino F, Ueno T, Cascinu S, Troiani T, Ballestrero A, Berardi R, Shishido J, Yoshizawa A,
Mori Y, Nagayama S, Morosini P, Toi M. A phase II study of neoadjuvant bevacizumab plus capecitabine andconcomitant radiotherapy in patients with locally advanced rectal cancer. Angiogenesis 15:141-50, 2012. Epub
2012 Jan 3.
245.
Sugie T, Murata-Hirai K, Iwasaki M, Morita CT, Li W, Okamura H, Minato N, Toi M, Tanaka Y.
Zoledronic acid-induced expansion of γδ T cells from early-stage breast cancer patients: effect of IL-18 on helper
NK cells. Cancer Immunol Immunother 62:677-87, 2013.
246.
Imami K, Sugiyama N, Imamura H, Wakabayashi M, Tomita M, Taniguchi M, Ueno T, Toi M, Ishihama Y.
Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell
Proteomics 2012;11(12):1741-57. doi: 10.1074/mcp.M112.019919. Epub 2012 Sep 10.
247.
Tanaka S, Ueno T, Sato F, Chigusa Y, Kawaguchi-Sakita N, Kawashima M, Fujisawa N, Yoshimura K,
Teramukai S, Fujiwara H, Fujita M, Toi M. Alterations of circulating endothelial cell and endothelial progenitor
cell counts around the ovulation. J Clin Endocrinol Metab 2012;97:4182-92. doi: 10.1210/jc.2012-1736. Epub
2012 Sep 4.
248.
Ito R, Morimoto N, Liem PH, Nakamura Y, Kawai K, Taira T, Tsuji W, Toi M, Suzuki S. Adipogenesis
using human adipose tissue-derived stromal cells combined with a collagen/gelatin sponge sustaining release ofbasic fibroblast growth factor. J Tissue Eng Regen Med 2014;8(12):1000-8. doi: 10.1002/term.1611. Epub 2012
Sep 21.
249.
Tsuji W, Inamoto T, Ito R, Morimoto N, Tabata Y, Toi M. Simple and longstanding adipose tissue
engineering in rabbits. J Artif Organs 2013;16(1):110-4. doi: 10.1007/s10047-012-0670-4. Epub 2012 Nov 1
250.
Takeuchi M, Sugie T, Abdelazeem K, Kato H, Shinkura N, Takada M, Yamashiro H, Ueno T, Toi M.
Lymphatic mapping with fluorescence navigation using indocyanine green and axillary surgery in patients withprimary breast cancer. Breast J 2012;18:535-41. doi: 10.1111/tbj.12004. Epub 2012 Sep 26.
28

251.
Iima M, Nakamoto Y, Kanao S, Sugie T, Ueno T, Kawada M, Mikami Y, Toi M, Togashi K. Clinical
Performance of 2 Dedicated PET Scanners for Breast Imaging: Initial Evaluation. J Nucl Med 53:1534-42, 2012.
Epub 2012 Aug 29.
252.
Ichikawa T, Sato F, Terasawa K, Tsuchiya S, Toi M, Tsujimoto G, Shimizu K. Trastuzumab produces
therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells. PLoS One 2012;7:e31422. doi:
10.1371/journal.pone.0031422. Epub 2012 Feb 27.
253.
Kitai T, Torii M, Sugie T, Kanao S, Mikami Y, Shiina T, Toi M. Photoacoustic mammography: initialclinical results. Breast Cancer 2014;21(2):146-53. doi: 10.1007/s12282-012-0363-0. Epub 2012 Apr 7.
254.
Kondo M, Hoshi SL, Ishiguro H, Toi M. Economic evaluation of the 70-gene prognosis-signature(MammaPrint®) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor
type 2-negative early stage breast cancer in Japan. Breast Cancer Res Treat 2012;133:759-68. doi:
10.1007/s10549-012-1979-7.
255.
Takada M, Sugimoto M, Ohno S, Kuroi K, Sato N, Bando H, Masuda N, Iwata H, Kondo M, Sasano H,
Chow LW, Inamoto T, Naito Y, Tomita M, Toi M. Predictions of the pathological response to neoadjuvant
chemotherapy in patients with primary breast cancer using a data mining technique. Breast Cancer Res Treat
2012;134:661-70. doi: 10.1007/s10549-012-2109-2. Epub 2012 Jun 12.
256.
Takada M, Sugimoto M, Naito Y, Moon HG, Han W, Noh DY, Kondo M, Kuroi K, Sasano H, Inamoto T,
Tomita M, Toi M. Prediction of axillary lymph node metastasis in primary breast cancer patients using a decision
treebased model. BMC Med Inform Decis Mak 2012;12:54. doi: 10.1186/1472-6947-12-54.
257.
Tsuji W, Teramukai S, Ueno M, Toi M, Inamoto T. Prognostic factors for survival after first recurrence inbreast cancer: a retrospective analysis of 252 recurrent cases at a single institution. Breast Cancer 2014;21:86-95.
doi: 10.1007/s12282-012-0358-x. Epub 2012 Apr 5.
258.
Toi M, Saeki T, Iwata H, Inoue K, Tokuda Y, Sato Y, Ito Y, Aogi K, Takatsuka Y, Arioka H. A
multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel inmetastatic breast cancer patients with anthracycline resistance. Breast Cancer 2014;21:20-7. doi:
10.1007/s12282-012-0344-3. Epub 2012 Mar 2.
259.
Suzuki Y, Saeki T, Aogi K, Toi M, Fujii H, Inoue K, Watanabe T, Fujiwara Y, Ito Y, Takatsuka Y, Iwata H,
Arioka H, Tokuda Y. A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, inpatients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing
regimen and taxane. Int J Clin Oncol 2013;18:590-7. doi: 10.1007/s10147-012-0421-9. Epub 2012 May 15.
260.
Chan MS, Wang L, Chanplakorn N, Tamaki K, Ueno T, Toi M, Loo WT, Chow LW, Suzuki T, Sasano H.
Effects of estrogen depletion on angiogenesis in estrogen- receptor-positive breast carcinoma--animmunohistochemical study of vasohibin-1 and CD31 with correlation to pathobiological response of the patientsin neoadjuvant aromatase inhibitor therapy. Expert Opin Ther Targets 2012;16 Suppl 1:S69-78. doi:
10.1517/14728222.2011.628938. Epub 2012 Feb 7.
261.
Toi M, Benson JR, Winer EP, Forbes JF, von Minckwitz G, Golshan M, Robertson JF, Sasano H, Cole BF,
Chow LW, Pegram MD, Han W, Huang CS, Ikeda T, Kanao S, Lee ES, Noguchi S, Ohno S, Partridge AH,
Rouzier R, Tozaki M, Sugie T, Yamauchi A, Inamoto T. Preoperative systemic therapy in locoregional
management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference. Breast
Cancer Res Treat 136:919-26, 2012. doi: 10.1007/s10549-012-2333-9. Epub 2012 Nov 11.
262.
Ueno T, Emi M, Sato H, Ito N, Muta M, Kuroi K, Toi M. Genome-wide copy number analysis in primarybreast cancer. Expert Opin Ther Targets 2012;16 Suppl 1:S31-5. doi: 10.1517/14728222.2011.636739. Epub 2012
Feb 8.

29

263.
Takeda K, Kanao S, Okada T, Kataoka M, Ueno T, Toi M, Ishiguro H, Mikami Y, Togashi K. Assessmentof CAD-generated tumor volumes measured using MRI in breast cancers before and after neoadjuvant
chemotherapy. Eur J Radiol 2012;81:2627-31. doi: 10.1016/j.ejrad.2011.12.013. Epub 2012 Jan 4.
264.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C,
Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R.
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death:meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378(9804):1707-16,
2011. Epub 2011 Oct 19.
265.
Ren YS, Qian NS, Tang Y, Liao YH, Yang YL, Dou KF, Toi M. Sodium channel Nav1.6 is up-regulated in
the dorsal root ganglia in a mouse model of type 2 diabetes. Brain Res Bull 2012;87(2-3):244-9. Epub 2011 Nov
3.
266.
Ishiguro H, Takashima S, Yoshimura K, Yano I, Yamamoto T, Niimi M, Yamashiro H, Ueno T, Takeuchi
M, Sugie T, Yanagihara K, Toi M, Fukushima M. Degree of freezing does not affect efficacy of frozen gloves forprevention of docetaxel-induced nail toxicity in breast cancer patients. Support Care Cancer 2012;20:2017-24.
doi:10.1007/s00520-011-1308-4. Epub 2011 Nov 16.
267.
Kanai M, Ishiguro H, Mori Y, Kitano T, Nishimura T, Matsumoto S, Yanagihara K, Chiba T, Toi M.
Temporary blood pressure drop after bevacizumab administration is associated with clinical course of advanced
colorectal cancer. Br J Cancer 2011;105(11):1693-6. doi: 10.1038/bjc.2011.398. Epub 2011 Oct 27.
268.
Qian N, Ueno T, Kawaguchi-Sakita N, Kawashima M, Yoshida N, Mikami Y, Wakasa T, Shintaku M,
Tsuyuki S, Inamoto T, Toi M. Prognostic significance of tumor/stromal caveolin-1 expression in breast cancer
patients. Cancer Sci 2011;102:1590-6. doi: 10.1111/j.1349-7006.2011.01985.x. Epub 2011 Jun 27.
269.
Toi M, Winer EP, Inamoto T, Benson JR, Forbes JF, Mitsumori M, Robertson JF, Sasano H, von Minckwitz
G, Yamauchi A, Klimberg VS. Identifying gaps in the locoregional management of early breast cancer: Highlightsfrom the Kyoto Consensus Conference. Ann Surg Oncol 2011;18(10):2885-92. doi: 10.1245/s10434-011-1666-7.
Epub 2011 Mar 23.
270.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M,
Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R. Relevance of breast
cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis ofrandomised trials. Lancet 378:771-784, 2011. Epub 2011 Jul 28.
271.
Han HS, Reis IM, Zhao W, Kuroi K, Toi M, Suzuki E, Syme R, Chow L, Yip AY, Glück S. Racialdifferences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer.
Eur J Cancer 47:2537-2545, 2011.
272.
Iwata H, Sato N, Masuda N, Nakamura S, Yamamoto N, Kuroi K, Kurosumi M, Tsuda H, Akiyama F,
Ohashi Y, Toi M. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy
for patients with primary breast cancer. Jpn J Clin Oncol 41:867-75, 2011.
273.
Takada M, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K,
Aogi K, Iwata H, Ueno T, Sasano H, Toi M. Relationship between body mass index and preoperative treatment
response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer. Breast
2012;21(1):40-5. doi: 10.1016/j.breast.2011.07.015. Epub 2011 Aug 19.
274.
Ali AM, Ueno T, Tanaka S, Takada M, Ishiguro H, Abdellah AZ, Toi M. Determining circulating
endothelial cells using CellSearch system during preoperative systemic chemotherapy in breast cancer patients.
Eur J Cancer 47:2265-2272, 2011. Jul 5. [Epub ahead of print]
275.
Takeda K, Kanao S, Okada T, Ueno T, Toi M, Ishiguro H, Mikami Y, Tanaka S, Togashi K. MRI
evaluation of residual tumor size after neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy. Eur J Radiol
2012;81:2148-53. doi:10.1016/j.ejrad.2011.05.013. Epub 2011 Jun 12.
30

276.
Kawaguchi K, Ishiguro H, Morita S, Nakamura S, Ohno S, Masuda N, Iwata H, Aogi K, Kuroi K, Toi M;
Japan Breast Cancer Research Group (JBCRG). Correlation between docetaxel-induced skin toxicity and the useof steroids and H(2) blockers: a multi-institution survey. Breast Cancer Res Treat 30:627-34, 2011 Jun 23. [Epubahead of print]
277.
Iwasaki M, Tanaka Y, Kobayashi H, Murata-Hirai K, Miyabe H, Sugie T, Toi M, Minato N. Expression andfunction of PD-1 in human γδ T cells that recognize phosphoantigens. Eur J Immunol 2011:41,345-55. Epub 2011
Jan 11.
278.
Toi M, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K,
Aogi K, Iwata H, Takada M, Ueno T, Saji S, Chanplakorn N, Suzuki T, Sasano H. Ki67 index changes,
pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromataseinhibition. Cancer Sci 102:858-865, 2011. Epub 2011 Feb 1
279.
Tang Y, Xu F, Tao K, Qian N, Toi M. Clinical Applications of Sentinel Lymph Node Biopsy in Ductal
Carcinoma in situ of the Breast: A Dilemma. Tohoku J Exp Med 224:1-5, 2011.
280.
Tang Y, Zeng X, He F, Liao Y, Qian N, Toi M. Caveolin-1 is related to invasion, survival, and poor
prognosis in hepatocellular cancer. Med Oncol 2012;29:977-84. doi: 10.1007/s12032-011-9900-5. Epub 2011 Mar
17.
281.
Tang Y, Liao Y, Kawaguchi-Sakita N, Raut V, Fakhrejahani E, Qian N, Toi M. Sinisan, a traditional Chinese
medicine, attenuates experimental chronic pancreatitis induced by trinitrobenzene sulfonic acid in rats. J
Hepatobiliary Pancreat Sci 2011;18:551-8. doi: 10.1007/s00534-010-0368-z.
282.
Takuwa H, Ueno T, Ishiguro H, Mikami Y, Kanao S, Takada M, Sugie T, Toi M. A case of metaplastic
breast cancer that showed a good response to platinum-based preoperative chemotherapy. Breast Cancer
2014;21(4):504-7. doi: 10.1007/s12282-011-0269-2. Epub 2011 Apr 28.
283.
Chow LW, Yip AY, Chu WP, Loo WT, Toi M. Bone metabolism and quality-of-life of postmenopausal
women with invasive breast cancer receiving neoadjuvant hormonal therapy: Sub-analyses from celecoxib
anti-aromatase neoadjuvant (CAAN) trial. J Steroid Biochem Mol Biol 2011;125(1-2):112-9. doi:
10.1016/j.jsbmb.2010.12.018. Epub 2011 Jan 12.
284.
Honda M, Saji S, Horiguchi S, Suzuki E, Aruga T, Horiguchi K, Kitagawa D, Sekine S, Funata N, Toi M,
Kuroi K. Clinicopathological analysis of ten patients with metaplastic squamous cell carcinoma of the breast. Surg
Today 41:328-32, 2011. Epub 2011 Mar 2
285.
Kondo M, Hoshi SL, Yamanaka T, Ishiguro H, Toi M. Economic evaluation of the 21-gene signature(Oncotype DX®) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based onJapanese validation study (JBCRG-TR03). Breast Cancer Res Treat 2011;127:739-49. doi:
10.1007/s10549-010-1243-y. Epub 2010 Nov 17.
286.
Procter M, Suter TM, de Azambuja E, Dafni U, Van Dooren V, Muehlbauer S, Climent MA, Rechberger E,
Liu WTW, Toi M, Coombes CR, Dodwell D, Pagani O, Madrid J, Hall M, Chen SC, Focan C, Muschol M, van
Veldhuisen DJ, Piccart-Gebhart MJ. Longer-term assessment of trastuzumab-related cardiac adverse events in theherceptin adjuvant (HERA) trial. J Clin Oncol 28:3422-8, 2010.
287.
Horiguchi S, Hishima T, Hayashi Y, Shiozawa Y, Horiguchi K, Kuroi K, Toi M, Funata N, Eishi Y.
HER-2/neu cytoplasmic staining is correlated with neuroendocrine differentiation in breast carcinoma. J Med
Dent Sci 57:155-63, 2010.
288.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Correa C, McGale P, Taylor C, Wang Y,
Clarke M, Davies C, Peto R, Bijker N, Solin L, Darby S. Overview of the randomized trials of radiotherapy inductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 2010;2010:162-77.
31

289.
Horiguchi K, Toi M, Horiguchi S, Sugimoto M, Naito Y, Hayashi Y, Ueno T, Ohno S, Funata N, Kuroi K,
Tomita M, Eishi Y. Predictive value of CD24 and CD44 for neoadjuvant chemotherapy response and prognosis in
primary breast cancer patients. J Med Dent Sci 2010; 57:165-75.
290.
Sugie T, Kassim KA, Hashimoto T, Yamagami K, Masai Y, Toi M. A novel method for sentinel lymph nodebiopsy by indocyanine green fluorescence technique in breast cancer. Cancers 2: 713-720, 2010.
291.
Kitagawa D, Saji S, Horiguchi S, Satoh Y, Horiguchi K, Toi M, Funata N, Kuroi K. Alternation of estrogen
receptor and progesterone receptor expression in primary breast cancer patients treated with neoadjuvant
chemotherapy. Breast J 2010;16:435-6. Epub
292.
Toi M, Iwata H, Yamanaka T, Masuda N, Ohno S, Nakamura S, Nakayama T, Kashiwaba M, Kamigaki S,
Kuroi K; Japan Breast Cancer Research Group-Translational Research Group. Clinical significance of the 21-genesignature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese
population. Cancer 116:3112-8, 2010.
293.
Aogi K, Yoshida M, Sagara Y, Kamigaki S, Okazaki M, Funai J, Fujimoto T, Toi M, Saeki T, Takashima S.
The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients withmetastatic breast cancer including triple-negative phenotype. Cancer Chemother Pharmacol 2011;67(5):1007-15.
doi: 10.1007/s00280-010-1390-1. Epub 2010 Jul 14.
294.
Chen L, Endler A, Uchida K, Horiguchi S, Morizane Y, Iijima O, Toi M, Shibasaki F. Int6/eIF3e silencing
promotes functional blood vessel outgrowth and enhances wound healing by upregulating hypoxia-induced factor
2alpha expression. Circulation 122:910-9, 2010.
295.
Toi M, Ohashi Y, Seow A, Moriya T, Tse G, Sasano H, Park BW, Chow LW, Laudico AV, Yip CH, Ueno
E, Ishiguro H, Bando H. The Breast Cancer Working Group presentation was divided into three sections: theepidemiology, pathology and treatment of breast cancer. Jpn J Clin Oncol 40 Suppl 1:i13-18 2010.
296.
Yiu CC, Chanplakorn N, Chan MS, Loo WT, Chow LW, Toi M, Sasano H. Down-regulation of heat-shockprotein 70 (HSP-70) correlated with responsiveness to neoadjuvant aromatase inhibitor therapy in breast cancer
patients. Anticancer Res 30:3465-72, 2010.
297.
Ishiguro H, Kondo M, Hoshi SL, Takada M, Nakamura S, Teramukai S, Yanagihara K, Toi M. Economic
evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients withhigh-risk early breast cancer in Japan. Clin Ther 32:311-326, 2010.
298.
Toi M, Sperinde J, Huang W, Saji S, Winslow J, Jin X, Tan Y, Ohno S, Nakamura S, Iwata H, Masuda N,
Aogi K, Morita S, Petropoulos C, Bates M. Differential survival following trastuzumab treatment based on
quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast
cancer. BMC Cancer 2010;10:56. [Epub ahead of print]
299.
Chanplakorn N, Chanplakorn P, Suzuki T, Ono K, Chan MS, Miki Y, Saji S, Ueno T, Toi M, Sasano H.
Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following
neoadjuvant aromatase inhibitor therapy in breast cancer patients. Breast Cancer Res Treat 2010;120(3):639-48.
doi: 10.1007/s10549-010-0785-3. Epub 2010 Feb 12.
300.
Kimura Y, Tsuji W, Yamashiro H, Toi M, Inamoto T, Tabata Y. In situ adipogenesis in fat tissue
augmented by collagen scaffold with gelatin microspheres containing basic fibroblast growth factor. J Tissue Eng
Regen Med 4:55-61, 2010.
301.
Toi M, Iwata H, Fujiwara Y, Ito Y, Nakamura S, Tokuda Y, Taguchi T, Rai Y, Aogi K, Arai T, Watanabe J,
Wakamatsu T, Katsura K, Ellis CE, Gagnon RC, Allen KE, Sasaki Y, Takashima S. Lapatinib monotherapy inpatients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results fromJapanese patients phase II studies. Br J Cancer 101:1676-82, 2009.
302.
Kondo M, Hoshi SL, Toi M. Economic evaluation of chemoprevention of breast cancer with tamoxifen andraloxifene among high-risk women in Japan. Br J Cancer 27: 281-290, 2009.
32

303.
Nakamura S, Yagata H, Ohno S, Yamaguchi H, Iwata H, Tsunoda N, Ito Y, Tokudome N, Toi M, Kuroi K,
Suzuki E. Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall
survival in metastatic breast cancer. Breast Cancer 2010;17(3):199-204. doi: 10.1007/s12282-009-0139-3. Epub
2009 Aug 1.
304.
Tsuji W, Inamoto T, Yamashiro H, Ueno T, Kato H, Kimura Y, Tabata Y, Toi M. Adipogenesis induced byhuman adipose tissue-derived stem cells. Tissue Eng Part A 15:83-93, 2009.
305.
Muta M, Yanagawa T, Sai Y, Saji S, Suzuki E, Aruga T, Kuroi K, Matsumoto G, Toi M, Nakashima E.
Effect of low-dose Paclitaxel and docetaxel on endothelial progenitor cells. Oncology 77:182-91, 2009.
306.
Kondo M, Hoshi SL, Toi M. Budget impact analysis of chemoprevention of breast cancer with tamoxifen
and raloxifene among high-risk women in Japan. Jpn J Clin Oncol 39:767-70, 2009.
307.
Kimura M, Tominaga T, Takatsuka Y, Toi M, Abe R, Koyama H, Takashima S, Nomura Y, Miura S,
Kimijima I, Tashiro H, Ohashi Y; Adjuvant CEF Research Group for Breast Cancer. Randomized trial of
cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate,
and fluorouracil with node-positive breast cancer in Japan. Breast Cancer 2010;17(3):190-8. doi:
10.1007/s12282-009-0132-x. Epub 2009 Jul 3.
308.
Dewan MZ, Takada M, Terunuma H, Deng X, Ahmed S, Yamamoto N, Toi M. Natural killer activity of
peripheral-blood mononuclear cells in breast cancer patients. Biomed Pharmacother 63:703-6, 2009.
309.
Aruga T, Suzuki E, Saji S, Horiguchi S, Horiguchi K, Sekine S, Kitagawa D, Funata N, Toi M, Sugihara K,
Kuroi K. A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy
correlates with favorable anti-tumor response in patients with breast cancer. Oncol Rep 22:273-8, 2009.
310.
Kiba T, Inamoto T, Nishimura T, Ueno M, Yanagihara K, Teramukai S, Kato H, Toi M, Fukushima M. The
reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph
node dissection (pathological stage I-III) 3 years after surgery. BMC Cancer 7;8:323, 2008.
311.
Tokudome N, Ito Y, Hatake K, Toi M, Sano M, Iwata H, Sato Y, Saeki T, Aogi K, Takashima S.
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter
phase II and pharmacokinetic study in Japan. Anticancer Drugs 19:753-9, 2008.
312.
Yagata H, Nakamura S, Toi M, Bando H, Ohno S, Kataoka A. Evaluation of circulating tumor cells inpatients with breast cancer: multi-institutional clinical trial in Japan. Int J Clin Oncol 3:252-6, 2008.
313.
Honma N, Saji S, Kurabayashi R, Aida J, Arai T, Horii R, Akiyama F, Iwase T, Harada N, Younes M, Toi
M, Takubo K, Sakamoto G. Oestrogen receptor-beta1 but not oestrogen receptor-betacx is of prognostic value in
apocrine carcinoma of the breast. APMIS 116:923-30, 2008.
314.
Chen F, Fujinaga T, Sato K, Sonobe M, Shoji T, Sakai H, Miyahara R, Bando T, Okubo K, Hirata T, Toi M,
Date H. Clinical features of surgical resection for pulmonary metastasis from breast cancer. Eur J Surg Oncol
35:393-7, 2008. Epub 2008 Jun 18
315.
Ueno T, Elmberger G, Weaver TE, Toi M, Linder S. The aspartic protease napsin A suppresses tumor
growth independent of its catalytic activity. Lab Invest 2008;88(3):256-63. doi: 10.1038/labinvest.3700718. Epub
2008 Jan 14.
316.
Chow LW, Yip AY, Loo WT, Lam CK, Toi M. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for
locally advanced breast cancer. J Steroid Biochem Mol Biol 111:13-7, 2008.
317.
Saji S, Toi M et al. Dose-Finding Phase I and Pharmacokinetic Study of capecitabine (Xeloda) in
combination with epirubicin and cyclophosphamide (CEX) inpatients with inoperable or metastatic breast cancer.
Oncology 72:330-337, 2008 [Epub ahead of print]
33

318.
Chow LW, Yip AY, Loo WT, Toi M. Evaluation of neoadjuvant inhibition of aromatase activity and signaltransduction in breast cancer. Cancer Lett 262:232-8, 2008. Epub 2008 Jan 14.
319.
Olofsson MH, Ueno T, Pan Y, Xu R, Cai F, van der Kuip H, Muerdter TE, Sonnenberg M, Aulitzky WE,
Schwarz S, Andersson E, Shoshan MC, Havelka AM, Toi M, Linder S. Cytokeratin-18 is a useful serum
biomarker for early determination of response of breast carcinomas to chemotherapy. Clin Cancer Res
13:3198-206, 2007.
320.
Toi M, Nakamura S, Kuroi K, Iwata H, Ohno S, Masuda N, Kusama M, Yamazaki K, Hisamatsu K, Sato Y,
Kashiwaba M, Kaise H, Kurosumi M, Tsuda H, Akiyama F, Ohashi Y, Takatsuka Y; for Japan Breast Cancer
Research Group (JBCRG). Phase II study of preoperative sequential FEC and docetaxel predicts of pathologicalresponse and disease-free survival. Breast Cancer Res Treat 2110;531-539, 2007.
321.
Kondo M, Hoshi SL, Ishiguro H, Yoshibayashi H, Toi M. Economic evaluation of 21-gene reverse
transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage
breast cancer in Japan. Breast Cancer Res Treat 112:175-87, 2008.
322.
Toi M, Ikeda T, Akiyama F, Kurosumi M, Tsuda H, Sakamoto G, Abe O. Predictive implications of
nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who wererandomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy. Int J Oncol
31:899-906, 2007.
323.
Suzuki E, Niwa R, Saji S, Muta M, Hirose M, Iida S, Shiotsu Y, Satoh M, Shitara K, Kondo M, Toi M. A
nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients.
Clin Cancer Res 13:1875-82, 2007.
324.
Oikawa T, Onozawa C, Kuranuki S, Igarashi Y, Sato M, Ashino H, Shimamura M, Toi M, Kurakata S.
Dipalmitoylation of radicicol results in improved efficacy against tumor growth and angiogenesis in vivo. Cancer
Sci 98:219-25, 2007.
325.
Dewan MZ, Terunuma H, Takada M, Tanaka Y, Abe H, Sata T, Toi M, Yamamoto N. Role of natural killer
cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo.
Breast Cancer Res Treat 104:267-75, 2007.
326.
Saeki T, Nomizu T, Toi M, Ito Y, Noguchi S, Kobayashi T, Asaga T, Minami H, Yamamoto N, Aogi K,
Ikeda T, Ohashi Y, Sato W, Tsuruo T. Dofequidar fumarate (MS-209) in combination with cyclophosphamide,
doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer. J Clin Oncol 25:411-7, 2007.
327.
Yamaguchi T, Bando H, Mori T, Takahashi K, Matsumoto H, Yasutome M, Herbert W, Toi M.
Overexpression of soluble vascular endothelial growth factor receptor in colorectal cancer: Association with
progression and prognosis. Cancer Sci 98:219-25, 2007.
328.
Asami Y, Kakeya H, Okada G, Toi M, Osada H. RK-9513, a new angiogenesis inhibitor produced byaspergillus fumigatus. J Antibiot 59: 724-728, 2006.
329.
Dewan MZ, Terunuma M, Toi M, Tanaka Y, Katano H, Deng X, Abe H, Nakasone T, Mori N, Sata T,
Yamamoto N. Potential role of natural killer cells in controlling growth and infiltration of AIDS-associatedprimary effusion lymphoma cells. Cancer Sci 97:1381-1387, 2006.
330.
Ueno T, Chow LW, Toi M. Increases in circulating VEGF levels during COX-2 inhibitor treatment in breast
cancer patients. Biomed Pharmacother 60:277-2779, 2006.
331.
Muta M, Matsumoto G, Nakashima E, Toi M. Mechanical analysis of tumor growth regression by thecyclooxygenase-2 Inhibitor, DFU, in a Walker256 rat tumor model: Importance of monocyte chemoattractant
protein-1 modulation. Clin Cancer Res 12:264-272, 2006.
34

332.
Saeki T, Kimura T, Toi M, Taguchi T. A Pilot Phase II study of capecitabine in advanced or recurrent breast
cancer. Breast Cancer 13:49-57, 2006.
333.
Bando H, Weich H, Horiguchi S, Funata N, Ogawa T, Toi M. The association between vascular endothelial
growth factor-C, its corresponding receptor, VEGFR-3, and prognosis in primary breast cancer: A study with 193
cases. Oncology Rep 15:653-659, 2006.
334.
Dewan MZ, Uchihara J, Terashima K, Honda M, Sata T, Ito M, Fujii N, Uozumi K, Tsukasaki K,
Tomonaga M, Kubuki Y, Okayama A, Toi M, Mori N, Yamamoto N. Efficient intervention of growth andinfiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir. Blood 107:716-724,
2006.
335.
Matsumoto G, Muta M, Umezawa K, Suzuki T, Misumi K, Tsuruta K, Okamoto A, Toi M. Enhancement of
the caspase-independent apoptotic sensitivity of pancreatic cancer cells by DHMEQ, an NF-kappa B inhibitor. Int
J Oncol 27:1247-55, 2005.
336.
Hiramatsu K, Takahashi K, Yamaguchi T, Matsumoto H, Miyamoto H, Tanaka S, Tanaka C, Tamamori Y,
Imajo M, Kawaguchi M, Toi M, Mori T, Kawakita M. N(1),N(12)-Diacetylspermine as a sensitive and specificnovel marker for early- and late-stage colorectal and breast cancers. Clin Cancer Res 11:2986-2990, 2005.
337.
Saji S, Kawakami M, Hayashi S, Yoshida N, Hirose M, Horiguchi S, Itoh A, Funata N, Schreiber SL,
Yoshida M, Toi M. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in
estrogen receptor-positive breast cancer. Oncogene 24:4531-4539, 2005.
338.
Matsumoto G, Namekawa J, Muta M, Nakamura T, Bando H, Tohyama K, Toi M, Umezawa K. Targetingof Nuclear Factor {kappa}B Pathways by Dehydroxymethylepoxyquinomicin, a novel Inhibitor of breast
carcinomas: Antitumor and antiangiogenic potential in vivo. Clin Cancer Res 11:1287-1293, 2005.
339.
Bando H, Weich HA, Brokelmann M, Horiguchi S, Funata N, Ogawa T, Toi M. Association between
intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. Br J Cancer
92:553-561, 2005.
340.
Toi M, Saeki T, Aogi K, Sano M, Hatake K, Asaga T, Tokuda Y, Mitsuyama S, Kimura M, Kobayashi T,
Tamura M, Tabei T, Shin E, Nishimura R, Ohno S, Takashima S. Late phase II clinical study of vinorelbine
monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes. Jpn J Clin
Oncol 35:310-315, 2005.
341.
Yasuno M, Mori T, Koike M, Takahashi K, Toi M, Takizawa T, Shimizu S, Yamaguchi T, Matsumoto H.
Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients withadvanced colorectal carcinoma. Oncol Rep 13:405-412, 2005.
342.
Iwata H, Nakamura S, Toi M, Shin E, Masuda N, Ohno S, Takatsuka Y, Hisamatsu K, Yamazaki K, Kusama
M, Kaise H, Sato Y, Kuroi K, Akiyama F, Tsuda H, Kurosumi M. Japanese Breast Cancer Research Group.
Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed bydocetaxel as preoperative chemotherapy for early stage breast carcinoma. Breast Cancer 12:99-103, 2005.
343.
Saeki T, Takashima S, Terashima M, Satoh A, Toi M, Osaki A, Toge T, Ohno S, Nomura N, Fukuyama Y,
Koizumi W, Taguchi T. A Japanese phase I study of continuous oral capecitabine in patients with malignant solid
tumors. Int J Clin Oncol 10:51-57, 2005.
344.
Ohno S, Toi M, Kuroi K, Nakamura S, Iwata H, Kusama M, Masuda N, Yamazaki K, Hisamatsu K, Sato Y,
Takatsuka Y, Shin E, Kaise H, Kurozumi M, Tsuda H, Akiyama F. Update results of FEC followed by docetaxel
neoadjuvant trials for primary breast cancer. Biomed Pharmacother Suppl 2:S323-324, 2005.
345.
Chow LW, Cheng CW, Wong JL, Toi M. Serum lipid profiles in patients receiving endocrine treatment forbreast cancer: The results from the Celecoxib Anti-Aromatase Neoadjuvant (CAAN) Trial. Biomed Pharmacother
Suppl 2:S302-305, 2005.
35

346.
Chow LW, Loo WT, Wai CC, Lui EL, Zhu L, Toi M. Study of COX-2, Ki67, and p53 expression to predict
effectiveness of 5-flurouracil, epirubicin and cyclophosphamide with celecoxib treatment in breast cancer patients.
Biomed Pharmacother Suppl 2:S298-301, 2005.
347.
Nakanishi C, Yamaguchi T, Iijima T, Saji S, Toi M, Mori T, Miyaki M. Germline mutation of the
LKB1/STK11 gene with loss of the normal allele in an aggressive breast cancer of Peutz-Jeghers syndrome.
Oncology 67:476-479, 2004.
348.
Zhu L, Chow WC, Loo WT, Guan X, Toi M. Her2/neu expression predicts the response to anti-aromataseneoadjuvant therapy in advanced breast cancer: Subgroup analysis from CAAN trial. Clin Cancer Res
10:4639-4644, 2004.
349.
Tominaga T, Kimura M, Asaga T, Yoshida M, Awane H, Koyama H, Takatsuka Y, Mitsuyama S, Ikeda T,
Ogita M, Aoyama H, Sano M, Abe R, Nishi T, Wada T, Danno M, Toi M, Takashima S.
1-hexylcarbamoyl-5-fluorouracil + cyclophosphamide + tamoxifen versus CMF + tamoxifen in women withlymph node-positive breast cancer after primary surgery: a randomized controlled trial. Oncol Rep 12:797-803,
2004.
350.
Matsumoto G, Rahman MA, Muta M, Nakamura T, Bando H, Saji S, Tsuruta K, Okamoto A, Toi M. DFU,
a selective COX-2 inhibitor, suppresses MCF-7 xenograft tumor growth in mice. Oncol Rep 12:281-285, 2004.
351.
Toi M, Bando H, Horiguchi S, Takada M, Kataoka A, Ueno T, Saji S, Muta M, Funata N, Ohno S.
Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer. Br J Cancer
90:2338-2343, 2004.
352.
Takada M, Kataoka A, Toi M, Bando H, Toyama K, Horiguchi S, Ueno T, Linder S, Saji S, Hayashi Y,
Funata N, Kinoshita J, Murakami S, Ohno S. A close association between alteration in growth kinetics byneoadjuvant chemotherapy and survival outcome in primary breast cancer. Int J Oncol 25:397-405, 2004.
353.
Bando H, Brokelmann M, Toi M, Alitalo K, Sleeman JP, Sipos B, Grone HJ, Weich HA. Immunodetection
and quantification of vascular endothelial growth factor receptor-3 in human malignant tumor tissues. Int J Cancer
111:184-191, 2004.
354.
Morita S, Toi M, Kobayashi T, Ito Y, Hozumi Y, Ohno S, Iwata H, Sakamoto J. Application of a continual
reassessment method to a phase I clinical trial of capecitabine in combination with cyclophosphamide andepirubicin (CEX) for inoperable or recurrent breast cancer. Jpn J Clin Oncol 34:104-106, 2004.
355.
Weich HA, Bando H, Brokelmann M, Baumann P, Toi M, Barleon B, Alitalo K, Sipos B, Sleeman J.
Quantification of vascular endothelial growth factor-C (VEGF-C) by a novel ELISA. J Immunol Methods
285:145-155, 2004.
356.
Toi M, Bando H, Ramachandran C, Melnick SJ, Imai A, Fife RS, Carr RE, Oikawa T, Lansky EP.
Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo. Angiogenesis
6:121-128, 2003.
357.
Chow WC, Wong JL, Toi M. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced
breast cancer: preliminary report. Steroid Biochem Mol Biol 86:443-447, 2003.
358.
Tominaga T, Koyama H, Toge T, Miura S, Sugimachi K, Yamaguchi S, Hirata K, Monden Y, Nomura Y,
Toi M, Kimijima I, Noguchi S, Sonoo H, Asaishi K, Ikeda T, Morimoto T, Ota J, Ohashi Y, Abe O.
Randomized controlled trial comparing oral doxifluridine plus oral cyclophosphamide with doxifluridine alone in
women with node-positive breast cancer after curative resection. J Clin Oncol 21:991-998, 2003.
359.
Ueno T, Toi M, Biven K, Bando H, Ogawa T, Linder S. Measurement of an apoptosis product in the sera ofbreast cancer patients. Eur J Cancer 39:769-774, 2003.
36

360.
Tominaga T, Adachi I, Sasaki Y, Tabei T, Ikeda T, Takatsuka Y, Toi M, Suwa T, Ohashi Y. Double-blind
randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal
women with advanced breast cancer. Ann Oncol 14:62-70, 2003.
361.
Biven K, Erdal H, Hagg M, Ueno T, Zhou R, Lynch M, Rowley B, Wood J, Zhang C, Toi M, Shoshan MC,
Linder S. A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring in patientsera. Apoptosis 8:263-268, 2003.
362.
Saji H, Toi M, Saji S, Koike M, Kohno K, Kuwano M. Nuclear expression of YB-1 protein correlates with
P-glycoprotein expression in human breast carcinoma. Cancer Lett 190:191-197, 2003.
363.

Ogura O, Kanzaki A, Bando H, Ogura T, Toi M, Takebayashi Y. Expression of thymidylate synthase andthymidine phosphorylase in human breast carcinoma: Implication for method to detect expression of thesemolecules in clinic. Cancer Lett 190:97-104, 2003.

364.

Kanzaki A, Nakayama K, Miyashita H, Shirata S, Nitta Y, Oubu M, Higashimoto M, Mutoh M, Mori S,
Konno S, Ogawa K, Toi M, Takebayashi Y. Mutation analysis of copper-transporting P-type adenosine
triphosphatase (ATP7B) in human solid carcinomas. Anticancer Res 23:1913-1915, 2003.

365.

Muta M, Matsumoto G, Hiruma K, Nakashima E, Toi M. Study of cancer gene therapy using
IL-12-secreting endothelial progenitor cells in a rat solid tumor model. Oncol Rep 10:1765-1769, 2003.

366.

Kuroi K, Bando H, Saji S, Toi M. Protracted administration of weekly docetaxel in metastatic breast cancer.
Oncol Rep 10:1479-1484, 2003.

367.

Muta M, Matsumoto G, Hiruma K, Saji S, Nakashima E, Toi M. Impact of vasculogenesis on solid tumor
growth in a rat model. Oncol Rep 10:1213-1218, 2003.

368.

Matsumoto G, Nagai S, Muta M, Tsuruta K, Okamoto A, Toi M. Survival benefit of KRN7000 immune
therapy in combination with TNP470 in hamster liver metastasis model of pancreatic cancer. Oncol Rep
10:1201-1206, 2003.

369.
Yamamoto Y, Yamashita J, Toi M, Muta M, Nagai S, Hanai N, Furuya A, Osawa Y, Saji S, Ogawa M.
Immunohistochemical analysis of estrone sulfatase and aromatase in human breast cancer tissues. Oncol Rep
10:791-796, 2003.
370.
Bando H, Toi M, Kitada K, Koike M. Genes commonly upregulated by hypoxia in human breast cancer
cells MCF-7 and MDA-MB-231. Biomed Pharmacother 57:333-340, 2003.
371.
Saji S, Omoto Y, Shimizu C, Horiguchi S, Watanabe T, Funata N, Hayashi S, Gustafsson JA, Toi M.
Expression of estrogen receptor (ER) beta-cx protein in ER alpha-positive breast cancer: Specific correlation withprogesterone receptor. Cancer Res 62:4849-4853, 2002.
372.
Toi M, Bando H, Ogawa T, Muta M, Hornig C, Weich HA. Significance of vascular endothelial growth
factor (VEGF)/ soluble VEGF receptor-1 relationship in breast cancer. Int J Cancer 98:14-18, 2002.
373.
Kanzaki A, Takebayashi Y, Bando H, Eliason JF, Watanabe S, Miyashita H, Fukumoto M, Toi M, Uchida T.
Expression of uridine and thymidine phosphorylase genes in human breast carcinoma. Int J Cancer 97:631-635,
2002.
374.
Tominaga T, Toi M, Abe O, Ohashi Y, Uchino J, Hayasaka H, Abe R, Izuo M, Enomoto K, Watanabe H,
Yoshida M, Taguchi T, Koyama H, Senoo T, Toge T, Monden Y, Hattori T, Nomura Y, Sugimachi K, Hirata K,
Nakazato H, Miura S, Morimoto T, Asaishi K, Kimijima I, Ota J, Sonoo H, Yamaguchi S; 5'-BC Study Group(5'-DFUR Adjuvant Chemotherapy for Breast Cancer Study Group). The effect of adjuvant
5'-deoxy-5-fluorouridine in early stage breast cancer patients: Results from a multicenter randomized controlled
trial. Int J Oncol 20:517-525, 2002.
37

375.
Asai G, Yamamoto N, Toi M, Shin E, Nishiyama K, Sekine T, Nomura Y, Takashima S, Kimura M,
Tominaga T. Pharmacokinetic and pharmacodynamic study of IST-622, a novel synthetic derivative ofchartreusin, by oral administration in a phase II study of patients with breast cancer. Cancer ChemotherPharmacol 49:468-472, 2002.
376.
Bando H, Matsumoto G, Bando M, Muta M, Ogawa T, Funata N, Nishihira J, Koike M, Toi M. Expressionof macrophage migration inhibitory factor in human breast cancer: Association with nodal spread. Jpn J Cancer
Res 93:389-396, 2002.
377.
Kanzaki A, Toi M, Neamati N, Miyashita H, Oubu M, Nakayama K, Bando H, Ogawa K, Mutoh M, Mori S,
Terada K, Sugiyama T, Fukumoto M, Takebayashi Y. Copper-transporting P-Type Adenosine Triphosphatase(ATP7B) is expressed in human breast carcinoma. Jpn J Cancer Res 93:70-77, 2002.
378.
Tsuruta K, Okamoto A, Toi M, Saji H, Takahashi T. Impact of selective Glisson transection on survival ofhepatocellular carcinoma. Hepatogastroenterology 49:1607-1610, 2002.
379.
Tominaga T, Toi M, Ohashi Y, Abe O. Representing the 5’-BC Study Group. Prognostic and predictive
value of thymidine phosphorylase activity in early-stage breast cancer patients. Clin Breast Cancer 1:55-64, 2002.
380.
Mandic A, Viktorsson K, Molin M, Akusjarvi G, Eguchi H, Hayashi S, Toi M, Hansson J, Linder S,
Shoshan MC. Cisplatin induces the proapoptotic conformation of bak in a deltamekk1-dependent manner. Mol
Cell Biol 21:3684-3691, 2001.
381.
Tsuneyoshi N, Fukudome K, Horiguchi S, Ye X, Matsuzaki M, Toi M, Suzuki K, Kimoto M. Expression
and anticoagulant function of the endothelial cell protein C receptor (EPCR) in cancer cell lines. Thromb
Haemoast 85:356-361, 2001.
382.
Saji H, Koike M, Yamori T, Saji S, Seiki M, Matsushima K, Toi M. Significant correlation of monocyte
chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer
9:1085-1091, 2001.
383.
Gasparini G, Toi M, Biganzoli E, Dittadi R, Fanelli M, Morabito A, Boracchi P, Gion M.
Thrombospondin-1 and -2 in node-negative breast cancer: correlation with angiogenic factors, p53, cathepsin D,
hormone receptors and prognosis. Oncology 60:72-80, 2001.
384.
Saji S, Okumura N, Eguchi H, Nakashima S, Suzuki A, Toi M, Nozawa Y, Saji S, Hayashi S. MDM2
enhances the function of estrogen receptor alpha in human breast cancer cells. Biochem Biophys Res Commun
281:259-265, 2001.
385.
Ohno O, Shima Y, Ikeda Y, Kondo SI, Kato K, Toi M, Umezawa K. Selective growth inhibition bysangivamycin of human umbilical vein endothelial cells. Int J Oncol 18:1009-1015, 2001.
386.
Kanzaki A, Toi M, Nakayama K, Bando H, Mutoh M, Uchida T, Fukumoto M, Takebayashi Y. Expressionof multi-drug resistance-related transporters in human breast carcinoma. Jpn J Cancer Res 92:452-458, 2001.
387.
Shitashige M, Toi M, Yano T, Shibata M, Matsuo Y, Shibasaki F. Dissociation of bax from a bcl-2/bax
heterodimer triggered by phosphorylation of serine 70 of bcl-2. J Biochem (Tokyo) 130:741-748, 2001.
388.
Nakayama K, Kanzaki A, Takebayashi Y, Toi M, Bando H, Nabei T, Miyazaki K, Fukumoto M. Different
features of angiogenesis between ovarian and breast carcinoma. Cancer Lett 170:161-167, 2001.
389.
Kuroi K, Tanaka C, Toi M. Clinical significance of plasma nucleosome levels in cancer patients.
Oncol 19:143-148, 2001.

Int J

390.

Kuroi K, Tanaka C, Toi M. Circulating levels of endostatin in cancer patients. Oncol Rep 8:405-409, 2001.

391.

Hattori K, Muta M, Toi M, Iizasa H, Shinsei M, Terasaki T, Obinata M, Ueda M, Nakashima E.
38

Establishment of bone marrow-derived endothelial cell lines from ts-SV40 T-antigen gene transgenic rats. Pharm
Res 18:9-15, 2001.
392.
Miyaki M, Iijima T, Hosono K, Ishii R, Yasuno M, Mori T, Toi M, Hishima T, Shitara N, Tamura K,
Utsunomiya J, Kobayashi N, Kuroki T, Iwama T. Somatic mutations of lKB1 and β-catenin genes ingastrointestinal polyps from patients with Peutz-Jeghers syndrome. Cancer Res 60:6311-6313, 2000.
393.
Eguchi H, Suga K, Saji H, Toi M, Nakachi K, Hayashi S. Different expression patterns of bcl-2 family
genes in breast cancer by estrogen receptor status with special reference to pro-apoptotic bak gene. Cell Death
Differ 7:439-446, 2000.
394.
Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, Koike M, Inadera H, Matsushima K. Significance ofmacrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis and survival in human breast
cancer. Clin Cancer Res 6:3282-3289, 2000.
395.
Kurebayashi J, Sonoo H, Inaji H, Nishimura R, Iino Y, Toi M, Kobayashi S, Saeki T. Endocrine therapies
for patients with recurrent breast cancer: Predictive factors for responses to first- and second-line endocrine
therapies. Oncology 59 Suppl1:31-37, 2000.
396.
Seki M, Toi M, Kobayashi K, Shitara K, Umezawa K, Seon BK, Kan M, Rhim J. Differential behaviour of
VEGF receptor expression and response to TNP-470 in two immortalized human endothelial cell lines. Int J
Oncol 17:525-533, 2000.
397.
Ueno T, Toi M, Koike M, Nakamura S, Tominaga T. Tissue factor expression in breast cancer tissues: Its
correlation with prognosis and plasma concentration. Br J Cancer 83:164-170, 2000.
398.
Mori K, Hasegawa M, Nishida M, Toma H, Fukuda M, Kubota T, Nagasue N, Yamana H, Hirakawa YS,
Chung K, Ikeda T, Takasaki K, Oka M, Kameyama M, Toi M, Fujii H, Kitamura M, Murai M, Sasaki H, Ozono S,
Makuuchi H, Shimada Y, Onishi Y, Aoyagi S, Mizutani K, Ogawa M, Nakao A, Kinoshita H, Tono T, Imamoto H,
Nakashima Y, Manabe T. Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenasein various human tumor tissues. Int J Oncol 17:33-38, 2000.
399.
Tozaki M, Toi M, Miyamoto Y, Fukuda K. Power doppler sonography of breast masses: Correlation of
doppler parameters with tumor angiogenesis and histological growth pattern. J Ultrasound Med 19:593-600, 2000.
400.
Toi M, Ueno T, Matsumoto H, Saji H, Funata N, Koike M, Tominaga T. Significance of thymidine
phosphorylase as a marker of protumor monocytes in breast cancer. Clin Cancer Res 5:1131-1137, 1999.
401.
Ueno T, Toi M, Tominaga T. Circulating soluble Fas concentration in breast cancer patients. Clin Cancer
Res 5:3529-3533, 1999.
402.
Toi M, Gion M, Saji H, Asano M, Dittadi R, Gilberti S, Locopo N, Gasparini G. Endogenousinterleukin-12: Relationship with angiogenic factors, hormone receptors and nodal status in human breast
carcinoma. Int J Oncol 15:1169-1175, 1999.
403.
Gasparini G, Toi M, Miceli R, Vermeulen PB, Dittadi R, Biganzoli E, Morabito A, Fanelli M, Gatti C,
Suzuki H, Tominaga T, Dirix LY, Gion M. Clinical relevance of vascular endothelial growth factor and thymidine
phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone
therapy. Cancer J Sci Am 5:101-111, 1999.
404.
Saji S, Nakashima S, Hayashi S, Toi M, Nozawa Y. Overexpression of MDM2 in MCF-7 promotes both
growth advantage and p53 accumulation in response to estradiol. Jpn J Cancer Res 90:210-218, 1999.
405.
Ishigaki S, Toi M, Ueno T, Matsumoto H, Muta M, Koike M, Seiki M. Significance of membrane-type1
matrix metalloproteinase expression in breast cancer. Jpn J Cancer Res 90:516-522, 1999.
406.

Kumeda S, Deguchi A, Toi M, Omura S, Umezawa K. Induction of G1 arrest and selective growth39

inhibition by lactacystin in human umbilical vein endothelial cells.

Anticancer Res 19:3961-3968, 1999.

407.
Sonoo H, Kurebayashi J, Iino Y, Inaji H, Watanabe T, Toi M, Kobayashi S, Sato B, Yoshimoto M.
Current status and controversial issues concerning endocrine therapy for patients with recurrent breast cancer inJapan. Breast Cancer 6:344-350, 1999.
408.
Kuroi K, Tanaka C, Toi M. Plasma nucleosome levels in node-negative breast cancer patients. Breast
Cancer 6:361-364, 1999.
409.
Katagiri T, Kasumi F, Yoshimoto M, Nomizu T, Asaishi K, Abe R, Tsuchiya A, Sugano M, Takai S, Yoneda
M, Fukutomi T, Nannba K, Makita M, Okazaki H, Hirata K, Okazaki M, Furutsuma Y, Morishita Y, Iino Y,
Karino T, Ayabe H, Hara S, Kajiwara T, Houga S, Shimizu T, Toi M, Yamazaki Y, Uchida T, Kunitomo K, Sonoo
H, Kuribayashi J, Shimotsuma K, Nakamura Y, Miki Y. High proportion of missense mutations of the BRCA1and BRCA2 genes in Japanese breast cancer families. J Hum Genet 43:42-48, 1998.
410.
Toi M, Taniguchi T, Ueno T, Asano M, Funata N, Sekiguchi K, Iwanari H, Tominaga T. Significance of
circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer. Clin Cancer Res
4:659-664, 1998.
411.
Gasparini G, Toi M, Verderio P, Ranieri G, Dante S, Bonoldi E, Boracchi P, Fanelli M, Tominaga T.
Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer:
Subanalysis in node-positive and nod-negative patients. Int J Oncol 12:1117-1125, 1998.
412.
Suzuki A, Toi M, Yamamoto Y, Saji S, Muta M, Tominaga T. Role of MDM2 overexpression indoxorubicin resistance of breast carcinoma. Jpn J Cancer Res 89:221-227, 1998.
413.
Umemura S, Komaki K, Noguchi S, Shiba E, Toi M, Kimijima I, Itoh H, Osamura YR. Prognostic factors
for node-negative breast cancers: Results of a study program by the Japanese Breast Cancer Society. Breast
Cancer 5:243-249, 1998.
414.
Ueno T, Toi M, Taniguchi T, Tominaga T. Serum hepatocyte growth factor levels in breast cancer patientswith distant metastases. The Cancer J 11:147-152, 1998.
415.
Kurizaki T, Toi M, Tominaga T. Relationship between matrix metalloproteinase expression and tumour
angiogenesis in human breast carcinoma. Oncol Rep 5:673-677, 1998.
416.
Kitamura M, Toi M, Arai K, Iwasaki Y, Suzuki H, Matsuo K. Concentrations of vascular endothelial
growth factor in the sera of gastric cancer patients. Oncol Rep 5:1419-1424, 1998.
417.
Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, Matsubara I, Vinante O, Bonoldi E,
Boracchi P, Gatti C, Suzuki H, Tominaga T. Prognostic significance of vascular endothelial growth factor protein
in node-negative breast carcinoma. J Natl Cancer Inst 89:139-147, 1997.
418.
Taniguchi T, Kitamura M, Arai K, Iwasaki T, Yamamoto Y, Igari A, Toi M. Increase in the circulatinglevel of hepatocyte growth factor in gastric cancer patients. Br J Cancer 75:673-677, 1997.
419.
Toi M, Gion M, Biganzoli E, Dittadi R, Boracchi P, Miceli R, Meli S, Mori K, Tominaga T, Gasparini G.
Co-determination of the angiogenic factors thymidine phosphorylase and vascular endothelial growth factor innode-negative breast cancer: prognostic implications. Angiogenesis 1:71-83, 1997.
420.
Toi M, Tanaka S, Bando M, Hayashi K, Tominaga T. Outcome of surgical resection for chest wallrecurrence in breast cancer patients. J Surg Oncol 64:23-26, 1997.
421.
Narita T, Kimura N, Mitsuoka C, Toi M, Sato M, Matsuura N, Matsumoto K, Nakamura T, Kannagi R.
Biological and clinical significance of hepatocyte growth factor in breast cancer. Int J Oncol 11:1305-1310, 1997.
422.

Tsuruta K, Toi M, Kondo M, Okamoto A. Removal of primary tumor might alter the growth rate of40

metastatic tumor in hepatocellular carcinoma. The Cancer J 10:53-55, 1997.
423.
Saji S, Toi M, Yamamoto Y, Tominaga T. The increase of apoptosis and the decrease of proliferation by
angiogenesis inhibitor in rat mammary tumors. Oncol Rep 4:111-114, 1997.
424.
Yamamoto Y, Toi M, Kondo S, Matsumoto T, Suzuki H, Kitamura M, Tsuruta K, Taniguchi T, Okamoto A,
Mori T, Yoshida M, Ikeda T, Tominaga T. Concentrations of vascular endothelial growth factor in the sera ofnormal control and cancer patients. Clin Cancer Res 2:821-826, 1996.
425.
Toi M, Kondo S, Suzuki H, Yamamoto Y, Inada K, Imazawa T, Taniguchi T, Tominaga T. Quantitative
analysis of vascular endothelial growth factor in primary breast cancer. Cancer 77:1101-1106, 1996.
426.
Umezawa K, Taniguchi T, Toi M, Ohse T, Tsutsumi N, Yamamoto T, Koyano T, Ishizuka M. Growth
inhibition of k-ras-expressing tumours by a new vinca alkaloid, conophylline, in nude mice. Drugs Exptl Clin Res
22:35-40, 1996.
427.
Inada K, Tominaga T, Toi M, Yamamoto Y, Abe M, Yamashita J, Ogawa M. Protective effect of leuprolide
acetate on 7, 12-dimethylbenz (a) anthracene (DMBA)-induced mammary carcinogenesis in rats. Eur J Surg
Oncol 22:583-587, 1996.
428.
Yamamoto Y, Toi M, Tominaga T. Prediction of the effect of 5'-deoxy-5-fluorouridine by the status ofangiogenic enzyme thymidine phosphorylase expression in recurrent breast cancer patients. Oncol Rep 3:863-865,
1996.
429.
Kitamura M, Arai K, Iwasaki Y, Toi M. Antitumor effect of the angiogenesis inhibitor TNP-470 and its
combination effect with 5-FU and PSK in colon 26 tumors. Oncol Rep 3:151-153, 1996.
430.
Inada K, Toi M, Yamamoto Y, Suzuki A, Kurisaki T, Suzuki H, Tominaga T. Immunocytochemical
analysis of MDM2 protein expression and its relevance to tumor angiogenesis in primary breast cancer. Oncol
Rep 3:667-671, 1996.
431.
Toi M, Inada K, Hoshina S, Suzuki H, Kondo S, Tominaga T. Vascular endothelial growth factor andplatelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast
cancer. Clin Cancer Res 1:961-964, 1995.
432.
Taniguchi T, Toi M, Inada K, Imazawa T, Yamamoto Y, Tominaga T. Serum concentrations of hepatocyte
growth factor in breast cancer patients. Clin Cancer Res 1:1031-1034, 1995.
433.
Yamamoto Y, Toi M, Yamada R, Tominaga T. Combination effect of an angiogenesis inhibitor
AGM-1470 with 5'-deoxy-5-fluorouridine, and with hormonal drugs in DMBA- induced rat mammary tumors.
Oncol Rep 2:793-796, 1995.
434.
Toi M, Hoshina S, Taniguchi T, Yamamoto Y, Ishitsuka H, Tominaga T. Expression of platelet-derived
endothelial cell growth factor/ thymidine phosphorylase in human breast cancer. Int J Cancer 64:79-82, 1995.
435.
Toi M, Inada K, Suzuki H, Tominaga T. Tumor angiogenesis in breast cancer: Its importance as aprognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res
Treat 36:193-204, 1995.
436.
Taniguchi T, Toi M, Tominaga T. Rapid induction of hepatocyte growth factor by heparin. Lancet
344:470, 1994.
437.
Toi M, Tominaga T, Osaki A, Toge T. Role of epidermal growth factor receptor expression in primarybreast cancer: Results of a biochemical study and an immunocytochemical study. Breast Cancer Res Treat
29:51-58, 1994.
438.

Toi M, Hoshina S, Takayanagi T, Tominaga T. Association of vascular endothelial growth factor
41expression with tumor angiogenesis and with early relapse in primary breast cancer.
85:1045-1049, 1994.

Jpn J Cancer Res

439.
Taniguchi T, Toi M, Tominaga T. Increase in the circulating level of hepatocyte growth factor in breast
cancer patients with distant metastases. Oncol Rep 1:1199-1201, 1994.
440.
Toi M, Takayanagi T, Souma R, Tominaga T. Inhibition of vascular endothelial growth factor induced
cell growth by an angiogenesis inhibitor AGM-1470 in capillary endothelial cells. Oncol Rep 1:423-426, 1994.
441.
Kitamura M, Takahashi K, Tominaga T, Toi M. Preventive effect of Whole Peptidoglycan (WPG) on theoccurrence of rat mammary tumors induced by 7,12- dimethylbenz (a) anthrancene (DMBA). Oncol Rep
1:309-312, 1994.
442.
Toi M, Kashitani J, Tominaga T. Tumor angiogenesis is an independent prognostic indicator in primarybreast carcinoma. Int J Cancer 55:371-374, 1993.
443.
Toi M, Harris AL, Bicknell R. cDNA transfection followed by the isolation of a MCF-7 breast cell line
resistant to tamoxifen in vitro and in vivo. Br J Cancer 68:1088-1096, 1993.
444.
Oikawa T, Ito H, Ashino H, Toi M, Tominaga T, Morita I, Murota S. Radicicol, a microbial celldifferentiation modulator, inhibits in vivo angiogenesis. Eur J Pharmacol 241:221-227, 1993.
445.
Toi M, Yamamoto Y, Imazawa T, Takayanagi T, Akutsu K, Tominaga T. Antitumor effect of theangiogenesis inhibitor AGM-1470 and its combination effect with tamoxifen in DMBA induced mammary tumorsin rats. Int J Oncol 3:525-528, 1993.
446.
Kuroi K, Osaki A, Yamada H, Toi M, Toge T, Takimoto Y, Kuramoto A, Arihiro K, Inai K. Primarysquamous cell carcinoma of the breast after cured Hodgkin's disease. Surg Today 23:81-84, 1993.
447.
Tominaga T, Toi M, Shirasaka T. Enhanced inhibition of thymidylate synthase by 5-fluorouracil and (6S)
leucovorin combination therapy for breast cancer. Anticancer Res 13 (6B):2425-2427, 1993.
448.
Toi M, Bicknell R, Harris AL. Inhibition of colon and breast carcinoma cell growth by interleukin-4.
Cancer Res 52:275-279, 1992.
449.
Toi M, Hattori T, Akagi M, Inokuchi K, Orita K, Sugimachi K, Dohi K, Nomura Y, Monden Y, Hamada Y,
Morimoto T, Ogawa N. Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK tochemotherapy in patients with primary breast cancer: 5-year results from the Nishi-Nippon Group of the Adjuvant
Chemoendocrine Therapy for Breast Cancer Organization. Cancer 70:2475-2483, 1992.
450.
Osaki A, Toi M, Yamada H, Kawami H, Kuroi K, Toge T. Prognostic significance of co-expression ofc-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients. Am J Surg 164:323-326,
1992.
451.
Mukaida H, Toi M, Hirai T, Yamashita Y, Toge T. Clinical significance of the expression of epidermal
growth factor and its receptor in esophageal cancer. Cancer 68:142-148, 1991.
452.
Toi M, Osaki A, Yamada H, Toge T. Epidermal growth factor receptor expression as a prognostic
indicator in breast cancer. Eur J Cancer 27:977-980, 1991.
42

453.
Toi M, Harris AL, Bicknell R. Interleukin-4 is a potent mitogen for capillary endothelium. Biochem
Biophys Res Commun 174:1287-1293, 1991.
454.
Toi M, Nakamura T, Mukaida H, Wada T, Osaki A, Yamada H, Toge T, Niimoto M, Hattori T.
Relationship between epidermal growth factor receptor status and various prognostic factors in human breast
cancer. Cancer 65:1980-1984, 1990.
455.
Toi M, Mukaida H, Wada T, Hirabayashi N, Toge T, Hori T, Umezawa K. Antineoplastic effect of
erbstatin on human mammary and esophageal tumors in athymic nude mice. Eur J Cancer 26:722-724, 1990.
456.
Niimoto M, Saeki T, Toi M, Nishiyama M, Hirai T, Yanagawa E, Hattori T. Prospective randomized
controlled study on bestatin in resectable gastric cancer; Third report. Jpn J Surg 20:186-191, 1990.
457.
Toi M, Wada T, Yamada H, Osaki A, Yamamoto A, Nakamura T, Niimoto M, Hattori T. Growth fractionsof breast cancer in relation to epidermal growth factor receptor and estrogen receptor. Jpn J Surg 20:327-330,
1990.
458.
Mukaida H, Yamamoto T, Hirai T, Toi M, Nakamura T, Wada T, Yamashita Y, Kawano K, Niimoto M.
Expression of human epidermal growth factor and its receptor in esophageal cancer. Jpn J Surg 20:275-282, 1990.
459.
Suehiro S, Hamada Y, Toi M, Nakamura T, Niimoto M, Hattori T. Nuclear DNA content in breast
carcinoma with special reference to the parameters of malignant potentiality. Jpn J Surg 20:115-118, 1990.
460.
Toi M, Hamada Y, Nakamura T, Mukaida H, Suehiro S, Wada T, Toge T, Niimoto M, Hattori T.
Immunocytochemical and biochemical analysis of epidermal growth factor receptor expression in human breast
cancer tissues: Relationship to estrogen receptor and lymphatic invasion. Int J Cancer 43:220-225, 1989.
461.
Suehiro S, Inai K, Tokuoka S, Hamada Y, Toi M, Niimoto M, Hattori T. Involvement of the nipple inearly carcinoma of the breast. Surg Gynecol Obstet 168:244-248, 1989.
462.
Toi M, Nakamura T, Wada T, Yamamoto A, Toge T, Niimoto M, Hattori T. The discrepancy between
immunocytochemical and biochemical assay of estrogen receptor in breast cancer patients treated by endocrine
therapy. Jpn J Surg 19:768-772, 1989.
463.
Toi M, Nakamura T, Wada T, Yamamoto A, Toge T, Niimoto M, Hattori T. The acceptable delay between
biopsy and radical mastectomy in breast cancer patients. Jpn J Surg 19:679-683, 1989.
464.
Toi M, Hamada Y, Seto Y, Tanimoto M, Nakamura T, Toge T, Niimoto M, Hattori T.
Immunocytochemical study on the variation in estrogen receptor of primary and nodal metastases of breast cancer.
Jpn J Surg 18:228-231, 1988.
Others:
1. Toi M, Takada M. Comments to the Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines
2022. Translational Breast Cancer Research 2022;3:21 (30 July 2022).
2.

Toi M, Ohno S, Saeki T, Nakamura S, Thürlimann B. For choosing axillary treatment, and adjuvant hormonal
treatment. Breast Cancer 2016;23(2):167-9. doi: 10.1007/s12282-015-0662-3. Epub 2015 Dec 21.

43

3.

Tsuda M, Ishiguro H, Yano I, Toi M. Re: Denosumab for patients with persistent or relapsed hypercalcemia ofmalignancy despite recent bisphosphonate treatment. J Natl Cancer Inst 2014;106. doi:pii: dju137.
10.1093/jnci/dju137. Print 2014 Jul. No abstract available.

4.

Ishiguro H, Toi M. Colony-stimulating factors for febrile neutropenia. N Engl J Med 2013;369(3):284.

5.

Ishiguro H, Kawaguchi K, Nishimura T, Toi M. Antipsychotics-containing regimen as an alternative to standard
antiemetics for delayed nausea induced by highly emetogenic chemotherapy. J Clin Oncol 2013;31(10):1377-8.

6.

Author’s response. Chan M, Wang L, Chanplakorn N, Tamaki K, Ueno T, Toi M, Loo W, Chow LW, Suzuki T,
Sasano H. Expert Opin Ther Targets 2013;17(1):106. No abstract available.

7.

Ohno S, Kuroi K, Toi M. An overview of the Japan Breast Cancer Research Group (JBCRG) activities. Breast
Cancer 2013;20:291-5. doi: 10.1007/s12282-012-0420-8. Epub 2013 Mar 15.

8.

Global Cancer Genomics Consortium. The Global Cancer Genomics Consortium: interfacing genomics andcancer medicine. Cancer Res 2012;72(15):3720-4. Epub 2012 May 24.

9.

Chow LW, Toi M. The clinical trials of the Organisation for Oncology and Translational Research (OOTR). Int J
Biol Markers 2012;27(4):e353-6. doi:10.5301/JBM.2012.10371.

10. Toi M. Acknowledgments - OOTR Annual Conference 2012 Proceedings. Int J Biol Markers 2013;27(4):285.
doi: 10.5301/JBM.2013.10605. [Epub ahead of print]
11. Author's response. Chan M, Wang L, Chanplakorn N, Tamaki K, Ueno T, Toi M, Loo W, Chow LW, Suzuki T,
Sasano H. Expert Opin Ther Targets 2013;17(1):106.
12. Toi M, Yasui W, Ito H, Tahara E. Recent progress in carcinogenesis, progression and therapy of breast cancer: the20th Hiroshima Cancer Seminar--the 4th Three Universities' Consortium International Symposium, October 2010:
31 October 2010, International Conference Center Hiroshima. Jpn J Clin Oncol 41:924-30, 2011. Epub 2011 May
12
13. Kuroi K, Toi M. A current perspective on the use of a weekly docetaxel dosing schedule in breast cancer.
www.siicsalud.com, 2006 (Review).
14. Toi M. Proinflammation in human tumor microenvironment: Its status and implication. Med Sci Monit
8:LE25-26, 2002.
和文業績
和文著書編集、監修
1． 戸井 雅和：乳癌診療 state of the art 科学に基づく最新診療：医歯薬出版株式会社 2022/9/6
2． 木下貴之、戸井雅和：オンコロジークリニカルガイド乳癌薬物療法 (オンコロジ-クリニカルガイド)：
南山堂、2013/11/10、2016/11/1
3． 戸井雅和：乳癌レビュー 2012：メディカルレビュー社、2011/12/01
4． 戸井 雅和：Triple Negative 乳癌-発症メカニズムから診断・治療まで：南山堂、2010/11/1
5． 戸井 雅和：みんなに役立つ乳癌の基礎と臨床：医薬ジャーナル、2009/7/1
44

6． 戸井雅和：乳癌レビュー 2009：メディカルレビュー社、2009/7/1
7． 戸井 雅和：乳がん薬物療法 (インフォームドコンセントのための図説シリーズ)：医薬ジャーナル、
2008/1/1、2012/9/1
8． 伊藤良則、戸井雅和： 乳腺疾患 state of arts（医学のあゆみ､別冊）医歯薬出版株式会社、2004．
9． 戸井雅和、笹野公伸：乳癌の抗アロマターゼ療法 医学出版社、2003．

和文著書分担執筆
1．堀口和美、戸井雅和：原発性乳癌に対する術後ホルモン療法の進め方 「乳腺疾患の臨床」坂元吾偉、
野口昌邦 監修、稲治英生、平岡眞寛、黒住昌史、伊藤良則（編）pp321-328、金原出版株式会社、2006．
2．
山城大泰、戸井雅和：分子生物学的特徴‘悪性度’
園尾博司（編） pp207-214、永井書店、2006．
3．

「よくわかる乳癌のすべて」飯野佑一、

戸井雅和（共同執筆者）：「ドクターズ・マニュアル」荒井邦佳（編）分光堂、2005．

4．
佐治重衡、戸井雅和：二期的（外来で行う）センチネルリンパ節生検「Atlas of Breast Surgery―乳癌の手術」 霞富士雄、植野映 （編）pp268-277、南江堂、2005．
5．
2005．

戸井雅和：トラスツズマブ「癌化学療法 update」西條長宏、鶴尾隆（編）pp138-14、中外医学社、

6．
吉田龍一、坂東裕子、戸井雅和： 乳癌「ガイドライン外来診療 2005」泉孝英（編）pp446-448、
日経メディカル開発、2005．
7．
佐治重衡、戸井雅和：再発乳癌に対するホルモン療法の選択「乳癌診療２頁の秘訣」光山昌珠（編）pp270-271、金原出版、2004．
8．
戸井雅和：原発性乳癌に対するアジュバント療法における化学療法とホルモン療法の併用「乳腺疾患 state of arts」（医学のあゆみ､別冊）伊藤良則、戸井雅和（編）pp290-292、医歯薬出版株式会社、2004．
9．
山城大泰、戸井雅和：良性疾患、女性化乳房症の診断と治療「乳腺疾患 state of arts」（医学のあゆみ､別冊）伊藤良則、戸井雅和（編）pp603-605、医歯薬出版株式会社、2004．
10．
坂東裕子、戸井雅和：乳癌と VEGF「乳腺疾患 state of arts」（医学のあゆみ､別冊）伊藤良則、
戸井雅和（編）pp26-29、医歯薬出版株式会社、2004．
11．
佐治重衡、松本岳、戸井雅和：新しい治療法の開発 （血管新生阻害剤、免疫療法の可能性、生物学的治療の探求） 「先端医療シリーズ 21・癌、乳癌の最新医療」小山博記・霞富士雄 （監修）pp200-206、
先端医療技術研究所、2003．
12．
黒井克昌、戸井雅和：主な外来化学療法の実際：都立駒込病院外科・昭和大学附属豊洲病院外科「癌の外来化学療法マニュアル」垣添 忠生（編）pp166-177、メディカルレビュー社、2003．
13．
戸井雅和、坂東裕子：血管新生と病態 腫瘍（転移）「血管新生研究の新展開」室田誠逸、佐藤靖
史（編）pp249-261、医薬ジャーナル社、2000．
14．
戸井雅和：腫瘍血管新生の意義とその関連因子「新臨床医のための分子医学シリーズ；血管新生の最前線 そのメカニズムと病態・治療」佐藤靖史（編）pp95-107、羊土社、1999．
45

15．
戸井雅和、上野貴之： 癌
メディカルレビュー社、1998．

病態生理・診断・治療「HGF の分子医学」松本邦夫（編）pp145-151、

16．
戸井雅和、冨永健：Ⅵ 合併症と工夫、2 腋窩静脈を損傷した場合の処置「乳線外科の要点と盲点」幕内雅敏（監修）霞富士雄（編）pp212-213、文光堂、1998．
17．
戸井雅和、冨永健：血管新生制御因子「癌診療の知識 97」阿部令彦（監修）、磯野可一、栗原稔、
北島政樹、大川智彦（編）pp89-99、篠原出版、1997．
18．
戸井雅和、山本豊、冨永健：PD-ECGF(Platelet-derived endothelial cell growth factor)「血管新生療法－基礎と臨床－」内田康美, 小塚 裕（編）pp67-73、真興交易（株）医書出版、1997．
19．
栗崎貴、戸井雅和、今沢隆、冨永健：乳癌多発家系における p53 の異常「家族性乳癌」阿部力哉（監修）野水整、土屋敦雄（編）pp97-104、篠原出版、1996．
20．
戸井雅和、冨永健：乳癌「Biochemical Modulation の基礎と臨床」金丸龍之介、小西敏郎（編）pp111-116、
医学書院、1995．
21．
戸井雅和：温泉談議「乳がんからの生還－乳がんと闘う最前線外科医達の手記－」冨永健(監修) 乳がん懇話会（編）pp59-61、日本小児医事出版、1990．
22．
戸井雅和：乳がんにおける急患「忘れ得ぬ患者さん達へ－乳がんと闘う若き医師達の手記－」冨永健(監修) 乳がん懇話会（編）pp195-201、日本小児医事出版発行、1989．
診療ガイドラインに関する出版物
1．
乳房温存療法ガイドライン 医療者向け－「標準的な乳房温存療法の実施要項の研究」班に基づく治療指針 厚生労働科学研究費補助金「がん臨床研究事業」標準的な乳房温存療法の実施要項の研究班（編）
金原出版（2005-10-20 出版）．
2．
患者さんのための乳房温存療法ガイドライン－正しい理解をもって治療を受けていただくために
厚生労働科学研究費補助金「がん臨床研究事業」標準的な乳房温存療法の実施要項の研究班（編）金原出版（2005-10-20 出版）．
和文雑誌編集、和文雑誌特集号編集など
1． 戸井雅和：別冊医学のあゆみ 乳癌診療 Update 最新診療コンセンサス 2012：2013/1/15
2． 戸井雅和：別冊医学のあゆみ がん分子標的治療の最先端 – 2008/12/10
3． 戸井雅和、大野真司他：CANCER BOARD of the BREAST（メディカルレビュー） 2015 年 3 月号（Vol.1
No.1）、2015 年 7 月号（Vol.1 No.2）、2016 年 2 月号（Vol.2 No.1）、2016 年 8 月号（Vol.2 No.2）、 2017年 2 月号（Vol.3 No.1）、2017 年 8 月号（Vol.3 No.2）、2018 年 2 月号（Vol.4 No.1）、2018 年 8 月号（Vol.4
No.2）、2019 年 3 月号（Vol.5 No.1）、2019 年 9 月号（Vol.5 No.2）、2020 年 5 月号（Vol.6 No.1）、2021 年
2 月号（Vol.6 No.2）
4． 西條長宏、戸井雅和他：がん分子標的治療（メディカルレビュー） 2015 年 3 月号（Vol.13 No.1）、2015
年 7 月号（Vol.13 No.2）、2015 年 9 月号（Vol.13 No.3）、2015 年 12 月号（Vol.13 No.4）、2016 年 3 月号（Vol.14
No.1）、2016 年 6 月号（Vol.14 No.2）、2016 年 9 月号（Vol.14 No.3）、2016 年 12 月号（Vol.14 No.4）、2017
年 3 月号（Vol.15 No.1）、2017 年 6 月号（Vol.15 No.2）、2017 年 9 月号（Vol.15 No.3）、2017 年 12 月号（Vol.15
No.4）、2018 年 3 月号（Vol.16 No.1）、2018 年 6 月号（Vol.16 No.2）、2018 年 9 月号（Vol.16 No.3）、2019
年 2 月号（Vol.16 No.4）、2019 年 6 月号（Vol.17 No.1）、2019 年 12 月号（Vol.17 No.2）、2020 年 8 月号（Vol.18
46

No.1）、2021 年 1 月号（Vol.18 No.2）、2021 年 9 月号（Vol.19 No.1）
5． 戸井雅和、他： CANCER BOARD 乳癌（メディカルレビュー） 2008 年（Vol.1 No.1）、2009 年（Vol.2
No.1）、2009 年（Vol.2 No.2）、 2010 年（Vol.3 No.1）、2010 年（Vol.3 No.2）、 2011 年（Vol.4 No.1）、2011
年（Vol.4 No.2）、2012 年 4 月号（Vol.5 No.1）、2012 年 10 月号（Vol.5 No.2）、2013 年 4 月号（Vol.6 No.1）、2014 年 1 月号（Vol.6 No.2）、2014 年 4 月号（Vol.7 No.1）、2014 年 12 月号（（Vol.7 No.2）
6． 戸井雅和：「ホルモン療法の進歩」癌と宿主 18（1）、2006．
7． 戸井雅和：「ホルモン療法の最近の進歩」細胞 36（10）、2004．
8． 戸井雅和：「癌と低酸素」癌と宿主 15（3）、2003．
9． 戸井雅和：「Neoadjuvant Therapy」癌と宿主 14（4）、2002．

和文総説
1.

三宅 可奈江, 片岡 正子, 松本 純明, 鳥井 雅恵, 石守 崇好, 八上 全弘, 磯田 裕義, 高田 正泰, 戸井
雅和, 中本 裕士：乳房専用 PET 読影標準化に向けて「dbPET レキシコン version 1.0」
：MEDICALNOW(0916-8745)90 号 Page30-36(2022.03)

2.

松本 純明, Zhang Qi, 戸井 雅和：腫瘍血管の光超音波イメージング：がん分子標的治療(1347-6955)19
巻 2 号 Page210-216(2022.01)

3.

片岡 正子, 三宅 可奈江, 松本 純明, 鳥井 雅恵, 石守 崇好, 八上 全弘, 高田 正泰, 戸井 雅和, 磯田
裕義, 中本 裕士：Nuclear Medicine Today 2021 キーワードから展望する核医学の技術開発と臨床応
用；乳房専用 PET を用いた任意型検診の実際と将来展望：INNERVISION(0913-8919)36 巻 10 号
Page13-16(2021.09)

4.

河口 浩介, 藤本 優里, 戸井 雅和：腸内細菌と乳がん：腸内細菌学雑誌(1343-0882)35 巻 3 号
Page155-163(2021.07)

5.

片岡 正子, 高田 正泰, 片岡 竜貴, 戸井 雅和：DCIS に対するマネジメント Risk-Stratified Screening：
日独医報(0912-0351)65 巻 1 号 Page20-30(2020.12)

6.

高田 正泰, 戸井 雅和：補助療法として経口 5-FU 製剤を用いた補助療法の最近の話題
癌と化学療法(0385-0684)47 巻 12 号 Page1678-1680(2020.12)

7.

中川 梨恵, 川口 展子, 戸井 雅和：固形腫瘍の網羅的なゲノム解析と分子標的；乳がんの遺伝子解析に基づく治療戦略：医学のあゆみ(0039-2359)275 巻 5 号 Page488-494(2020.10)

8.

松本 純明, 戸井 雅和：Women's Imaging 2020 Breast Imaging Vol.15 乳がんの個別化医療、ゲノム医療の幕開けと画像診断の展望；乳がん画像診断の最新技術動向 光超音波イメージングの技術と研究・開発の動向：INNERVISION(0913-8919)35 巻 8 号 Page48-51(2020.07)

9.

鈴木 栄治, 戸井 雅和：新しい臨床関連研究法の下での臨床研究の現況と課題；全国臨床研究グループとしての取り組み：医学のあゆみ(0039-2359)273 巻 8 号 Page635-641(2020.05)

POTENT 試験：

10. 高田 正泰, 戸井 雅和：State of the ART 乳癌における Immuno-Oncology ：Cancer Board of the Breast47

(2189-356X)5 巻 2 号 Page89-93(2019.09)
11. 鈴木 栄治, 戸井 雅和：乳がんの免疫チェックポイント阻害療法 ：臨床免疫・アレルギー科(1881-1930)72 巻 3 号 Page271-275(2019.09)
12. 松本 純明, 関口 博之, 浅尾 恭史, 高田 正泰, 片岡 正子, 櫻井 孝規, 八木 隆行, 椎名 毅, 富樫 かおり, 戸井 雅和：乳がん診療における光超音波イメージング ：Rad Fan (1348-3498)17 巻 7 号
Page13-21(2019.06)
13. 高田 正泰, 戸井 雅和：エストロゲン受容体陽性 HER2 陰性乳癌に対するティーエスワン(TS-1)術後療法 ：カレントテラピー (0287-8445)37 巻 2 号 Page137-141(2019.02)
14. 鈴木 栄治, 戸井 雅和：新薬展望 2019(第 III 部)；治療における最近の新薬の位置付け、新薬の広場
癌治療薬： 医薬ジャーナル (0287-4741)55 巻増刊 Page331-335(2019.01)

乳

15. 鳥井 雅恵, 戸井 雅和：閉経前ホルモン受容体陽性早期乳癌に対する内分泌療法 ：日本臨床(0047-1852)76 巻 5 号 Page740-746(2018.05)
16. 鳥井 雅恵, 戸井 雅和：乳癌と血管新生阻害薬 ：生体の科学 (0370-9531)68 巻 4 号 Page334-338(2017.08)
17. 高田 正泰, 戸井 雅和：最新ナビゲーション手術の実現と可能性；MIPS 利用がもたらす臨床的有用性と今後の展望 ：新医療 (0910-7991)44 巻 5 号 Page70-73(2017.05)
18. 高田 正泰, 戸井 雅和：診断・治療の進歩 経口 FU 剤のポジショニング ：医学のあゆみ (0039-2359)261
巻 5 号 Page514-520(2017.04)
19. 華井 明子, 高田 正泰, 戸井 雅和：乳がんの手術治療とリハビリテーション ：Journal of ClinicalRehabilitation (0918-5259)26 巻 2 号 Page131-137(2017.02)
20. 坂井 義治(京都大学 外科学講座), 上本 伸二, 戸井 雅和, 伊達 洋至, 池田 義, 坂田 隆造：新専門医制度の夜明け、ピンチをチャンスに；地域医療を支える魅力的な広域連携型プログラムを目指して、京都大学の取り組み：日本外科学会雑誌 (0301-4894)117 巻 6 号 Page594-596(2016.11)
21. 鳥井 雅恵, 植弘 奈津恵, 戸井 雅和：乳がんの HER2 およびエピジェネティクスマーカー ：生体の科
学 (0370-9531)67 巻 5 号 Page468-469(2016.10)
22. 植弘 奈津恵, 戸井 雅和：ゲノム解析結果に基づく治療開発の実際 網羅的遺伝子解析結果に基づく治療選択 ：医学のあゆみ (0039-2359)258 巻 5 号 Page425-430(2016.07)
23. 川島 雅央, 戸井 雅和：リン脂質による乳癌の分子診断 ：医学のあゆみ (0039-2359)257 巻 12 号
Page1203-1209(2016.06)
24. 松本 純明, 浅尾 恭史, 金尾 昌太郎, 片岡 正子, 椎名 毅, 戸井 雅和：光超音波技術の乳癌診断への応
用 ：乳癌の臨床 (0911-2251)31 巻 1 号 Page7-17(2016.03)
25. 戸井 雅和：女性がん医療の最前線；総論、女性と医療：BIO Clinica (0919-8237)30 巻 10 号
Page936-937(2015.09)
26. 佐藤 史顕, 戸井 雅和：疾患・臓器からみた固形がん分子標的治療
標的治療：日本臨床 (0047-1852)73 巻 8 号 Page1364-1372(2015.08)

乳腺腫瘍ゲノム進化の解析と分子27. 山口 絢音, 佐治 重衡, 戸井 雅和：閉経前ホルモン受容体陽性早期乳がんに対する術後内分泌療法 ：腫瘍内科 (1881-6568)15 巻 5 号 Page438-443(2015.05)
48

28. 佐藤 史顕, 佐治 重衡, 戸井 雅和：ますます臨床利用が進む遺伝子検査-その現状と今後の展開そして
課題-(第 2 章)分子標的治療のための体細胞遺伝子検査の現況； 乳がん：遺伝子医学 MOOK
(1349-2527)28 号 Page81-86(2015.04)
29. 佐藤 史顕, 佐治 重衡, 戸井 雅和：State of the ART(1883-1699)7 巻 2 号 Page119-126(2014.12)

Genetic tumor evolution ：Cancer Board 乳癌

30. 嶌原 康行, 森本 泰介, 細谷 亮, 坂井 義治, 上本 伸二, 戸井 雅和, 小西 靖彦：若手外科医の育成―大学と関係病院の連携；京都大学外科交流センターにおける若手外科医の確保と育成：日本外科学会雑誌(0301-4894)115 巻臨増 3 Page17-19(2014.08)
31. 上野 貴之, 戸井 雅和：がん薬物治療薬の作用機序 ホルモン療法薬 抗エストロゲン薬(SERM)・ア
ロマターゼ阻害薬 ：日本臨床 (0047-1852)72 巻増刊 2 最新がん薬物療法学 Page145-150(2014.02)
32. 高田 正泰, 戸井 雅和：乳癌診療の新しい展開 I；外科診療の新たな展開：Pharma Medica (0289-5803)32
巻 4 号 Page39-45(2014.04)
33. 多久和 晴子, 戸井 雅和：State of the ART HER2 dual blockade ：Cancer Board 乳癌 (1883-1699)7 巻 1号 Page24-32(2014.03)
34. 木曾 末厘乃, 佐治 重衡, 戸井 雅和：乳がんにおける血管新生の制御 ：最新医学 (0370-8241)68 巻 12号 Page2665-2671(2013.12)
35. 高田 正泰, 戸井 雅和：State of the ART Nomogram/algorithm model：Cancer Board 乳癌 (1883-1699)6
巻 2 号 Page124-130(2013.12)
36. 戸井 雅和：乳癌治療戦略の最適化 ：BIO Clinica (0919-8237)28 巻 9 号 Page806-810(2013.08)
37. 河口 浩介, 石黒 洋, 戸井 雅和：癌分子標的治療 up to date；乳癌分子標的治療薬の臨床応用：癌の臨
床 (0021-4949)58 巻 6 号 Page321-327(2012.12)
38. 戸井 雅和：臨床医学の展望 2013；乳腺外科学：日本医事新報 (0385-9215)4635 号 Page78-83(2013.02)
39. 鍛 利幸, 戸井 雅和：進化する超音波検査～第 31 回超音波ドプラ研究会臨床研究集～；乳腺における光超音波について ：Rad Fan (1348-3498)10 巻 14 号 Page67-69(2012.11)
40. 石黒 洋, 佐治 重衡, 戸井 雅和：腫瘍性疾患の分子標的薬 乳がん 分子標的薬の臨床薬理学的特徴 ：日本臨床 (0047-1852)70 巻増刊 8 分子標的薬 Page443-446(2012.11)
41. 河口 浩介, 石黒 洋, 戸井 雅和：キナーゼ阻害薬の新しい展開；乳癌治療におけるキナーゼ阻害薬の新しい展開 ：BIO Clinica (0919-8237)28 巻 1 号 Page28-32(2013.01)
42. 増田 慎三, 戸井 雅和, 黒井 克昌：多施設共同大規模データベースの意義 JBCRG (Japan Breast Cancer
Research Group)の現況と展望 ：日本臨床 (0047-1852)70 巻増刊 7 乳癌 Page763-772(2012.09)
43. 鈴木 栄治, 戸井 雅和：乳癌の治療戦略；分子標的薬治療、分子標的治療薬の使い分け、現状と展望：
日本臨床 (0047-1852)70 巻増刊 7 乳癌 Page620-626(2012.09)
44. 光藤 悠子, 高田 正泰, 戸井 雅和：乳癌の治療戦略；化学療法と外科手術による集学的治療(multidisciplinary treatment)の概念 ：日本臨床 (0047-1852)70 巻増刊 7 乳癌 Page571-575(2012.09)
45. 鍛 利幸, 戸井 雅和：乳癌の検査・診断 画像診断(新しい device を含む)；光超音波マンモグラフィを49

用いた乳癌診断法：日本臨床 (0047-1852)70 巻増刊 7 乳癌 Page326-330(2012.09)
46. 増田 慎三, 戸井 雅和, 笠井 宏委：On going clinical study Neo-LaTH 試験(HER2 陽性乳癌におけるDual-HER2 blockage 療法±ホルモン療法の検討 ランダム化第 II 相試験 ：Cancer Board 乳癌(1883-1699)5 巻 2 号 Page175-177(2012.10)
47. 高田 正泰, 戸井 雅和：State of the ART 腋窩マネジメント ：Cancer Board 乳癌 (1883-1699)5 巻 2 号
Page126-133(2012.10)
48. 熊谷 洋一, 戸井 雅和, 川田 研郎, 河野 辰幸： 表在食道癌の血管新生 拡大内視鏡観察と分子生物学との関連：Gastroenterological Endoscopy (0387-1207)54 巻 7 号 Page2062-2072(2012.07)
49. 石黒 洋, 戸井 雅和：内分泌療法中の日本人乳癌患者において、薬物代謝酵素遺伝子多型が活性薬物血中濃度に及ぼす影響 ：臨床薬理の進歩 (0914-4366)33 号 Page9-15(2012.06)
50. 熊谷 洋一, 戸井 雅和, 石畝 亨, 川田 研郎, 石田 秀行, 河野 辰幸： 血管新生の見地からみた食道癌の発育進展：胃と腸 (0536-2180)47 巻 9 号 Page1428-1434(2012.08)
51. 松本 純明, 吉川 清次, 戸井 雅和：State of the ART(1883-1699)5 巻 1 号 Page20-28(2012.04)
52. 戸井 雅和：乳癌治療の動向
Page1-25(2011.12)

Tumor dormancy therapy ：Cancer Board 乳癌

サブタイプ治療を中心に：天理医学紀要 (1344-1817)14 巻 1 号

53. 鈴木 栄治, 戸井 雅和：癌の抗血管新生療法の課題と展望 臨床編： 血管医学 (1345-9031)13 巻 1 号
Page67-70(2012.02)
54. 井上 将, 戸井 雅和： HER ファミリー受容体の二量体化：がん分子標的治療 (1347-6955)10 巻 1 号
Page19-25(2012.01)
55. 山城 大泰, 戸井 雅和： 抗癌剤とバイオマーカー-個別化医療を目指して；乳癌のバイオマーカー：成人病と生活習慣病 (1347-0418)41 巻 9 号 Page1073-1077(2011.09)
56. 鍛 利幸, 戸井 雅和： 蛍光 navigation の現状と展望：外科治療 (0433-2644)105 巻 2 号
Page165-173(2011.08)
57. 戸井 雅和, Fakhrejahani Elham： State of the ART 血管新生の制御：Cancer Board 乳癌 (1883-1699)4 巻
2 号 Page135-142(2011.09)
58. 佐藤 史顕, 戸井 雅和： マイクロ RNA 発現解析技術の最近の進歩：血管医学 (1345-9031)12 巻 3 号
Page223-232(2011.08)
59. 石黒 洋, 戸井 雅和： 乳癌最前線；腫瘍内科医の考える「乳がん薬物療法」：クリニシアン (0387-1541)58
巻 7 号 Page803-808(2011.07)
60. 高田 正泰, 戸井 雅和： 術前薬物療法は乳癌手術を縮小させるか；術前化学療法と乳房温存術：臨床
外科 (0386-9857)66 巻 7 号 Page898-902(2011.07)
61. 西村 友美, 杉江 知治, 川島 雅央, 鍛 利幸, 戸井 雅和：ICG 蛍光測定法を用いたセンチネルリンパ節
生検 手術 (0037-4423)65 巻 5 号 Page541-544(2011.05)
62. 高田 正泰, 戸井 雅和： 乳癌治療-病態別治療の体系化；原発性乳癌の病態と治療指針 腋窩の診断と治療：カレントテラピー (0287-8445)29 巻 5 号 Page413-419(2011.05)
50

63. 山城 大泰, 戸井 雅和： 用語解説 PARP-1：Cancer Board 乳癌 (1883-1699)4 巻 1 号 Page109(2011.03)
64. 川口 展子, 上野 貴之, 戸井 雅和：がん幹細胞と支持細胞を標的とする薬剤の開発；乳がんのがん幹細胞様集団を標的とする薬剤の開発：最新医学 (0370-8241)66 巻 3 号 Page393-400(2011.03)
65. 杉江 知治, 田中 義正, 岩崎 雅史, 戸井 雅和, 湊 長博：乳癌のバイオロジーと臨床 診断と治療への応用；ビスホスホン酸によるγδ型 T 細胞を標的とした乳癌免疫療法の開発 ：乳癌の臨床(0911-2251)25 巻 6 号 Page623-630(2011.02)
66. 山城 大泰, 戸井 雅和： 癌の治療成績：日本と欧米の相違外科治療 (0433-2644)104 巻 2 号
Page163-168(2011.02)
67. 高田 正泰, 戸井 雅和：がん治療における外科的治療の役割；乳癌拡大治療から温存、縮小手術、そして非切除へ：癌と化学療法 (0385-0684)38 巻 2 号 Page173-178(2011.02)
68. 山城 大泰, 戸井 雅和：秒進分歩する癌研究と分子標的治療；発癌から浸潤・転移に至るメカニズム解明とトランスレーショナルリサーチの最前線、臨床応用研究編:トランスレーショナルリサーチの最前線；治療からのリバーストランスレーション：HER2 標的治療薬、乳癌治療での臨床効果と耐性克服に向けて：実験医学 (0288-5514)29 巻 2 号 Page353-358(2011.02)
69. 上野 貴之, 戸井 雅和：がん治療最前線 米国癌学会(ASCO)のトピックスを中心に；臓器部位別の治療
戦略 乳がん 転移性乳がんの治療：がん治療レクチャー (2185-5684)1 巻 1 号 Page18-22(2010.10)
70. 黒井 克昌, 柏 喜代美, 戸井 雅和, 中村 清吾, 岩田 広治, 大野 真司, 増田 慎三, 青儀 健二郎, 佐藤信昭, 笹野 公伸： 臨床試験グループの現状と問題点；Japan Breast Cancer Research Group(JBCRG)：腫瘍内科 (1881-6568)6 巻 4 号 Page360-368(2010.10)
71. 山城 大泰, 戸井 雅和： 再発・転移乳がんへの最新のアプローチ；転移のみられる乳がんへの対応 再発・転移乳がんの個別化治療と分子標的治療薬：臨床腫瘍プラクティス (1880-3083)6 巻 4 号
Page425-430(2010.11)
72. 川島 雅央, 上野 貴之, 戸井 雅和：エネルギー代謝と乳癌： Cancer Board 乳癌 (1883-1699)3 巻 2 号
Page168-173(2010.10)
73. Author：藤澤 憲良, 上野 貴之, 戸井 雅和：State of the ART 乳癌の末梢循環腫瘍細胞(circulating tumor
cells:CTC)： Cancer Board 乳癌 (1883-1699)3 巻 2 号 Page123-129(2010.10)
74. 山城 大泰, 戸井 雅和：分子標的薬治療 癌から他疾患までの治癒をめざして；疾患別分子標的薬治療の現状と今後の展望、悪性腫瘍；乳癌の分子標的治療、治癒をめざして：日本臨床 (0047-1852)68 巻 10
号 Page1854-1858(2010.10)
75. 辻 和香子, 山城 大泰, 戸井 雅和：広範囲 血液・尿化学検査免疫学的検査[第 7 版] その数値をどう読むか；プロスタノイド、サイトカイン、増殖因子、ケモカイン 塩基性線維芽細胞増殖因子(FGF-2)：
日本臨床 (0047-1852)68 巻増刊 7 広範囲血液・尿化学検査 免疫学的検査(4) Page118-120(2010.07)
76. 川口 展子, 上野 貴之, 戸井 雅和：広範囲 血液・尿化学検査免疫学的検査[第 7 版] その数値をどう読むか；プロスタノイド、サイトカイン、増殖因子、ケモカイン 血管内皮増殖因子：日本臨床(0047-1852)68 巻増刊 7 広範囲血液・尿化学検査 免疫学的検査(4) Page106-109(2010.07)
77. 山城 大泰, 戸井 雅和：がん治療のエビデンスと臨床試験、乳癌： 外科治療 (0433-2644)103 巻 2 号
Page161-169(2010.08)
51

78. 山城 大泰, 戸井 雅和：進行癌の治療戦略；胸壁・胸郭浸潤乳癌の治療戦略：外科 (0016-593X)72 巻 7号 Page743-748(2010.07)
79. 戸井 雅和：乳癌の治療最前線： 成人病と生活習慣病 (1347-0418)40 巻 5 号 Page511-515(2010.05)
80. 辻 和香子, 戸井 雅和：遺伝子診断を用いた術後治療の選択(Oncotype DX、MammaPrint)： コンセンサ
ス癌治療 (1347-4618)9 巻 2 号 Page98-100(2010.05)
81. 青儀 健二郎, 岩田 広治, 上野 貴之, 高橋 將人, 徳永 えり子, 元村 和由, 山本 豊, 戸井 雅和：タキ
サン系抗癌剤の抗腫瘍効果予測因子はなにか：Cancer Board 乳癌 (1883-1699)3 巻 1 号
Page39-46(2010.04)
82. 柏葉 匡寛, 石黒 洋, 大野 真司, 川端 英孝, 中村 清吾, 坂東 裕子, 増田 慎三, 戸井 雅和：臨床エビ
デンスからの視点による TC 療法の展開： Cancer Board 乳癌 (1883-1699)3 巻 1 号 Page28-38(2010.04)
83. 松村 有希子, 山城 大泰, 戸井 雅和：分子標的治療薬、Trastuzumab とその課題： Biotherapy(0914-2223)24 巻 2 号 Page178-182(2010.03)
84. 杉江 知治, 田中 義正, 戸井 雅和：乳癌治療における新しい展開 ゾレドロン酸と乳癌抗腫瘍免疫： 癌と化学療法 (0385-0684)36 巻 13 号 Page2555-2559(2009.12)85. 川口 展子, 上野 貴之, 戸井 雅和：State of the ART
巻 2 号 Page95-101(2009.10)

乳癌の幹細胞： Cancer Board 乳癌 (1883-1699)2

86. 山城 大泰, 戸井 雅和：分子標的治療薬を用いた乳癌治療の現状と将来： 外科治療 (0433-2644)101 巻 6号 Page721-728(2009.12)
87. 上野 貴之, 戸井 雅和：腫瘍をめぐる Q&A 遺伝子発現プロファイルに基づく癌分類は、どの段階まで進んでいますか： Surgery Frontier (1340-5594)16 巻 3 号 Page381-383(2009.09)
88. 戸井 雅和, 上野 貴之, 山城 大泰：検査 UPDATE：乳癌治療における検査戦略
宝函 (0912-0912)30 巻 1 号 Page4-10(2009.04)

Oncotype DX 検査： SRL

89. 山城 大泰, 戸井 雅和：EGFR を介したシグナル伝達と抗 HER2 抗体および小分子阻害剤 乳癌を中心に： 癌と化学療法 (0385-0684)36 巻 7 号 Page1067-1071(2009.07)
90. 松村 有希子, 上野 貴之, 戸井 雅和：遺伝子診断(BRCA1/BRCA2)： 腫瘍内科 (1881-6568)3 巻 6 号
Page642-646(2009.06)
91. 辻 和香子, 杉江 知治, 戸井 雅和：DIF と乳癌： コンセンサス癌治療 (1347-4618)8 巻 2 号
Page112-113(2009.05)
92. 上野 貴之, 戸井 雅和：分子標的薬開発の新展開、c-met 阻害剤の現状： 細胞 (1346-7557)41 巻 9 号
Page364-368(2009.08)
93. 多久和 晴子, 上野 貴之, 戸井 雅和：乳がんと骨髄由来の播種腫瘍細胞(DTCs)、循環血液中腫瘍細胞(CTCs)： がん分子標的治療 (1347-6955)7 巻 3 号 Page190-194(2009.07)
94. 山城 大泰, 戸井 雅和：新しい乳癌治療薬；血管新生抑制剤： 乳癌の臨床 (0911-2251)24 巻 3 号
Page301-307(2009.07)
52

95. 山城 大泰, 戸井 雅和：最新治療トピックス 最新の治療戦略 術前薬物療法の新展開 JBCRG Studyのあゆみ： 医学のあゆみ (0039-2359)230 巻 1 号 Page57-61(2009.07)
96. 戸井 雅和, 笹野 公伸, Ellis Matthew J.：閉経後乳癌における術前ホルモン療法の可能性： 癌と化学療法 (0385-0684)36 巻 6 号 Page1035-1042(2009.06)
97. 山城 大泰, 戸井 雅和：がん薬物療法学；基礎・臨床研究のアップデート、作用機序からみた抗悪性腫
瘍薬の分類：分子標的治療薬 抗体 トラスツズマブ： 日本臨床 (0047-1852)67 巻増刊 1 がん薬物療法学 Page240-245(2009.01)
98. 河口 浩介山城 大泰, 戸井 雅和：乳癌診療の最新情報；分子標的治療薬への期待： Pharma Medica(0289-5803)27 巻 2 号 Page47-52(2009.02)
99. 山城 大泰, 戸井 雅和：癌の血管新生と阻害薬；乳癌と血管新生： BIO Clinica (0919-8237)24 巻 5 号
Page424-429(2009.05)
100. 戸井 雅和, 山城 大泰：State of the ART 術前薬物療法の進歩： Cancer Board 乳癌 (1883-1699)2 巻 1号 Page21-32(2009.03)
101. 戸井 雅和, 芳林 浩史：乳癌診療における乳腺 MRI Update；乳癌の診療：日独医報 (0912-0351)54 巻 1号 Page6-15(2009.02)
102. 戸井 雅和：時代の課題、高齢者腫瘍学(Geriatric Oncology)；高齢者乳癌の治療： 日本癌治療学会誌(0021-4671)43 巻 3 号 Page1241(2008.10)
103. 高田 正泰, 石黒 洋, 戸井 雅和：Breast and Endocrine Tumor；乳腺・内分泌腫瘍治療について： 癌と化学療法 (0385-0684)35 巻 13 号 Page2344-2350(2008.12)
104. 上野 貴之, 戸井 雅和：癌のバイオマーカー；バイオマーカー： 癌と化学療法 (0385-0684)36 巻 1 号
Page15-20(2009.01)
105. 戸井 雅和, 山城 大泰：治療 TODAY、最新の乳癌化学療法： SRL 宝函 (0912-0912)29 巻 2 号
Page28-35(2008.12)
106. 大塚 恒博, 有賀 智之, 松浦 千恵子, 矢嶋 多美子, 関根 進, 北川 大, 堀口 和美, 鈴木 栄治, 佐治 重衛, 黒井 克昌, 戸井 雅和, 宇都宮 譲二：Nipple Aspiration Fluid 研究 研究グループの立ち上げと採取方法について： 乳癌の臨床 (0911-2251)23 巻 6 号 Page562-563(2008.12)
107. 芳林 哲史, 石黒 洋, 戸井 雅和：乳がんに対する補助薬物療法： 腫瘍内科 (1881-6568)2 巻 6 号
Page500-509(2008.12)
108. 戸井 雅和, 芳林 浩史, 河口 浩介, 多久和 晴子, 山崎 万梨子, 上野 貴之, 杉江 知治：State of the ART
センチネルリンパ節： Cancer Board 乳癌 (1883-1699)1 巻 1 号 Page12-18(2008.09)
109. 高田 正泰, 戸井 雅和：St. Gallen 2007 に基づいた乳癌テーラーメイド補助療法；Triple negative での補助療法と今後の展望： 臨床外科 (0386-9857)63 巻 8 号 Page1087-1091(2008.08)
110. 山城 大泰, 戸井 雅和：遺伝子多型とがん薬物治療薬；Trastuzumab と Fcγ： 癌と化学療法(0385-0684)35 巻 7 号 Page1097-1100(2008.07)
53

111. 上野 貴之, 戸井 雅和：Oncotype DX： 腫瘍内科 (1881-6568)2 巻 5 号 Page440-445(2008.10)
112. 戸井 雅和：治療薬シリーズ；標的分子薬―乳がん治療における新しい標的療法の可能性： 日本薬理学
雑誌 (0015-5691)132 巻 3 号 Page177-179(2008.09)
113. 上野 貴之, 戸井 雅和：DNA チップ/マイクロアレイ臨床応用への実際―個別化医療 Oncotype DX、
MammaPrint：遺伝子医学 MOOK (1349-2527)10 号 Page328-334(2008.06)
114. 山城 大泰, 戸井 雅和：80 歳以上高齢者のがん治療を考える、乳癌： 外科治療 (0433-2644)99 巻 2 号
Page144-149(2008.08)
115. 戸井 雅和： 乳癌の外科治療：日本外科系連合学会誌 (0385-7883)33 巻 2 号 Page227-228(2008.04)
116. 上野 貴之, 戸井 雅和：臨床ゲノム研究 成果と課題；癌と遺伝学、乳癌関連遺伝子の臨床応用の現状：
医学のあゆみ (0039-2359)225 巻 9 号 Page866-872(2008.05)
117. 杉江 知治, 戸井 雅和：知っておきたい乳癌治療の進歩；乳癌化学療法の進歩、術前化学療法と化学放射線療法： 外科治療 (0433-2644)98 巻 6 号 Page911-917(2008.06)
118. 山城 大泰, 石黒 洋, 戸井 雅和： 妊娠中に発見された悪性腫瘍の取り扱い；妊娠中に発見される乳癌：
産婦人科の実際 (0558-4728)57 巻 4 号 Page669-675(2008.04)
119. 山城 大泰, 戸井 雅和： 外科医に必要ながん化学療法の知識；がん化学療法の実際―乳癌―進行乳癌の化学療法：外科治療 (0433-2644)98 巻増 Page694-701(2008.04)
120. 戸井 雅和：がん分子標的治療の最先端、モノクローナル抗体 抗 VEGF 療法；原発性乳癌に対する治療応用が視野に： 医学のあゆみ (0039-2359)224 巻 1 号 Page11-15(2008.01)
121. 上野 貴之, 戸井 雅和：がん分子標的治療の最先端；低分子阻害剤
医学のあゆみ (0039-2359)224 巻 1 号 Page51-54(2008.01)

チロシンキナーゼ阻害剤

c-met：

122. 上野 貴之, 戸井 雅和： 乳癌(原発性乳癌)分子プロファイリングに関する進歩：癌と化学療法(0385-0684)34 巻 13 号 Page2218-2223(2007.12)
123. 高田 正泰, 戸井 雅和：Neoadjuvant Therapy の適応と効用、乳癌プライマリーケモテラピー： 癌と化
学療法 34 巻 11 号 Page1730-1734(2007.11)
124. 戸井 雅和： 乳癌(原発性乳癌)：癌と化学療法 34 巻 13 号 Page2217(2007.12)
125. 柏葉 匡寛(岩手医科大学), 若林 剛, 中村 清吾, 黒井 克昌, 岩田 広治, 大野 真司, 増田 慎三, 佐藤
信昭, 麻賀 太郎, 山本 尚人, 青儀 健二郎, 佐藤 康幸, 黒住 昌史, 津田 均, 秋山 太, 戸井 雅和：術前薬物療法の break through、JBCRG03 Docetaxel 75mg/m2 followed by FEC100mg/m2 による術前化学療法
JBCRG01,02 からの review と breakthrough： 乳癌の臨床 (0911-2251)22 巻 5 号 Page372-375(2007.11)
126. 山城 大泰、戸井 雅和：分子標的治療薬の最近の話題、Herceptin (Trastuzumab)：癌と化学療法(0385-0684)34 巻 8 号 Page1173-1176(2007.08)
127. 戸井 雅和：がん治療 update 乳癌：日本癌治療学会誌 (0021-4671)42 巻 3 号 Page935-942(2007.09)
54

128. 芳林 浩史、戸井 雅和：各がんの外来化学療法、乳癌の標準的化学療法を外来で行うために： 医学のあゆみ (0039-2359)222 巻 13 号 Page1019-1022(2007.09)
129. 山城 大泰、 戸井 雅和：化学ホルモン療法の現状と今後 Adjuvant care としての化学療法とホルモン療法の使い分け;カレントテラピー (0287-8445)25 巻 8 号 Page676-680(2007.08)
130. 上野 貴之、 戸井 雅和：バイオマーカーが医療・創薬戦略を変える、バイオマーカーと乳癌治療：細胞工学 (0287-3796)26 巻 9 号 Page1026-1030(2007.08)
131. 加藤 大典, 戸井 雅和：乳癌 2007 年の乳癌術後補助化学療法；最新医学 (0370-8241)62 巻 6 月増刊
Page1282-1292(2007.06)
132. 北川 大, 戸井 雅和：再発・進行乳癌治療の現状と展望：日本臨床 (0047-1852)65 巻増刊 6 乳癌
Page396-401(2007.06)
133. 鈴木 栄治, 戸井 雅和：HER family をターゲットとした分子標的治療：Interface on Cancer Therapy、乳がんに対するトラスツズマブ治療効果におけるさらなる改善の可能性：がん分子標的治療 (1347-6955)5
巻 1 号 Page14-21(2007.01)
134. 倉田 昌直, 鶴田 耕二, 戸井 雅和：肝細胞癌切除後の長期成績向上を目指して；術後補助療法、血管新生抑制薬の可能性. 外科 (0016-593X)69 巻 5 号 553-563(2007.05)
135. 戸井雅和、牟田真理子：正常血管と腫瘍血管．生体の科学 57:579-584, 2006.
136. 戸井雅和、北川大：アロマターゼインヒビターの最近の進歩．Pharma Medica 24:35-37, 2006.
137. 戸井雅和：乳癌治療におけるアジュバント療法．Mebio

23：14-21、2006．

138. 高田正泰、戸井雅和：乳癌の化学療法－最近の動向．95;627-637、2006．
139. 有賀智之、佐治重衡、戸井雅和：予後をどのように予測するか（ER、PgR、HER2 などの検討）．臨床
腫瘍プラクティス 2：152-156、2006．
140. 岩田広治、戸井雅和、黒井克昌、中村清吾：炎症性乳癌全国アンケート結果．乳癌の臨床 21：201-208、2006．
141. 鈴木栄治、戸井雅和：トラスツズマブ 抗がん剤を知る、薬剤選択のための知識．臨床腫瘍プラクティ
ス 2：198-200、2006．
142. 鈴木栄治、戸井雅和：術前化学療法．日本臨床 64：536-539、2006．
143. 佐治重衡、戸井雅和：抗 HER 療法との併用．癌治療と宿主 18：47-52、2006．
144. 鈴木栄治、戸井雅和：Dual inhibitor for TK．血液・腫瘍科 51：606-608、 2005．
145. 山城大泰、戸井雅和：塩基性繊維芽細胞増殖因子．広範囲、尿化学検査、免疫学的検査、その数値をどう読むか（プロスタノイド、サイトカイン、増殖因子、ケモカイン） 日本臨床 63：113-115、2005．
55

146. 坂東裕子、戸井雅和：VEGF．広範囲、尿化学検査、免疫学的検査、その数値をどう読むか（プロスタ
ノイド、サイトカイン、増殖因子、ケモカイン）． 日本臨床 63：113-115、2005．
147. 堀口和美、戸井雅和：レトロゾール－最近の話題．総合臨床 54：2509-2511、2005．
148. 山城大泰、戸井雅和：トラスツズマブの効果と今後の課題．癌治療と宿主 17：251-256、2005．
149. 戸井雅和：癌治療における anti-tumor 作用と pro-tumor 反作用．治療学 39：200、2005．
150. 佐治重豊、平田公一、佐々木常雄、久保田哲郎、古畑智久、福井次矢、石岡千加史、小山弘、新保卓郎、
戸井雅和、松井邦彦、朝永万佐男、坂巻壽、陣内逸郎、塚崎邦弘、渡辺隆、清水一之、村上博和、大野竜三（がん診療ガイドライン委員会幹事委員会）：抗がん剤適正使用のガイドライン-造血器腫瘍-．臨
床血液 46：1233-1247、2005．
151. 佐治重衡、戸井雅和：閉経前乳癌の治療（分子標的のプロトタイプとしてのホルモン療法）．MebioOncology 2：42-47、2005．
152. 戸井雅和：乳癌. 特集「世界に知る癌治療の新戦略
331-334、2005．

2005 年 ASCO でのﾄﾋﾟｯｸｽ」．癌治療と宿主 17：153. 佐治重衡、戸井雅和：乳癌におけるアロマターゼ阻害剤の新たな展開. 性ステロイド依存性腫瘍の内分泌療法における新たな展開．Medical Science Digest 31：52-55、2005．
154. 山城大泰、戸井雅和：腫瘍の悪性化における血管系のかかわり．Molecular Medicine 42：669-675、2005．
155. 佐治重衡、堀口和美、鈴木栄治、戸井雅和：新規アロマターゼ阻害剤 letrozole の特性について． 乳癌の臨床 20：216-221、2005．
156. 川上雅代、佐治重衡、戸井雅和：COX-2 と発癌（癌、腫瘍学）．医学のあゆみ

212：704-705、2005．

157. 佐治重衡、戸井雅和：Capecitabine と個別化医療への可能性． 癌治療と宿主 16：47-52、2004．
158. 川上雅代、佐治重衡、戸井雅和：乳癌ホルモン療法の controversy． 癌と化学療法 31：181-187、2004．
159. 山城大泰、遠山和美、坂東裕子、佐治重衡、戸井雅和：乳癌における『標準治療』について．外科治療
90：190-196、2004．
160. Singh Sharat, 戸井雅和、芝崎太：eTAG による治療効果予測．細胞36：415-419、2004．

161. 吉田龍一、戸井雅和：乳癌遺伝子研究の現状．性差と医療 1：187-193、2004．
162. 佐治重衡、戸井雅和：乳癌における術後補助内分泌療法． 細胞 473：396-399、2004．
56

163. 山城大泰、戸井雅和：乳癌に対するトラスツズマブ治療の位置づけ、乳癌に対する分子標的治療の進歩．
医学のあゆみ 208：245-250、2004．
164. 川喜多正夫、平松恭子、杉本雅行、高橋慶一、戸井雅和：尿で判る癌の検査、ジアセチルスペルミン 尿中ジアセチルポリアミンとその臨床的意義．臨床病理 52：321-327、2004．
165. 戸井雅和:カペシタビンによる乳癌治療の新たな可能性． Mebio 20：20-27、2003．
166. 戸井雅和、新藤克之、坂東裕子、堀口慎一郎、佐治重衡：トラスツズマブにおける最近の話題と将来への展望．がん分子標的治療 1：206-212、2003．
167. 佐治重衡、新藤克之、戸井雅和：制癌剤の効果増強 抗 Her2 抗体、抗 EGFR 抗体、抗 VEGF 抗体． Surgery
Frontier 10：189-196、2003．
168. 高田正泰、戸井雅和、坂東裕子、堀口慎一郎、佐治重衡：抗 HER２モノクローナル抗体（トラスツズマブ）．Molecular Medicine 40：1166-1174、 2003．
169. 佐治重衡、奥山裕美、遠山和美、戸井雅和：乳癌の治療薬における副作用．緩和医療学 5：316-324、2003．
170. 佐治重衡、戸井雅和：血管新生抑制剤． 血液・腫瘍科 4739：258-265、2003．
171. 松本岳、戸井雅和：COX-2 インヒビター． 分子細胞治療 2：116-117、2003．
172. 高田正泰、坂東裕子、熊谷洋一、松本岳、戸井雅和：腫瘍低酸素の臨床的評価．癌治療と宿主 15：245-254、2003．
173. 戸井雅和、佐治重衡、坂東裕子、遠山和美、黒井克昌：乳癌治療における｢標準｣について．外科 65：
949-954、2003．
174. 黒井克昌、戸井雅和：男性乳癌． 癌と化学療法 30：599-605、2003．
175. 新藤克之、坂東裕子、堀口慎一郎、佐治重衡、戸井雅和：ヒト化抗 Her2 モノクローナル抗体(trastuzumab,
Herceptin TM)治療の有用性、問題点、展開．癌の臨床 49：101-108、2003．
176. 戸井雅和、佐々木健、坂東裕子、松本岳、佐治重衡：乳癌の進展と血管のかかわり．実験医学 20：1133-1139、2002．
177. 中西史、戸井雅和、佐治重衡、坂東裕子：乳房切除術の適応． 日本外科学会雑誌 103：821-824、2002．
178. 松本岳、戸井雅和：腫瘍血管新生因子を標的とした抗体療法 2)血管内皮細胞．
204-208、2002．

Surgery Frontier 9：179. 戸井雅和、佐治重衡、坂東裕子：欧米における乳癌最新化学療法．総合臨床 51：2695-2696、2002．
57

180. 堀口慎一郎、林幸子、清水辰一郎、堀井理絵、森山佐知子、比島恒和、船田信顕、佐治重衡、戸井雅和：
乳癌における HercepTest 判定基準の問題点 FISH 法との比較検討をふまえて．日本病理学会会誌 91：
157、2002．
181. 戸井雅和：乳癌における最近の知見． 癌治療と宿主 14：213-218、2002．
182. 佐治重衡、黒井克昌、戸井雅和：乳癌化学療法－最新のガイドライン． 外科治療 87：48-55、2002．
183. 戸井雅和：標準的治療の『標準』と『ものさし』( 新世紀の癌治療)．癌治療と宿主 14：119-122、2002．
184. 黒井克昌、田中智香子、坂東裕子、佐治重衡、林和雄、戸井雅和：進行･再発乳癌に対する Biweekly
Paclitaxel 療法の有用性． 癌と化学療法 29：55-60、2002．
185. 戸井雅和、佐治重衡、坂東裕子、黒井克昌：乳癌における標準的治療について．カレントテラピー 20：
52-58、2002．
186. 坂東裕子、戸井雅和：特集
7-14、2002．

知っておくべき術中診断法 II．乳癌の術中診断． 臨床雑誌「外科」64：187. 戸井雅和、坂東裕子、佐治重衡、松本岳：癌の血管新生．Biotherapy 15：663-668、2001．
188. 佐治重衡、廣岡信一、戸井雅和： UFT の特性を考慮した化学療法の可能性．Tumor Dormancy Therapy 3：
283-288、2001．
189. 戸井雅和、坂東裕子、佐治重衡：血管新生を標的とした治療． Practical Oncology 14：9-11、2001．
190. 佐治重衡、戸井雅和： 乳癌のホルモン療法．内分泌・糖尿病科 12：398-407、2001．
191. 坂東裕子、戸井雅和：血管新生／血管形成と幹細胞． 血液･腫瘍科 42：533-536、2001．
192. 松本岳、戸井雅和： 腫瘍関連マクロファージ（TAM）．Surgery Frontier 8：186-189、2001．
193. 黒井克昌、戸井雅和、冨永

健： 乳癌に対する胸筋合併乳房切除術．臨床外科 56：359-363、2001．

194. 松本岳、戸井雅和：腫瘍血管新生/腫瘍免疫の接点、血管新生研究の新しい展開．医学のあゆみ（別冊）194：787-791、2000．
195. 黒井克昌､戸井雅和：癌転移に対する分子標的治療、Herceptin．医学のあゆみ 194：989-990、2000．
196. 戸井雅和：HER2 の臨床的意義を探る（乳癌の Novel Strategy への期待）．Mebio 17：6-12、2000．
197. 戸井雅和、坂東裕子：特集

血管新生と疾患、固形癌と腫瘍血管系． Mebio 17：49-55、2000．
58

198. 黒井克昌、戸井雅和： 第 VI 編 予後因子、9．血管新生. 日本臨床 58 増刊（乳癌の診断と治療－最新の研究動向－）435-441、2000．
199. 田中智香子、戸井雅和：第 V 編 進行・再発乳癌の治療 2．2）e．カペシタビン. 日本臨床 58 増刊（乳癌の診断と治療－最新の研究動向－）279-283、2000．
200. 戸井雅和、松本岳： 微小残存癌細胞とその臨床的意義．癌と化学療法 27：1315-1336、2000．
201. 戸井雅和、松本岳、坂東裕子、黒井克昌：抗血管新生療法とホルモン療法、そのコンセプトの類似性と予後因子・治療効果予測因子の応用．癌と化学療法 27：1212-1216、2000．
202. 松本岳､戸井雅和：血管新生のプロセスと調節因子、その役割と測定． 臨床検査 44：1610-1616、2000．
203. 佐治久、戸井雅和：乳癌における monocyte chemoattractant protein-1 (MCP-1) の発現とその意義． 血液･腫瘍科 41：260-267、2000．
204. 戸井雅和：続々と見つかる血管新生抑制因子、期待される抗腫瘍効果．科学と生物 38：706-708、2000．
205. 黒井克昌､戸井雅和：乳癌と血管新生． 乳癌の臨床（特集2000．

乳癌基礎研究の最新情報）15：503-511、206. 坂東裕子、戸井雅和：炎症性サイトカイン． 血管と内皮（特集 癌と血管新生）10：35-44、2000．
207. 佐治久、戸井雅和：乳癌と血管新生－マクロファージ． Molecular Medicine 37：322-329、2000．
208. 戸井雅和：Tumor dormancy 理論に基づくホルモン療法、化学療法． Tumor Dormancy therapy 2：21-25、
2000．
209. 戸井雅和、堀口慎一郎：腫瘍と血管新生． 医学のあゆみ 191：547-553、1999．
210. 戸井雅和、中島康：特集 癌転移学の治療への応用、血管新生． Mebio 16：40-49、1999．
211. 戸井雅和、黒井克昌：腫瘍血管と血管新生因子． 細胞（特集1999．

血管新生の分子機構と病態）31：96-101、212. 黒井克昌、戸井雅和：予後因子としての血管新生． 臨床科学（特集1999．

腫瘍と血管新生）35：140-148、213. 戸井雅和、関みな子：培養系ヒト内皮細胞を用いた血管新生阻害剤の評価． Biotherapy 13：675-678、1999．
214. 戸井雅和、佐治久：Thymidine phosphorelase を標的とする治療． Biotherapy 13：166-172、1999．
59215. 戸井雅和: 転移の治療：血管をターゲットにした転移の治療．実験医学 16 増刊： 2145-2150、1998．
血管新生と疾病、腫瘍血管と血管新生因子． 最新医学 53：2641-2648、1998．

216. 黒井克昌、戸井雅和：特集

217. 戸井雅和： 血管新生阻害剤． 癌と化学療法 25：2003-2009、1998．
218. 戸井雅和、上野貴之： 腫瘍血管新生の関連因子． Molecular Medicine 35：1232-1241、1998．
219. 戸井雅和：再発乳癌の治療．Pharma Media 16：67-73、1998．
220. 戸井雅和：ヒト乳癌と癌遺伝子・癌抑制遺伝子、乳癌． 現代医療 30：2017-2022、1998.
221. 戸井雅和、佐治重衡： 特集
1998．

転写因子と癌－最近の進歩、転写因子と乳癌． 血液・腫瘍科 37：34-43、222. 戸井雅和：Tumor angiogenesis をめぐって、TP を中心に、乳癌．Practical Oncology 11：6-8、1998．
223. 戸井雅和、上野貴之、冨永健：血管新生阻害剤．組織培養工学 12(臨時増刊号) 23：507-510、1997．
224. 戸井雅和： VEGF/ 受容体などの血管新生制御因子． 癌と化学療法 24：2202-2206、1997．
225. 戸井雅和、山本豊、冨永健： 乳癌の予後と血管新生．癌治療と宿主 9：180-188、1997．
226. 戸井雅和、佐治重衡、冨永健：新しい Biotherapy の標的について-血管新生-． Biotherapy 11：738-742、
1997．
227. 冨永健、本田志延、戸井雅和、林和雄： 乳房切除術－拡大乳房切除術． 外科治療 76：491-498、1997．
228. 戸井雅和：腫瘍血管新生とその制御． Oncology & Chemotherapy 13：30-36、1997．
229. 冨永健、長屋直樹、戸井雅和、林和雄：乳がん術式の選択と治療成績． 臨床と研究 74：815-821、1997．
230. 戸井雅和、山本豊、冨永健：乳癌における PyNPase と血管新生． 癌治療と宿主 9：141-147、1997．
231. 佐治重衡、戸井雅和、冨永健：血管新生から見た乳癌の悪性度、血管新生は何を反映するのか．日本外科学会雑誌 97：368-374、1996．
232. 土屋敦雄、野水整、菅野正彦、阿部力哉、安藤二郎、内田賢、岡崎稔、紅林淳一、戸井雅和、中井亨、
野口眞三郎、福富隆志、柳生聖子、佐々木隆一郎：本邦における遺伝性乳癌の統計． 外科 58：146-151、
1996．
233. 戸井雅和、冨永健：乳癌アンギオジェネシス． 癌と化学療法 23：659-666、1996．

60

234. 山本豊、戸井雅和、谷口忠明、冨永健： 転移と血管新生． Practical Oncology 9：4-5、1996．
235. 冨永健、戸井雅和、山本豊：乳癌の予後因子としてみた血管新生． Biotheraphy 10：958-962、1996．
236. 戸井雅和：腫瘍血管新生とその阻害について、血管新生と癌の予後との関わり． Practical Oncology 8：
24-25、1995．
237. 戸井雅和、山本豊、谷口忠明、冨永健：血管新生と growth factor． Surgery Frontier 2：269-273、1995．
238. 戸井雅和、佐治重衡、冨永健： 腫瘍の悪性度の指標としての P53、乳癌．Surgery Frontier 2：397-401、1995.
239. 山本豊、戸井雅和、冨永健：Vascular endothelial growth factor(VEGF)． Surgery Frontier 2：124-127、1995．
240. 戸井雅和、谷口忠明、山本豊、佐治重衡、北村正次、冨永健：血管新生因子と血行性転移． 消化器外科 18：1965-1970、1995．
241. 戸井雅和：Vascular endothelial growth factor と腫瘍血管新生． 病理と臨床 12：1275-1279、1994.
242. 冨永健、戸井雅和：乳癌組織中の微小血管． 現代医療 26：1801-1804、1994．
243. 冨永健、戸井雅和：予後と腫瘍血管．現代医療 26：1839-1842、1994．
244. 冨永健、稲田一雄、戸井雅和：定型手術と拡大手術、その適応と治療成績． 臨床外科 49：55-62、1994.
245. 戸井雅和、冨永健：乳癌． Practical Oncology 7：2-3、1994．
246. 戸井雅和、冨永健：血管新生とその阻害剤． 外科治療 71：183-190、1994．
247. 戸井雅和、冨永健：乳がんに対する術前術後の補助化学療法． 外科治療 68：24-29、1993．
248. 戸井雅和：乳癌予後因子の有機的臨床応用． カレントテラピー 11：274-277、1993．
249. 稲田一雄、戸井雅和、冨永健：生態侵襲と増殖因子．救急医学 17：922-926、1993．
250. 冨永健、林和雄、戸井雅和：乳癌に対する胸筋温存療法の適応についての考察、我々の経験から． 臨
床と研究 70：3414-3420、1993．
251. 戸井雅和：癌遺伝子と乳癌． 臨床外科 48：1433-1441、1993．
252. 戸井雅和、冨永健：乳がんと biochemical-modulation． Practical Oncology 5：13-15、1992．
253. 梅沢一夫、戸井雅和：増殖因子作用の阻害剤と臨床応用の可能性．蛋白質核酸酵素 36：467-473、1991．
254. 戸井雅和、新本稔、服部孝雄：内分泌療． 臨床成人病 19：1906-1910、1989．
255. 新本稔、頼島敬、高上真一、戸井雅和、野宗義博、服部孝雄：制癌剤の種類と副作用、使用上の注意．
臨床消化器内科 4：1903-1911、1989．
256. 新本稔、和田務、河野和明、向田秀則、佐伯和利、戸井雅和、佐伯俊昭、平井敏弘、服部孝雄：再発胃がんの療法． 臨床外科 44：811-815、1989．
257. 濱田雄蔵、新本稔、世戸芳博、荒田寿彦、久松和史、戸井雅和、峠哲哉、柳川悦朗、服部孝雄：乳がん．
61

臨床と研究 63：774-779、1986．

座談会
1. 戸井 雅和, Curigliano Giuseppe, 松村 保広, 石田 竜弘：新しいドラッグデリバリーシステムによる抗悪性腫瘍薬；最新の免疫腫瘍微小環境の理解と ADC、DDS の革新的イノベーション：がん分子標的治療(1347-6955)19 巻 2 号 Page183-191(2022.01)
2.

戸井 雅和, 三木 義男, 小川 誠司, 山本 信之：Somatic/germline 変異とがん医療 研究の最前線と臨床展
開 ：がん分子標的治療 (1347-6955)17 巻 1 号 Page62-68(2019.06)

3.

戸井 雅和, 武藤 学, 土原 一哉, 柴田 龍弘：Precision Medicine とクリニカルシーケンス： がん分子標的治療 (1347-6955)15 巻 1 号 Page48-55(2017.03)

4.

中川 和彦(近畿大学 医学部内科学講座腫瘍内科部門), 戸井 雅和, 向原 徹, 佐藤 太郎：分子標的治療を含む 併 用 療 法 は 進 行 固 形 が ん の 治 癒 を 目 指 せ る か ? ： が ん 分 子 標 的 治 療 (1347-6955)13 巻 3 号
Page352-358(2015.10)

5.

山本 信之, 戸井 雅和, 吉野 孝之, 片桐 豊雅：ゲノム解析に基づく新しい分子標的治療】分子標的薬が効
果を示さない腫瘍とその理由 ：がん分子標的治療 (1347-6955)12 巻 4 号 Page426-432(2015.01)

6.

戸井 雅和, Slamon Dennis J., 柏葉 匡寛, 増田 慎三, 山本 豊：乳癌に対する抗 HER2 療法： Cancer
Board 乳癌 (1883-1699)6 巻 1 号 Page33-43(2013.04)

7.

戸井 雅和, 中川 和彦, 大津 敦：がん種別の個別化治療の最前線： がん分子標的治療 (1347-6955)10 巻 1号 Page6-12(2012.01)

8.

戸井 雅和, 大野 真司, 岩田 広治, 川端 英孝：乳癌治療病態別治療の体系化；乳癌治療の動向： カレント
テラピー (0287-8445)29 巻 5 号 Page448-457(2011.05)

9.

戸井 雅和, Johnston Stephen, 岩瀬 弘敬, 大野 真司, 高橋 俊二, 岩田 広治, 佐治 重衡：HER2 陽性転移性乳癌の治療戦略： Pharma Medica (0289-5803)29 巻 5 号 Page72-81(2011.05)

10. 戸井 雅和, Chow Louis Cheong Wing, Hu Zhen, Huang Chiun-Sheng, Noh Dong-Young, 杉江 知治：アジ
アにおける乳腺専門医の教育： Cancer Board 乳癌 (1883-1699)4 巻 1 号 Page89-96(2011.03)
11. 戸井 雅和, 青儀 健二郎, 岩田 広治, 大野 真司：EBCTCG による最新メタアナリシスの検討 ホルモン療法、化学療法、化学療法・ホルモン療法の併用、個別化： Cancer Board 乳癌 (1883-1699)4 巻 1 号
Page67-74(2011.03)
12. 大津 敦, 土井 俊彦, 戸井 雅和：抗 HER2 療法の新しい展開： がん分子標的治療 (1347-6955)8 巻 3 号
Page174-182(2010.07)
13. 石岡 千加史, 安井 明, 戸井 雅和：DNA 修復とがん治療の分子標的、基礎と臨床：がん分子標的治療(1347-6955)8 巻 2 号 Page82-93(2010.04)
14. 戸井 雅和, 大野 真司, 五味 直哉, 笹野 公伸, 南 博信：乳癌の診断・治療における他科との連携： Cancer
Board 乳癌 (1883-1699)1 巻 1 号 Page6-11(2008.09)
15. 戸井 雅和, 佐谷 秀行, 笹野 公伸：細胞死： がん分子標的治療 (1347-6955)6 巻 3 号 Page136-144(2008.07)
16. 西尾 和人, 戸井 雅和, 塩津 行正, 鶴尾 隆： がんバイオマーカー研究の現状と展望(座談会)：HUMANSCIENCE (0915-8987)19 巻 2 号 Page4-11(2008.03)
62

17. 野口 眞三郎, 岩瀬 弘敬, 戸井 雅和：乳癌研究の進歩と展望 乳癌診療における(乳腺)外科医の役割 乳癌診療の今後の展望： 新薬と臨牀 (0559-8672)56 巻 12 号 Page1932-1940(2007.12)
18. 戸井 雅和, 岩田 広治：HER family をターゲットとした分子標的治療、Anti-HER therapy (座談会/特集) がん分子標的治療 (1347-6955)5 巻 1 号 Page6-13(2007.01)
19. 福岡正博、大津敦、戸井雅和、飛内賢正：抗体を用いた分子標的治療． がん分子標的治療 4：86-95、2006．
20. 池田正、戸井雅和、野口眞三郎、笹野公伸：進行再発乳癌薬物療法の過去、現在、未来．Medico 37： 106-114、2006．
21. 畠清彦、鶴雄隆、戸井雅和、藤原康弘：分子標的治療における今後の動向．治療学 38：1367-1377、2004．
22. 塚越茂、峠哲哉、戸井雅和、清水敬生、畠清彦：世界に知る癌治療の新戦略． 癌治療と宿主 15：368-381、
2003．
23. 塚越茂、佐々木康綱、戸井雅和、向山雄人、峠哲哉：新世紀の癌治療． 癌治療と宿主 14：6-19、2002．
24. 霞富士雄、園尾博司、野口眞三郎、高塚雄一、戸井雅和：乳癌の診断と治療、特集 乳癌診断・治療の現状と展望． 日本医師会雑誌 125：1685-1700、2001．
25. 室田誠逸、佐藤靖史、渋谷正史、戸井雅和：特集 血管新生 血管新生研究の新展開．治療学 l34：77-91、2000．
26. 冨永健、Harris AL、Klijn JGM、池田正、戸井雅和：乳癌の増殖・予後因子とその臨床応用．KARKINOS
7：175-186、1994．

和文その他
1.

戸井雅和、佐治重衡、堀川奈生子、吉川史恵、坂上瑠璃子：治験管理室訪問、東京都立駒込病院臨床試験科-がん治療の最前線を支える-．癌と化学療法 33、2006（印刷中）.

2.

戸井雅和、堀口和美：日本人における乳がんの動向．実験治療 680：4-10、2006．

3.

戸井雅和：原発性乳癌治療アルゴリズム、最近の変更点、問題点．癌治療と宿主 18：93、2006．

4.

戸井雅和：診療報酬改訂にみる臨床と病理の関係．Histo-Logic Japan 34：8-9、2006．

5.

佐治重衡、遠山和美、鈴木栄治、有賀智之、坂東裕子、戸井雅和：当院における乳癌外来化学療法の取り組
み．医薬の門 46：104-106、2006．

6.

戸井雅和：再発転移乳がんの治療の考え方．毎日ライフ９月特集号、pp58-63、2005．

7.

戸井雅和：検査・治療・予防の最前線.乳癌治療のこれから． 別冊 NHK 今日の健康「乳がん」pp106-109、
2005．

8.

戸井雅和、遠山和美：乳癌の化学予防、＜治す＞から＜ならない＞時代へ． メディカル朝日 5 月号：26-30、
2004．

9.

トラスツズマブ病理部会：ＨＥＲ２検査ガイド、ハ－セプチンの適正な症例選択のための．
2003（同病理部会委員）
．

改訂第２版

10. 戸井雅和：抗悪性腫瘍剤カペシタビンの有用性について．メディカル朝日 10 月号、p42、2003．
63

11. 戸井雅和：再発、転移がんの治療効果に確かな手ごたえが．がん治療最前線 3：21-24、2003．
12. 戸井雅和：乳癌術後化学療法における効果的予測因子研究の展開．TIPS&TRAPS 8：6-7、2003．
13. 戸井雅和、佐治重衡：乳癌再発防止にどこまで有用か、進化したホルモン療法．メディカル朝日 31：38-41、
2002．
14. 戸井雅和： 乳癌に対する標準的治療、術前・術後化学療法を中心として、癌治療 2002．JAMA 日本語版
9 月号付録（毎日新聞社）、pp8-15、2002．
15. 戸井雅和：もっと知りたい乳がんのこと：手術療法、術前術後の補助療法．あなたにエール 1 月号 pp94-97、2002．
16. トラスツズマブ病理部会： ＨＥＲ２検査ガイド、ハ－セプチンの適正な症例選択のための．
理部会委員）．

2001（同病

17. 戸井雅和：最近の話題、HER2 過剰発現転移性乳がんに対する化学療法と HER2 モノクローナル抗体の併用．Key Trial「がん」7：51-59、2001．
18. 戸井雅和：乳癌におけるテーラーメード医療の進展． Schneller 44：6-11、2001．
19. 戸井雅和、佐治重衡、坂東裕子、堀口慎一郎：予後因子の新しい方向性．Mamma 38：10-14、2001．
20. 黒井克昌、戸井雅和：がんの悪性度の病態解析-がん細胞の性格を知る、特に固形がんについて-． 臨床看護25：249-255、1999．
21. 戸井雅和、黒井克昌：マトリックスメタロプロテナーゼ． Mamma 32：16-17、1999．
22. 戸井雅和：癌治療の今日：肺がん・乳がんの外科療法． ナース専科 18：36-39、1998．
23. 戸井雅和：癌細胞の糧道を絶つ． 日経ヘルス、月刊経営塾 8 月号：51-55、1998．
24. 戸井雅和：乳癌の診断． 毎日ライフ 8 月特集号、pp58-61、1997．
25. 戸井雅和：血管新生からみた乳癌の悪性度． 実験治療 646：27-29、1997．
26. 戸井雅和、上野貴之、冨永健：乳癌領域における新しい腫瘍マーカー．Medico 28：12460-12462、1997．
27. 戸井雅和：血管新生． Mamma 24：6-7、1996．
28. 戸井雅和、冨永健：閉経前と閉経後乳がんの内分泌環境を再考する． Mamma 18：1-4、1994．
29. 冨永健、戸井雅和、林和雄、星名聖剛、稲田一雄：乳房温存手術のポイント－我々の方法． Mamma 18：
10-11、1994．
30. 戸井雅和：血管新生阻害薬． Medico 26：11364-11367、1995．
31. 冨永健、戸井雅和、林和雄、星名聖剛、稲田一雄：乳房温存療法． 癌治療今日と明日 16：19-22、1994．
32. 戸井雅和：Antiestrogens の作用機作と耐性に関する研究の進展． Mamma 18：4-5、1994．
33. 戸井雅和、冨永健：乳癌における血管新生． Breast Cancer Today 10：2-9、1994．
34. 冨永健、池田正、戸井雅和：乳癌治療最近の話題． 癌治療,今日と明日 15：4-13、1993．
64

和文原著
1.

坂東 裕子, 笠井 宏委, 青儀 健二郎, 大谷 彰一郎, 津川 浩一郎, 森岡 由香, 山口 ひとみ, 吉波 哲大, 橋
本 郁子, 相馬 道郎, 戸井 雅和, 増田 慎三, 大野 真司, JBCRG-Q06 研究委員会：医師主導治験の実施体制
整 備 状 況 と 課 題 に つ い て 乳 癌 診 療 施 設 に 対 す る ア ン ケ ー ト 調 査 (JBCRG Q-06) ： 乳 癌 の 臨 床(0911-2251)32 巻 6 号 Page477-483(2017.12)

2.

黒井 克昌, 戸井 雅和, 大野 真司, 中村 清吾, 岩田 広治, 増田 慎三, 佐藤 信昭, 津田 均, 黒住 昌史, 秋
山 太：術前化学療法を施行したホルモンレセプター陽性乳癌におけるリンパ節転移の予後因子としての意
義 JBCRG-01 、 JBCRG-02 、 JBCRG-03 の プ ー ル 化 解 析 ： 乳 癌 の 臨 床 (0911-2251)31 巻 5 号
Page413-422(2016.10)

3.

稲本 俊, 高田 正泰, 藤田 貴久子, 桑垣 陽子, 平野 加奈子, 徳永 幸子, 永田 明, 戸井 雅和：乳腺疾患患者初診時の医療情報の収集とデータベース化のためのタッチパネルを用いた問診システムの開発： 天理医療大学紀要 (2187-6126)2 巻 1 号 Page111-119(2014.03)

4.

中川 政幸, 宮地 利明, 林 達也, 金尾 昌太郎, 谷口 正洋, 東村 亨治, 戸井 雅和, 富樫 かおり：浸潤性乳管癌と線維腺腫における Triexponential 拡散解析： 日本放射線技術学会雑誌 (0369-4305)70 巻 3 号
Page199-205(2014.03)

5.

黒井 克昌, 戸井 雅和, 大野 真司, 中村 清吾, 岩田 広治, 増田 慎三, 佐藤 信昭, 津田 均, 黒住 昌史, 秋
山 太：病理学的完全奏効 ypT0/isypN0 の臨床的意義 JBCRG-01、JBCRG-02、JBCRG-03 のプール化解
析： 乳癌の臨床 (0911-2251)28 巻 6 号 Page585-595(2013.12)

6.

山賀 郁, 浅尾 恭史, 鳥井 雅恵, Fakhrejahani Elham, 高田 正泰, 鍛 利幸, 金尾 昌太郎, 片岡 正子, 三
上 芳喜, 杉江 知治, 椎名 毅, 戸井 雅和：光超音波マンモグラフィを用いた乳癌診断法の開発： 日本レーザー医学会誌 (0288-6200)34 巻 1 号 Page24-29(2013.06)

7.

金澤 麻衣子, 増田 慎三, 黒井 克昌, 阿部 恭子, 戸井 雅和：通院化学療法を受ける乳癌患者へのリスクマ
ネジメントに関する現状と課題： 乳癌の臨床 (0911-2251)28 巻 1 号 Page134-135(2013.02)

8.

露木 茂, 坪田 優, 河口 浩介, 川口 展子, 若狭 朋子, 新宅 雅幸, 三上 芳喜, 戸井 雅和, 河野 幸裕：術前診 断 が 困 難 で あ っ た 胸 筋 浸 潤 を 伴 う 浸 潤 性 小 葉 癌 の 1 例 ： 乳 癌 の 臨 床 (0911-2251)27 巻 3 号
Page343-347(2012.06)

9.

杉江 知治, 戸井 雅和, 山内 智香子, 石黒 洋, 三上 芳喜, 岡村 隆仁, 加藤 大典, 山内 清明, 稲本 俊：遺伝性・家族性乳がん診療のコンセンサス 多施設アンケート結果から： 家族性腫瘍 (1346-1052)12 巻 2 号
Page45-49(2012.05)

10. 西村 友美, 山城 大泰, 清水 華子, 光藤 悠子, 鳥井 雅恵, 辻 和香子, 上野 貴之, 竹内 恵, 杉江 知治, 金
尾 昌太郎, 石黒 洋, 三上 芳喜, 戸井 雅和：術前高用量トレミフェン療法が著効した閉経後乳癌の 1 例： 乳癌の臨床 (0911-2251)26 巻 6 号 Page711-716(2011.12)
11. 友滝 愛, 廣田 沙耶, 寺本 藍, 横堀 真, 大橋 靖雄, 戸井 雅和：一般住民コントロールの応諾割合とマッチ
ン グ方法 乳酸菌 摂取と 乳がん発 症の関連 性を 検討する ケース・ コン トロール 研究 ： 薬理と 治療(0386-3603)39 巻 Suppl.2 Page S211-S221(2011.05)
12. 大越 香江, 祝迫 惠子, 阪口 晃一, 久保 肇, 戸井 雅和：ライフスタイル中立的な乳癌検診を目指して；ライフスタイルの多様性に応じた乳癌検診をいかに提供するか： 日本乳癌検診学会誌 (0918-0729)19 巻 1 号
Page53-59(2010.03)
13. 加藤 大典, 戸井 雅和, 稲本 俊, 杉江 知治, 金尾 昌太郎, 岡村 隆仁, 諏訪 裕文, 鍛 利幸, 山内 智香子,
光森 通英, 三上 芳喜：乳房部分切除後の断端陽性に対する取扱いの比較検討 41 施設へのアンケートによ65

る調査結果から： 乳癌の臨床 (0911-2251)24 巻 1 号 Page158-159(2009.03)
14. 有賀 智之, 大塚 恒博, 松浦 千恵子, 矢嶋 多美子, 関根 進, 北川 大, 堀口 和美, 鈴木 栄治, 佐治 重衡,
黒井 克昌, 戸井 雅和, 宇都宮 譲二：Nipple Aspiration Fluid 研究 重要性と発展性について： 乳癌の臨
床 (0911-2251)24 巻 1 号 Page140-141(2009.03)
15. 山崎 万梨子, 杉江 知治, 高田 正泰, 戸井 雅和：術前の個別化治療により病理学的完全奏効が得られた乳癌の 1 例： 治療学 (0386-8109)43 巻 3 号 Page335-338(2009.03)
16. 芳林 浩史, 石黒 洋, 高田 正泰, 竹内 恵, 山城 大泰, 上野 貴之, 加藤 大典, 吉川 清次, 金尾 昌太郎, 山
内 智香子, 三上 芳喜, 戸井 雅和：Docetaxel と Cyclophosphamide 併用術前化学療法が著効した乳癌の 1
例： 癌と化学療法 (0385-0684)35 巻 6 号 Page987-990(2008.06)
17. 中村 清吾(聖路加国際病院 ブレストセンター), 増田 慎三, 岩田 広治, 戸井 雅和, 黒井 克昌, 黒住 昌史,
津田 均, 秋山 太： 原発乳癌に対する FEC followed by docetaxel 100mg/m2 併用療法による術前化学療法の検討 JBCRG02：乳癌の臨床 (0911-2251)23 巻 2 号 Page111-117(2008.04)
18. 増田 慎三, 戸井 雅和, 高塚 雄一, 中村 清吾, 岩田 広治, 大野 真司, 黒井 克昌, 日馬 幹弘, 久松 和史,
山崎 弘資, 辛 栄成, 佐藤 康幸, 海瀬 博史, 柏葉 匡寛, 岩瀬 弘敬, 黒住 昌史, 津田 均, 秋山 太：乳癌周術期化学療法の現状および Supportive Care の工夫 JBCRG01 試験アンケートより： 癌と化学療法(0385-0684)34 巻 10 号 Page1609-1615(2007.10)
19. 澤田祐香、佐治重衡、山城大泰、坂東裕子、遠山和美、戸井雅和：FEC100-DOC75 術前化学療法により病理学的完全奏効（pCR）を得た局所進行乳癌の 1 例．治療学 39：201-203、2005．
20. 佐伯俊昭、戸井雅和、 峠 哲哉、 笹野公伸、 野口眞三郎、渡辺 亨、池田 正、 田部井敏夫、高塚雄一、
木村盛彦、高嶋成光：乳がん薬物療法の現状（内分泌療法）．乳癌の臨床 18： 457-469、2003．
21. 有広光司、寺本成一、中場寛行、小関萬里、片岡健、戸井雅和、黒井克昌、船田信顕、立秋優子、小原政信、
吉里勝利：ヒト乳癌組織に浸潤するリンパ球と乳癌細胞との相互作用． 乳癌基礎研究 12、pp39-44、2003．
22. 渡辺亨、佐野宗明、戸井雅和、佐伯俊昭、神田和弘、三浦重人、稲冶英生、園尾博司、佐伯英行、西村令喜、
藤田芳江：抗エストロゲン剤耐性閉経後乳癌に対する Exemestane の後期第 II 相試験． 癌と化学療法 29：1211-1221、2002．
23. 黒井克昌、田中智香子、坂東裕子、佐治重衡、林和雄、戸井雅和：進行・再発乳癌に対する Biweekly Paclitaxel
療法の有用性．癌と化学療法 29：55-60、2002．
24. 児玉ひとみ、屠聿揚、石渡淳一、篠原義政、片柳直子、久保田憲、村上徹、黒井克昌、林和雄、戸井雅和：
家族歴とＣＥＡ高値を契機に発見された多発性内分泌腫瘍症２Ａ型（ＭＥＮ２Ａ）の 1 症例． 日本内科学会雑誌、90：121-124、2001．
25. 黒井克昌、坂東裕子、永井成勲、田中智香子、林和雄、戸井雅和：進行・再発乳癌に対する Weekly Docetaxal
療法の有用性． 癌と化学療法 28：797-802、2001．
26. 松本岳、永井成勲、戸井雅和、石山哲、黒井克昌、鶴田耕二、岡本篤武、高橋俊雄：KRN7000 の膵癌肝転移抑制効果． 日本外科学会雑誌 102：421、 2001．
27. 園尾博司、紅林淳一、飯野佑一、塚本泰司、稲治英生、渡辺亨、戸井雅和：再発乳癌のホルモン療法の現況（日本乳癌学会評議員に対するアンケート調査より）． 乳癌の臨床 15：183-189、2000．
28. 永井成勲、戸井雅和、黒井克昌、林和雄、冨永健：前治療に anthracycline 系抗癌剤を投与した進行・再発
乳癌症例に対する docetaxel の有効性について． 癌と化学療法 26：2037-2042、1999．
66

29. 小山富子、戸井雅和：血中 HGF の正常範囲に関する検討． 月刊「臨床と研究」別冊 75：2751-2756、1998．
30. 坂東裕子、戸井雅和、冨永健：遺伝性乳癌とその遺伝子検査に関するアンケート調査． 日本医事新報 3865：
43-47、1998．
31. 野水整、土屋敦雄、阿部力哉、浅石和昭、飯野佑一、内野賢、岡崎裕、岡崎稔、紅林淳一、戸井雅和、野口
眞三郎、福富隆志、片桐豊雅、三木義男、中村祐輔：わが国における遺伝性乳癌の臨床病理学的検討． 癌の臨床 44：433-440、1998．
32. 成田達彦、戸井雅和、関口潔、岩成宏子、松浦奈美、木村尚子、光岡ちか子、神奈木玲児： 消化器癌・乳癌患者における血清 HGF の検討． 癌と化学療法 24：2159-2161、 1997．
33. 阿部克己、鈴木謙三、鎌田憲子、小池盛雄、戸井雅和、横山佳明、牛見尚史、増本智彦：乳癌の転移に対するホルモン療法中の肺血栓塞栓症の 2 例． 臨床放射線 42：719-722、 1997．
34. 本 田 志 延 、 戸 井 雅 和 、 清 水 辰 一 郎 、 林 和 雄 、 冨 永 健 ： 乳 癌 に お け る 補 助 化 学 療 法 と し て の CEF(Cyclophosphamide, Epirubicin, 5-fluorouracil)療法、その耐用性に関する検討． 癌と化学療法 24：679-683、1997．
35. 長 屋 直 樹 、 戸 井 雅 和 、 砂 原 誠 司 、 栗 本 文 彦 、 冨 永 健 ： 高 感 度 hyper pressure liquid
chromatography-radioimmunoassay (HPLC-RIA)による乳癌組織中 estrone (E1), estradiol (E2)濃度測定とその臨床的意義． 癌と化学療法 24：329-336、1997．
36. 細村幹夫、戸井雅和、林和雄、冨永健、田中荘一、坂東正士、迫間隆昭、小池盛雄：脳転移が先行した潜在性乳癌の 1 例．日本臨床外科学会雑誌 57：850-853、1996．
37. 戸井雅和、谷口忠明、林和雄、冨永健：再発乳癌に対する 5'-deoxy-5-fluorouridine + medroxypregesterone
acetate 療法の効果． 癌と化学療法 22：799-804、1995．
38. 谷口忠明、戸井雅和、林和雄、冨永健：乳癌肝転移の治療成績の検討． 乳癌の臨床 10：563-568、1995．
39. 稲田一雄、戸井雅和、星名聖剛、林和雄、冨永健：n0 乳癌における予後因子の検討, 腫瘍血管新生の意義．
癌と化学療法 22(Suppl I)：59-65、1995．
40. 山根明子、田村俊美、斉藤久子、江崎まり子、戸井雅和、秋山秀樹：告知希望に関するアンケートの意義について－告知された経験のある患者へのアンケート． 癌の臨床 41：1817-1822、1995．
41. 稲田一雄、戸井雅和、今沢隆、星名聖剛、林和雄、冨永健：乳癌における P53 蛋白過剰発現の意義、予後因子としてまた乳癌 High-risk 症例における高頻度発現．癌と化学療法 21：817-821、1994．
42. 戸井雅和、林和雄、冨永健：乳がんにおける術後補助療法としての高用量 CAF (cyclophosphamide,adriamycin, 5-FU)療法の耐用性に関する検討． 癌と化学療法 21：2057-2060、1994．
43. 黒井克昌、大崎昭彦、川見弘之、戸井雅和、峠哲哉：n0 乳癌における予後因子の検討．癌の臨床 38：757-761、
1992．
44. 黒井克昌、大崎昭彦、川見弘之、戸井雅和、峠哲哉、武田晋平、有広光司、井内康輝：早期乳癌に対する乳房温存療法の検討． 広島医学 45：777-780、1992．
45. 黒井克昌、川見弘之、大崎昭彦、山田裕典、戸井雅和、峠哲哉：早期乳がんの診断に関する臨床的検討． 広
島医学 45：296-302、1992．
46. 黒井克昌、大崎昭彦、川見弘之、山田裕典、戸井雅和、峠哲哉、有広光司、井内康輝：臨床病理学的所見からみた乳がんのダブリングタイムの検討、特に c-erb B-2 蛋白、epidermal growth factor receptor との関係
67

について．乳がんの臨床 6：216-220、 1991．
47. 黒井克昌、戸井雅和、川見弘之、大崎昭彦、山田裕典、峠哲哉：科研費研究課題の成果、サーモグラフィによる乳腺診断の計量化ならびに新たな臨床応用に関する研究． INNERVISION 6：11-12、1991．
48. 黒井克昌、大崎昭彦、川見弘之、山田裕典、戸井雅和、峠哲哉、有広光司、井内康輝：マンモグラフィー、
サーモグラフィーによる腫瘍進展範囲の予測． 乳癌の臨床 6：384-389、1991．
49. 大崎昭彦、戸井雅和、山田裕典、川見弘之、黒井克昌、峠哲哉：乳がんにおける c-erbB-2 蛋白質および
epidermal growth factor receptor 共発現の予後因子としての意義． 乳癌の臨床 6：19-26、1991．
50. 大崎昭彦、戸井雅和、山田裕典、川見弘之、黒井克昌、峠哲哉：乳がんにおける c-erbB-2 蛋白質の発現とその予後因子としての意義． 癌と化学療法 18：1181-1185、1991．
51. 黒井克昌、山田裕典、川見弘之、大崎昭彦、戸井雅和、峠哲哉、有広光司、井内康輝：乳頭異常分泌に対す
る乳管内視鏡検査． 広島医学 44：187-188、1991．
52. 吉中建、八木正人、大田垣純、戸井雅和、峠哲哉：5'-DFUR+MMC+Etoposide+MPA の 4 剤併用により著効を示した再発乳がんの 1 例． 癌と化学療法 18：115-118、1991．
53. 宮原栄治、戸井雅和、和田務、山田裕典、大崎昭彦、柳川悦朗、峠哲哉：乳がんにおける腫瘍マーカー
NCC-ST-439 の発現の臨床的検討． 癌の臨床 36：2023-2026、1990．
54. 大崎昭彦、戸井雅和、山田裕典、黒井克昌、峠哲哉：乳がんにおける estrogen receptor(ER)の免疫組織学
的検討、予後との関係について．乳癌の臨床 5：507-512、1990．
55. 有広光司、Nasima Khatun, 井内康輝、黒井克昌、川見弘之、大崎昭彦、山田裕典、戸井雅和、峠哲哉、滝本泰生、蔵本淳：乳腺の扁平上皮癌． 広島医学 43：1337-1338、1990．
56. 戸井雅和、和田務、大崎昭彦、山田裕典、柳川悦朗、峠哲哉：早期乳がんにおける超音波診断． 広島医学 43：
1375-1379、1990．
57. 田中卓、山本篤志、山田裕典、和田務、中村隆志、戸井雅和、新本稔、服部孝雄、大瀧慈、務中昌巳：被爆者における乳がんの特異性についての検討． 広島医学 43：423-425、1990．
58. 山田裕典、戸井雅和、和田務、大崎昭彦、峠哲哉：乳がん肝転移症例の治療． 広島医学 43：1211-1215、
1990．
59. 野間浩介、松木啓、戸井雅和、柳川悦朗、峠哲哉：頚部リンパ節転移が先行した IIc 様胃がんの一例． 広島
医学 44：594-597、1990．
60. 大崎昭彦、戸井雅和、和田努、山田裕典、峠哲哉：再発進行乳がんにおける CAF 療法の予後に及ぼす効果．
乳癌の臨床 5：124-128、1990．
61. 山田裕典、戸井雅和、大崎昭彦、和田務、峠哲哉：ヒト乳癌組織における transforming growth factor alphaの発現． 医学のあゆみ 153：547-548、1990．
62. 佐伯俊昭、地主和人、金隆史、戸井雅和、佐伯和利、吉中建、柳川悦朗、新本稔、服部孝雄：切除不能・再発固形がんに対する cyclophosphamide を加えた methotrexate-5-fluorouracil 時間差療法の臨床成績の検討．
癌と化学療法 16：827-831、1989．
63. 新本稔、和田務、河野和明、向田秀則、佐伯和利、戸井雅和、佐伯俊昭、平井敏弘、服部孝雄：再発胃がん
に対する外科的治． 外科治療 60：28-32、1989．
64. 戸井雅和、新本稔、和田務、山本篤志、中村隆志、服部孝雄：腫瘤非触知性乳がんの診断におけるサ−モグ
68ラフィ−の有用性． 乳癌の臨床 4：238-242、1989．
65. 和田務、戸井雅和、中村隆志、山本篤志、柳川悦朗、峠哲哉、新本稔、服部孝雄：チロシンキナーゼ活性阻
害剤 erbstatin のヒト乳癌細胞株 MCF-7 に対する抗腫瘍効果についての検討．医学のあゆみ 150：555-556、
1989．
66. 和田務、戸井雅和、中村隆志、山本篤志、峠哲哉、新本稔、服部孝雄：ヌードマウス可移植性ヒト乳癌細胞株 MCF-7 の増殖に及ぼす顎下腺摘出および上皮細胞成長因子投与の影響． 医学のあゆみ 148：625-626、
1989．
67. 戸井雅和、中村隆志、向田秀則、大崎昭彦、山田裕典、和田務、峠哲哉、新本稔：乳がんにおける epidermal
growth factor receptor 発現の予後因子としての意義． 乳癌の臨床 4：618-621、1989．
68. 戸井雅和、中村隆志、和田務、山本篤志、新本稔、服部孝雄：微細石灰化像から乳がんを疑った腫瘤非触知
性乳腺病変の検討． 広島医学 42：340-344、1989．
69. 戸井雅和：乳がんにおける estrogen receptor, epidermal growth factor, epidermal growth factor receptor
に関する免疫組織化学的、生化学的研究．日本外科学会雑誌 89：725-736、1988．
70. 向田秀則、平井敏弘、戸井雅和、中村隆志、山下芳典、河野和明、峠哲哉、新本稔、服部孝雄：ヌ−ドマウ
ス可移植ヒト食道がんにおける epidermal growth factor receptor の測定及びその増殖に及ぼす影響．
Oncologia 21： 55-60、1988．
71. 和田務、戸井雅和、中村隆志、山本篤志、新本稔、服部孝雄：原発性両側乳がん症例の検討． 乳癌の臨床 3：449-453、1988．
72. 54． 戸井雅和、中村隆志、和田務、山本篤志、柳川悦朗、峠哲哉、新本稔、服部孝雄：
乳がんにおける生検の問題点、生検からの期間が予後に及ぼす影響と穿刺吸引細胞診の pitfalls．広島医学 41：
1898-1902、1988．
73. 高山孝弘、戸井雅和、末広真一、濱田雄蔵、中村隆志、和田務、新本稔、服部孝雄：乳腺に原発した偏平上
皮がんの 1 例． 広島医学 41：1843-1845、1988．
74. 野村雍夫、田代英哉、久松和史、戸井雅和：再発・進行乳癌に対する第 2 次内分泌療法としての MPA の効
果、特に前治療とホルモン・レセプターとの関連について． 癌と化学療法 15：513-518、1988．
75. 地主和人、白水倶弘、戸井雅和、岡直剛、井口潔、服巻勝正、下田悠一郎、宮本祐一、小柳孝太郎：術前に診断された肝嚢胞腺癌の 1 治験例． 外科診療 28：513-516、1987．
76. 戸井雅和、濱田雄蔵、向田秀則、世戸芳博、谷本雅伯、峠哲哉、新本稔、服部孝雄：乳がんにおける epidermal
growth factor receptor ならびに estrogen receptor の測定． 医学のあゆみ 141：875-876、1987．
77. 戸井雅和、濱田雄蔵、末広真一、世戸芳博、谷本雅伯、峠哲哉、新本稔、服部孝雄：微細石灰化像のみで発見されたいわゆる触知不能の乳がんの 1 例． 乳癌の臨床 2：279-282、1987．
78. 濱田雄蔵、世戸芳博、谷本雅伯、戸井雅和、新本稔、服部孝雄：乳腺疾患に対する超音波診断法の最近の進歩． 広島医学 40：792-797、1987．
79. 谷本雅伯、濱田雄蔵、戸井雅和、世戸芳博、新本稔、服部孝雄：広島大学原医研外科における乳がん重複がん症例の検討． 広島医学 40：1372-1375、1987．
80. 武田晋平、戸井雅和、児玉久光、峠哲哉、新本稔、服部孝雄：嚢腫十二指腸吻合術後 17 年目に嚢胞摘出術を行った先天性総胆管拡張症の 1 例． 広島医学 40：297-299、1987．
69

81. 戸井雅和、濱田雄蔵、世戸芳博、久松和史、末広真一、峠哲哉、新本稔、服部孝雄：乳がんの estrogen receptor
assay におけるモノクロ−ナル抗体を用いた免疫組織化学的方法と dextran coated charcoal(DCC)法の比較．
癌と化学療法 13：3056-3062、1986．
82. 濱田雄蔵、新本稔、世戸芳博、久松和史、戸井雅和、峠哲哉、服部孝雄：被爆者乳がん患者の疫学的考察．
乳癌の臨床 1：119-121、1986．
83. 久松和史、濱田雄蔵、世戸芳博、戸井雅和、峠哲哉、新本稔、服部孝雄：超音波診断装置を用いた乳がん集
団検診のこころみについて． 広島医学 39：856-861、1986．
84. 久松和史、峠哲哉、柳川悦朗、濱田雄蔵、世戸芳博、山田博文、戸井雅和、服部孝雄：乳がん患者における末梢血、リンパ節および腫瘍内浸潤リンパ球の免疫学的活性． 癌と化学療法 13：2555-2561、1986．
85. 戸井雅和、濱田雄蔵、世戸芳博、久松和史、峠哲哉、新本稔、服部孝雄：新しい超音波装置を用いた乳腺の診断． 広島医学 39：991-997、1986．
86. 戸井雅和、濱田雄蔵、世戸芳博、久松和史、末広真一、新本稔、服部孝雄：モノクロ−ナル抗体を用いた酵
素抗体法による乳がん estrogen receptor の測定． 医学のあゆみ 136：227-228、 1986．
87. 白水倶弘、児玉久光、戸井雅和：接触法による乳腺超音波診断、とくに乳癌腫瘤の超音波像パターン分類について． 日本臨床外科医学会雑誌 46：165-172、1985．
88. 戸井雅和、白水倶弘、米村智弘、江崎武春、岡直剛、吉田猛朗、鶴丸廣長：消化器癌の腹膜播種に対するCis-diamminedichloroplatinum 腹腔内投与、CDDP i.p． 癌の臨床 31：522-526、1985．
89. 戸井雅和、白水倶弘、林田裕、米村智弘、江崎武春、岡直剛、鶴丸廣長、鴨井逸馬、内田哲、宮本祐一：十二指腸腺管絨毛腺腫の 1 例． 消化器外科 8：1911-1915、1985．
90. 戸井雅和、松木啓、中上和彦、弘野正司、新本稔、服部孝雄：異型上皮巣に併存した微少胃がんの 1 例およびその病理組織学的解析． 癌の臨床 30：519-523、1984．

70